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Dementia is a progressive neurological syndrome characterised by cognitive 
impairment, in particular with alterations in learning and memory. Alzheimer’s 
disease and vascular dementia are the two most common forms of this syndrome. 
Although the pathophysiology of dementia is unknown, changes in several proteins 
are believed important in its development. These changes could be, to some extent, 
explained by microRNAs. MicroRNAs are posttranscriptional regulators of gene 
expression that repress protein synthesis. This thesis attempts to investigate the role of 
microRNAs in dementia from a more rigorous and biologically relevant perspective. I 
propose a hypothesis-driven approach considering some factors that have not been 
taken into account previously. I hypothesise that the levels of certain microRNAs with 
converging functions would be expressed differently in post-mortem brain tissue of 
patients diagnosed with Alzheimer’s disease, vascular dementia and non-demented 
elderly, investigated using novel reference genes and two new formulas proposed to 
improve microRNA quantification. 
 
A first panel of microRNAs was selected based on their proposed effects on proteins 
that have been implicated in Alzheimer´s disease. The levels of these microRNAs were 
significantly different in the Alzheimer’s disease group. A second panel was selected 
for potential roles on proteins related to hypoxia, vascular dysfunction and the renin 
angiotensin system. Unexpectedly, no change was observed in the vascular dementia 
group whilst a statistically significant difference was observed in the Alzheimer´s 
disease group. Finally, the presence of selected microRNAs was explored in cell culture 
as potential modelling construct. My results provide new candidates and more 
rigorous approaches to the study of microRNAs in dementia research. This work will 
inform future research in the emerging field of microRNAs in dementia whilst also 
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Chapter 1.- Introduction 
 
 
1.1. The clinical problem of dementia 
 
Dementia is a chronic and progressive neurological syndrome characterized by 
impairment in cognitive capacities such as, reasoning, learning, memory, orientation, 
language, and emotional stability (1,2). In 2012, the World Health Organization 
declared this syndrome as a priority condition for public heath due to its high 
incidence of nearly 7.7 million per year and derived elevated costs for health systems 
(1). Around 70% of all dementia cases are caused by Alzheimer’s disease (AD), which 
can be described to exist in two forms according to its onset. First is the rare early-onset 
(<65 years) familial AD type, which an autosomal dominantly inherited form of AD 
caused by mutations in APP, PSEN1 and PSEN2. Second is the most common sporadic 
late-onset (>65 years) form of AD, which represents 95% of all AD cases (1,3,4). 
 
The second most common form of dementia (and how it will be referred to in this 
thesis) is vascular dementia (VaD), which accounts for about 15% of dementia cases. A 
further 10% of dementia cases are due to Lewy bodies’ dementia and around 5% is 
associated to other conditions and comorbidities. Importantly, these categories are 
arguably artificially distinct and more commonly many people with dementia have 
one or more forms of pathology, giving rise to a mixed phenotype, often called mixed 
dementia (1,3,4). Post-mortem histopathological analysis remains the gold standard for 
accurate diagnosis of dementia and it usually as a result of this form of diagnosis that 
the true extent of comorbidities is identified. 
 
1.2. The neuropathology of Alzheimer’s disease 
 
The histopathology of AD is characterised by intracellular neurofibrillary tangles, 
extracellular amyloid plaques, astrogliosis and reactive microglia. It also involves 
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vascular changes such as cortical microinfarcts, lacunar infarcts in the basal ganglia 
and cortical petechial microbleeds, as is also often observed in VaD. Moreover, some of 
these features are also linked to cerebral amyloid angiopathy, a risk factor for 
haemorrhage, caused by the deposition of a 40 amino acid variant of the amyloid beta 
peptide within the blood vessels of the brain, particularly in the posterior parietal and 
occipital areas of the brain (5). 
 
1.2.1. Neurofibrillary tangles 
 
Neurofibrillary tangles are composed of hyperphosphorylated forms of microtubule 
associated tau protein (5,6). Tau protein is coded by the MAPT gene, which is 
conserved across vertebrates with 182 orthologues, indicating that the gene has been 
preserved by natural selection (7). Tau is highly expressed in the brain and it is mainly 
an axonal protein in mature neurons (6,8). Most of tau is bound to microtubules and 
allows their stabilisation and assembly. Microtubules stabilisation in turn, permits 
arrangement of the neuronal cytoskeleton and allows axonal transport after neuronal 
maturation (8,9). 
 
Although neurofibrillary tau tangles are a pathological hallmark of AD, they are not 
exclusive of AD. Indeed there are several tauopathies, the collective term used to 
describe disorders caused by tau phosphorylation, abnormal splicing and levels of tau 
or mutations in MAPT. These include AD, corticobasal degeneration, Down’s 
syndrome, frontotemporal dementia, Pick’s disease, postencephalic parkinsonism and 
progressive supranuclear palsy, and even include dementia resulting from repeated 
head injury in the form of chronic traumatic encephalopathy (CTE) (9). 
 
Mutations in the MAPT gene impair the binding of tau to microtubules, similarly 
phosphorylation of tau at serine/threonine residues regulates its binding to 
microtubules and its hyperphosphorylation is associated with aberrant aggregation in 
disease (6,8). Tau phosphorylation alter the conformation and neutralizes the positive 
charge of the microtubule-binding domain of tau, detaching tau from microtubules and 
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destabilising them (6,8,9). Phosphorylated and detached tau accumulates in neuronal 
neurites, axons and cell bodies forming insoluble filaments and, eventually, 
neurofibrillary tangles in three main stages (5,8). 
 
First, precursors of tangles are recognised by diffuse tau staining in the cytoplasm of 
neurons without recognised pathology, with conserved dendrites and a centred 
nucleus. Second, mature intracellular neurofibrillary tangles are composed of tau 
aggregates that destabilise the cytoskeleton and move the nucleus to the periphery. 
Tau aggregates also extend to distorted neurites and to the proximal segment of the 
axon affecting neuronal morphology and neurotransmitter trafficking. Third, 
extraneuronal tangles are released after the death of neurons containing tau tangles, 
identified by the absence of nucleus and cytoplasm (5). 
 
In addition, tau phosphorylation and tangle deposition follows a spatiotemporal 
pattern across the cerebral cortex that correlates with the progression of disease and 
symptoms. Braak and Braak described this evolution of tau pathology as six stages. 
The neurofibrillary tangles first appear in the transentorhinal and entorhinal cortex 
(stage I), followed by the cornus ammonis region 1 (stage II) and then in the subiculum 
in the hippocampus (stage III). Next, tangles appear in the amygdala, thalamus and 
claustrum (stage IV), continuing to isocortical areas, first associative areas (stage V) 
and then to primary sensory, motor and visual areas (stage VI) (5). 
 
As mentioned, MAPT gene conservation across species suggests a function preserved 
by natural selection. Tau phosphorylation is observed in other mammals when they 
hibernate and in other situations such as hypothermia and induced-anaesthesia (10–
13). This is likely to have a neuroprotective effect reducing metabolic demands in the 
brain. For instance, therapeutic hypothermia is used in human medicine for brain 
injuries to reduce the metabolic demand, decreasing excitotoxicity, free radical 
formation and inflammation (14). During hypothermia, synaptic contacts between 
mossy fibres and hippocampal neurons present regressive or retractable changes that 
are reversible once euthermia is restablished (15). 
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Arendt et al have shown that highly phosphorylated tau in paired helical filaments is 
present in torpor during hibernation. The distribution of phosphorylated tau also 
followed a consistent pattern similar to Braak stage, being most intense in the 
entorhinal cortex, hippocampus, and isocortical areas. Phosphorylated tau in neurons 
of the cornus ammonis region 3 was paralleled by the regression of synaptic contacts of 
the mossy fiber system terminating on cornus ammonis region 3 apical dendrites. 
Mossy fiber afferentation was restored in arousal along with a reduction of 
phosphorylated tau in the cornus ammonis region 3 neurons (16). 
 
A neuroprotective role for tau phosphorylation is reinforced by the fact that cellular 
antioxidant induction and tau expression oppose each other. Similarly, embryonic 
neurons that survive after treatment with oxidants have more phosphorylated tau in 
comparison to those that didn’t survive (12). These findings together suggest that 
phosphorylation of tau might be a neuroprotective and physiological mechanism by 
which neurons reduce the metabolic demand in order to cope with adverse conditions 
or brain insults. However, the reversibility of phosphorylated tau in mentioned above 
studies still remains controversial to what is observed in AD brain. 
 
Arendt et al suggested that brain hypometabolism triggers tau phosphorylation and 
that periods of recovery are necessary for the reversibility of tau. If hypometabolism 
continues and hyperphosphorylation of tau persists, the physiological protective 
mechanism becomes a chronic and aberrant dysfunction that impedes the recovery of 
tau, allows its propagation in a prion-like manner and leads to neurodegeneration (17). 
Thus, tau phosphorylation might initiate as a physiological protective mechanism 
triggered by a cerebral insult that after chronicity turns into an irreversible state that 
propagates across the cortex giving the flourished clinical manifestation of dementia. 
 
1.2.2. Amyloid plaques and cerebral amyloid angiopathy 
 
Amyloid plaques and cerebral amyloid angiopathy (CAA) are caused by deposits of 
two isoforms of amyloid beta (Aβ). The former is caused by insoluble Aβ that is 
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generally 42 (Aβ-42), and to a lesser extent 43 (Aβ-43) amino acids in length, whilst the 
latter is caused by soluble Aβ of 40 amino acids in length (Aβ-40), which is the most 
predominant form of Aβ. Aβ is derived from processing of the amyloid precursor 
peptide (APP) once it is transported to the cellular membrane and processed by β- and 
ɣ-secretases(18). Similar to MAPT, APP that encodes for APP is conserved across 
vertebrates, with 182 orthologues, indicating preservation by natural selection (7). 
 
Aβ levels and metabolism are regulated by neuronal activity and the most prominent 
site of Aβ secretion are distal axons and synapses (18,19).  Aβ is secreted from synapses 
as a consequence of neuronal activity and it serves as a feedback loop or physiological 
mechanism to restrict synaptic transmission and maintain physiological levels of 
neuronal activity (20). Patients with temporal lobe epilepsy, where neuronal activity is 
exacerbated without control, develop Aβ plaques (19). 
 
Soluble oligomers of Aβ, both Aβ-40 and Aβ-42, derived from AD patients have been 
shown to increase long-term depression (LTD), whilst inhibiting long-term 
potentiation (LTP). LTD and LTP are mechanisms of synaptic plasticity necessary for 
learning and memory. These oligomers also decreased dendritic spine density in vitro, 
whilst in vivo, intracerebroventricular injection of Aβ oligomers impaired memory 
tasks in normal rats (21). Although Aβ-40 is less prone to aggregation and is the most 
common Aβ species; apart from its effect in synaptic plasticity, it could have further 
implications by affecting vascular permeability, cause damage to the blood brain 
barrier and even raise blood pressure (22). 
 
CAA is a small vessel disease characterised by deposits of Aβ-40 in the tunica media of 
leptomeningeal and cortical capillaries, small arterioles and medium-size arteries, 
particularly in posterior parietal and occipital lobes of the brain. CAA disrupts the 
vessel wall and can cause haemorrhages and CAA is linked to the cortical petechial 
microbleeds observed in AD brain (5). Moreover, microbleeds observed using 
magnetic resonance imaging (MRI) in patients, have been associated with microinfarcts 
observed at post-mortem (also observed in AD brain), with an odds ratio of 8 (23). 
24 
 
It could be possible that amyloid production starts as a compensatory mechanism to 
reduce neuronal activity and in doing so, Aβ ends up deposited in the tunica media of 
vessels causing cerebral amyloid angiopathy. Imbalance between amyloid production, 
clearance and degradation are thought to be key factors in the development of Aβ -
related pathology in AD and CAA. 
 
Clearance of Aβ is believed to occur by perivascular drainage, suggested by the Aβ 
deposition that is seen in cerebral vessels and which follow the intramural perivascular 
drainage pathways. Age-related changes to glycoproteins and proteoglycans in 
vascular basement membranes, are believed to reduce their efficiency to clear Aβ and 
other solutes (24). The possession of ε4 variant ApoE, the greatest non-causative genetic 
risk factor for AD and VaD, also affects the flexibility of vascular membranes. Along 
with age, the greatest non-modifiable risk factor for AD, these structural changes and 
the properties of the resulting ApoE ε4 protein are thought to contribute to the failure 
of perivascular drainage of Aβ (24). Other processes believed to contribute to clearance 
of Aβ include phagocytosis and further degradation of Aβ occurs by perivascular 
macrophages, astrocytes and microglia (24,25). 
 
1.2.3. Astrogliosis and reactive microglia 
 
Microglia are macrophages or phagocytes in the brain, predominantly responsible for 
clearance of Aβ either by phagocytosis or local release of Aβ degrading enzymes. 
Reactive microglia, immunoglobulins and components of the complement cascade are 
found accompanying Aβ deposits in AD brain and mouse models of AD (26). After 
activated by neuronal debris or protein aggregates, microglia first extend their 
processes to the site of injury, and then migrate to the site and initiate an innate 
immune response (27). 
 
After receptor ligation, microglia engulfs fibrillary Aβ by phagocytosis, and Aβ enters 
the endosomal/lysosomal pathway. Soluble Aβ can be directly degraded by a 
extracellular proteases released by microglia, most importantly neprilysin and insulin 
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degrading enzyme (27). Binding of Aβ to different receptors results in activation of 
microglia and production of proinflammatory cytokines and chemokines(27). Chronic 
activation of microglia can have a deleterious effect rather than beneficial for Aβ 
clearance. A phenotype of microglia found in conditions of chronic stress (dark 
microglia) exhibited a highly activated phenotype with strong expression of receptors 
such as CD11b and TREM2 and extensive encircling of synaptic clefts when the 
microglia were associated with amyloid deposits (26). 
 
Reactive astrocytes are found surrounding Aβ plaques in a pattern similar to glial 
scarring (25) in both human AD brain and animal models (27). Similar to microglia, 
astrocytes can also engulf Aβ by phagocytosis. Phagocytosis of Aβ by astrocytes 
requires ApoE and astrocyte-dependent lipidation of ApoE increases the capability of 
microglia to clear Aβ. After exposure to Aβ, astrocytes release Aβ-degrading proteases, 
such as neprilysin, insulin degrading enzyme, endothelin-converting enzyme and 
angiotensin-converting enzyme. Furthermore, astrocytes also release cytokines, 
interleukins, nitric oxide, and other cytotoxic molecules that exacerbate the 
neuroinflammatory response(27). 
 
In addition to the role of astrocytes in Aβ phagocytosis, astrocytes might also react to 
early vascular damage. Perivascular drainage occurs in the space located between 
endothelial cells and astrocytic endfeet, expressing the water channel aquaporin-4 (28). 
Indeed, astrocytes might become reactive earlier due to a response to vascular damage. 
Analysis of astrogliosis alongside Aβ deposition by PET scan of presymptomatic 
autosomal dominant AD carriers showed that fibrillar Aβ deposition was observed 17 
years before the expected symptoms onset; at about the same time, astrocytosis was 
significantly elevated and then steadily declined, whilst Aβ plaque deposition 
increased with disease progression (29). Similarly, in APPswe transgenic mice, 





1.2.4. Vascular changes 
 
Both AD and VaD demonstrate vascular changes such as cortical microinfarcts, lacunar 
infarcts in the basal ganglia and cortical petechial microbleeds. Some of these features 
are also linked to CAA caused by the deposition of a 40 amino acid variant of the Aβ 
peptide within the blood vessels of the brain, particularly in the posterior parietal and 
occipital areas of the brain (5). 
 
Cerebral microinfarcts are microscopic lesions of tissue damage caused by occlusion of 
cerebral blood flow. In contrast, microbleeds are derived from extravasation of cerebral 
blood flow into the brain parenchyma. Interestingly, post-mortem microinfarcts have 
been associated with previous microbleeds, as seen in patients’ records of antemortem 
magnetic resonance imaging; this reached an odds ratio (OR) of 8.6. This 8-fold 
association is thought to be due to the vascular damage and BBB disruption caused by 
CAA pathology (23). 
 
Both microinfarcts and microbleeds are common findings at post-mortem and are also 
both associated with cognitive decline regardless of the presence or not of dementia 
(31,32). Aβ accumulation in the form of CAA can cause vessel fragility and vascular 
haemorrhagic leakage, but also thickening of the microvasculature and occlusion of the 
vessel (23). Microinfarcts are caused by CAA, arteriolosclerosis, microemboli and 
hypoperfusion (31). Cortical microinfarcts but not subcortical microinfarcts are 
associated with cognitive impairment, in particular amongst individuals with risk 
factors for dementia (32). 
 
1.3. Clinical presentation of dementia 
 
Dementia due to AD is typically characterised as an insidious decline in cognitive 
functioning. Initial memory impairment is restricted to learning and short-term 
memory (i.e. anterograde amnesia). While these changes might be considered initially 
as benign forgetfulness, which is common in normal aging, memory decline derived 
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from AD pathology is progressive and irreversible. Early symptoms of AD are 
associated with selective damage to particular neuroanatomical networks with clinical 
deficits consistent with the anatomical locus of impact (33,34). 
 
Evolution of the disease is gradual; progression also affects areas of cognition, such as, 
language, visuospatial, and executive abilities (34). Whilst AD progression is slow and 
gradual, cognitive deterioration in VaD is often fluctuating or stepwise. The clinical 
and neuropathological presentation of VaD is diverse and can include multi-infarct 
dementia, dementia due to infarction of specific brain areas, and subcortical ischemic 
vascular dementia (33). 
 
1.4. Epidemiology of dementia 
 
Globally, it has been estimated that dementia has a prevalence of 50 million (1,4). AD 
and other dementias are more common in women than in men; however this has been 
attributed to the greater longevity of women as there is no significant difference in the 
incidence between genders. Racial and ethnic differences in the prevalence and 
incidence of dementia might also exist, yet there is some evidence that indicates that 
differences based on race and ethnicity do not persist in rigorous analyses (35). 
 
The prevalence of AD rises at exponential rates directly with age as it is the greatest 
risk factor for developing AD. At age 65 years, 10% of people have AD and it increases 
to 32% at age 85 years or older (35). In the United States, of people who have AD, 4% 
are 65 years old or younger, 16% are between 65 and 74 years old, 44% between 75 and 
84 years old and  36% 85 years old or older (35). Other risk factors are cerebrovascular 
disease, diabetes, hypertension, smoking, obesity and dyslipidaemia (4). 
 
In contrast, there are protective factors that reduce the risk of AD. Higher education 
and occupational accomplishment are proposed to reduce the risk of developing AD. 
Similarly, a diet rich in omega-3 fatty acids, vegetables, fruits, cereals, legumes and fish 
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is protective. Along with a Mediterranean-style diet, regular aerobic exercise is 
associated with a reduced risk for AD (4). 
 
A recent study investigated the relation between a healthy lifestyle and a lower risk for 
dementia considering the genetic risk in 196 383 individuals. Although the changes in 
percentages observed in the study are quite low, it should be noted that the study 
represents an eight year follow up in individuals with an average age of 64 years (36). 
Nonetheless, this study considers the debate of nature versus nurture. The authors 
found that an unfavourable lifestyle and a high genetic risk were significantly 
associated with a higher risk for dementia. Conversely, a favourable lifestyle was 
associated with a lower risk in individuals with high genetic risk. 
 
1.5. Genetics of dementia 
 
Some studies suggest that AD has a strong genetic component with heritability up to 
80% of AD cases (37,38). The rare early-onset (<65 years) familial AD type represents 
5% of all AD cases. This autosomal dominantly inherited form of AD is caused by more 
than 200 mutations in the genes APP, PSEN1 and PSEN2 (38). The amyloid precursor 
peptide (APP) is encoded by the APP gene. Processing of the amyloid precursor 
peptide (APP) through the amyloidogenic pathway by β- and ɣ-secretases derives into 
the production of Aβ, which fibrillises and deposits in the parenchyma as amyloid 
plaques or in the blood vessels as cerebral amyloid angiopathy (18). 
 
Presenilin (PSEN1 or PSEN2) are part of the ɣ-secretase, which is a complex composed 
by four different proteins, presenilin, nicastrin, APH-1 (anterior pharynx-defective 
phenotype) and PEN-2 (presenilin enhancer) (39). Most of the mutations in APP, 
PSEN1 and PSEN2 result in an increase in the ratio of Aβ42:Aβ40. This promotes 
aggregation of Aβ into fibrils and ultimately amyloid plaques. The mutations related to 




In contrast, the genetic risk factors for the sporadic form of AD (95% of all cases) are 
neither sufficient nor necessary to cause AD. Mutations that contribute for the late- 
onset of AD are thought to work as a complex genetic pattern in conjunction with life 
exposure events and environmental factors (38). By far, the greatest genetic risk factor 
for AD and VaD is the presence of the APOE ε4 allele, which is also associated with 
increased risk of CAA and CAA-related haemorrhages, normal aging-related cognitive 
decline, hyperlipidaemia, hypercholesterolemia, atherosclerosis, cardiovascular and 
cerebrovascular disorders (40). 
 
In addition to APOE, some other genes associated with the sporadic form of AD are 
SORL1 (Sortilin Related Receptor 1), ACE (Angiotensin converting enzyme), PICALM 
(Phosphatidylinositol Binding Clathrin Assembly Protein), BIN1 (Bridging Integrator-
1), ABCA7 (ATP-binding cassette sub-family A member 7), MS4A4 (Membrane-
Spanning 4-Domains, Subfamily A, Member 4A), EPHA1 (Ephrin Receptor A1), CD33 
(Siglec-3), CLU (Clusterin), CD2AP (CD2-associated protein) and CR1 (Complement 
receptor type 1) (37,38,41). Genome wide association studies have also integrated the 
data from multiple genes that increase the risk for AD. These genes together are 
involved in cholesterol metabolism and immune response (42). 
 
Similarly, the risk for developing dementia can be also attributed to the simultaneous 
presence of a number of genes that together potentiate the risk. Using the Polygenic 
Linkage disequilibrium- Adjusted Risk Score (POLARIS) method, Baker et al 
confirmed previously known risk genes for developing dementia and found three 
novel genes. The three genes discovered early this year 2019 were RORA (RAR Related 
Orphan Receptor A), PPARGC1A (PPARG Coactivator 1 Alpha), and ZNF423 (Zinc 
Finger Protein 423) (119). 
 
1.6. Hypotheses of Alzheimer’s disease 
 
The pathogenesis of AD has previously been explained predominantly by two 
hypotheses: the cholinergic hypothesis and the Aβ cascade hypothesis. The cholinergic 
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hypothesis describes that the early loss of cholinergic function is a major contributor to 
the progressive cognitive decline in AD. The cholinergic basal forebrain, which is 
affected at early stages in AD, is responsible for the main cholinergic input to the 
hippocampus and its appropriate function is necessary to avoid cognitive impairment. 
The loss of cholinergic function is caused by reduced synthesis of the neurotransmitter 
acetylcholine, altered transport or death of cholinergic neurons that lead to impairment 
of its input to the cortex, thus causing deficits in memory and attention (44). 
 
The Aβ cascade hypothesis states that Aβ accumulates due to an imbalance between its 
production, degradation or clearance from the brain (43). Aβ deposition in the brain 
can be in the form of amyloid plaques and most commonly as cerebral amyloid 
angiopathy. Aβ oligomers can cause synaptic and mitochondrial failure, cellular 
membrane destabilization, inflammation, hyperphosphorylation of tau and tangle 
formation (4,43). 
 
Other hypotheses that have been proposed are the vascular hypothesis, where vascular 
changes are thought to affect clearance of Aβ; the inflammatory hypothesis, where 
inflammation responds to Aβ accumulation; the mitochondrial cascade hypothesis, 
where inheritance of genes related to mitochondrial function affects energy utilization; 
and the oxidative stress hypothesis, where changes in the antioxidant system and 
higher levels of oxidative damage contribute to the progression of AD (45). 
Nonetheless, none of these hypotheses is able to fully explain the changes observed in 
AD pathology. 
 
1.7. An introduction to microRNAs 
 
MicroRNAs (miRNAs) are non-coding RNA sequences with a median length of 22–23 
nucleotides. These miRNAs are present under physiological and pathological 
circumstances (46,47). Deletion of proteins that participate in the biogenesis of miRNAs 
produce detrimental and non-viable phenotypes, suggesting the essential participation 




MiRNAs suppress protein production through the complementary base pairing of the 
RNA sequences to the target protein mRNA. This is mediated through a seed-pairing 
region of 6-8 nucleotides at the 5’ end of the miRNA (Figure 1.E). MiRNAs mediate 
proteome remodeling and also interact with other non-coding RNAs that represent 
98% of the genome. Non-coding RNAs include transfer and ribosomal RNA, small 
nuclear (snRNA) and nucleolar RNA (snoRNA), small interference RNA (siRNA), 







Figure 1.1 miRNA biogenesis and function. 
 
miRNA biogenesis and function (A) Primary miRNAs are cleaved in the nucleus by 
DROSHA and DGCR8. (B) Once the primary miRNA is cleaved, the nuclear transport 
receptor exportin 5 binds the pre-miRNA to export it to the cytoplasm. (C) Dicer, TRBP 
and PACT convert the pre-miRNA into the mature miRNA. (D) The guide strand is 
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loaded into the RNA-induced silencing complex (RISC). (E) Complementary pairing 
with the seed region to mRNAs determines target binding and guides argonaute 
proteins to stop translation. (F) Deadenylase complexes cause destabilization of the 
transcript and further degradation by RNase activity. 
 
1.7.1 miRNA biogenesis and function 
 
Canonical miRNA biogenesis starts with transcription of the primary miRNA by RNA 
polymerase II and III (Figure 1.A) (49). The sequences for 52% of human miRNAs are 
located in intergenic regions, 40% in intronic regions and 8% are in exons (51). 
Intergenic miRNAs are individually expressed through promoter elements. MiRNAs of 
the same family, that share the seed region and have the same targets, can be situated 
in different chromosomes and expressed in diverse conditions. 
 
Intronic and exonic miRNAs that are clustered within 50 kilobases from each other 
usually have similar expression patterns whilst those spaced further apart tend not to 
(52). Nonetheless, some exemptions exist to this phenomenon and some miRNAs that 
are separated by more than 50 kilobases have been found to be highly correlated, 
which is likely to be a consequence of co-expression (53). The differential localisation 
and expression of miRNAs is likely to be an evolutionary response to environmental 
insults and the required response of specific cell functions. In accordance, the higher 
complexity of the organism, the higher number of miRNAs that are expressed (54–56). 
 
The primary miRNA (Figure 1.A)  is cleaved by a nuclear microprocessor complex 
comprised by the RNase III endoribonuclease DROSHA and its double-stranded RNA-
binding protein DGCR8 –DiGeorge Critical Region 8 (57). Cleavage of the primary 
miRNA by DROSHA/DGCR8 (Figure 1.A) results in a 60 nucleotide stem-loop 
structure with a 3'-overhang, the pre-miRNA (46,57). In addition, another layer of 
complexity exists as the primary miRNA can be subject to RNA editing by ADARs 
(adenosine deaminases acting on RNA) that modify adenosine to inosine producing 




After the primary miRNA is produced, the nuclear transport receptor exportin 5 
specifically recognizes the 3'-overhang end and stem-loop of the pre-miRNA and 
exports it (Figure 1.B) from the nucleus to the cytoplasm (58). In the cytoplasm, the 
RNase III enzyme Dicer and binding partners, TRBP (trans-activation response RNA 
binding protein) and PACT (protein activator of RNA‐activated protein kinase), 
recognize the 3’ overhang and cleave the pre-miRNA into the mature miRNA, 
liberating a nucleotide duplex (approximately 22 nucleotides) with 2 nucleotides 
protruding at the 3’ end (47,49). 
 
Although TRBP and PACT are not essential to this process, they facilitate Dicer-
mediated cleavage by stabilizing it. Unwinding of the duplex leads to the generation of 
2 strands, the guide (3’) and passenger (5’) strands. Most of the effects that are 
attributed to miRNAs are mediated by the 3’ form. In contrast, the 5’ form comprises 
less than 10% of all miRNA reads in humans (58). The guide strand is loaded into the 
RNA-induced silencing complex (RISC) and the passenger strand is degraded by 
RNases. Modifications to the miRNA can also be produced at this step by trimming 
and capping of the mature miRNA and are called isomirs. 
 
In contrast, non-canonical miRNA biogenesis is independent of DROSHA/DGCR8 
processing in the nucleus. If an intron, lacking the sequence of the stem region of a 
primary miRNA and with the appropriate size to generate a pre-miRNA, it can be 
exported to the cytoplasm and further processed as a pre-miRNA and generate a 
mirtron. Alongside mirtrons, other RNA sequences derived from transfer RNA and 
small nucleolar RNA have been found to be loaded into the RISC complex and act as 
miRNAs, for example miRNA-451 (48,49,52). 
 
Either as a result of canonical or non-canonical biogenesis, the miRNA guide strand 
and argonaute proteins (Figure 1.D) form the RISC, a ribonucleoprotein complex that 
mediates mRNA degradation, destabilization or translational inhibition. 
Complementary base pairing of the miRNA seed region (2nd to 8th position on the 5’ 
end) to the mRNA determine target binding and guide argonaute proteins (Figure 1.E) 
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(51). In humans, only argonaute 2 cleaves target mRNAs (52). MiRNA levels are 
dependent on argonautes, and as such down or upregulation of argonaute results in 
diminished or augmented miRNA levels respectively (59). 
 
After the complementary coupling of the miRNA seed region, mRNA can be 
destabilized by deadenylation, degraded by argonaute 2 RNase activity and protein 
translation repressed. Argonaute 2, also called eukaryotic translation initiation factor 
2C, blocks the action of other translation initiator factors and ribosomal subunits. 
Accumulation of untranslated mRNA in the cytoplasm permits argonaute 2 to recruit 
members of the GW182 protein family, enriched in cytoplasmic areas called processing 
bodies, p-bodies (60). 
 
GW182 binding to argonaute 2 at the 3’ untranslated region (UTR) of the targeted 
mRNA permits de-adenylase complexes to have access to the poly(A) tail of the 
mRNA. This leads to de-adenylation, destabilization of the transcript and further 
degradation by RNase activity (61). The final effect on protein or mRNA levels is 
determined by where the miRNA binds to the mRNA sequence as 5 diverse types of 
miRNA binding have been described (47,62). The majority of miRNA effects are 
produced by binding at the 3’ UTR of the mRNA and further processing as described 
previously, non-canonical binding sites represent less than 1% (63). 
 
1.8. miRNAs in dementia 
 
More than 100 miRNAs have been reported to be dysregulated in AD (64). Nonetheless 
that has been considerable inconsistent between studies, likely related to the different 
methods used to measure miRNAs, as well as biomaterials studied given that miRNA 
expression is tissue and cell specific. Other contributing factors to some of the 
consistencies relate to the composition (e.g. diagnoses) and sizes of sample cohorts 
investigated, particularly since miRNAs may contribute to or be subject to the presence 
of comorbidities, which would undermine the statistical power and specificity of 
studies (64,65). Increasing the number of individuals and increasing the specificity of 
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studies might enable better discrimination between the effects of dysregulated 
miRNAs, wherein one may be able to more readily differentiate changes in miRNAs 
between different forms of dementia and in comparison to other neurodegenerative 
disorders. 
 
1.8.1 Technical complexities related to research of miRNAs 
 
MiRNA detection and measurement with high sensitivity and specificity is 
challenging. The target sequence is present in the primary transcript, the precursor and 
the mature miRNA. Furthermore, some miRNAs within the same family differ by just 
a single nucleotide (66,67). MiRNA measurement can be achieved by different methods 
that will be examined in detail in Chapter 4. Notably, despite there is yet no specific 
consensus paper, qRT-PCR has been extensively used and cited as the ‘gold standard’ 
measurement tool in miRNA research. This method is argued to provide reliable 
quantification and specificity using stem-loop primers and is recommended for 
validation of miRNAs found by next generation sequencing (NGS) (66,68). 
Furthermore, qRT-PCR which is relatively economical, can be used in conjunction with 
miRNA binding predicting software (of which a number exist with different scope) 
when unbiased methods are unavailable. 
 
As alluded to, different miRNA binding predicting software programmes exist, but 
with different assumptions and parameters and this can yield different findings. By 
way of example, Zhao et al suggested that TREM2 expression was regulated by miR-
34a using independent bioinformatics algorithms (69). However, when analysed by 
TargetScan and MiRanda miRNA binding predicting software, which examines only 
the 3’ UTR, no binding sites are found. The existence of a site in the rarely used coding 
region of the transcript could not be excluded. Thus, such software, while helpful in 
providing supportive data should not be exclusively used and relied upon in isolation. 
 
Another significant challenge is that miRNAs can target numerous proteins and 
similarly a single protein can be targeted by many miRNAs. Thus it is plausible that 
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only a combination of miRNAs can feasibly produce a relevant physiological response 
and so the effects of miRNAs on their targets should be viewed in the context of a 
whole functional analysis (70). For example, Geekiyanage et al proposed that miR-137 
regulated serine palmitoyltransferase and in turn Aβ in AD (71). However, 
examination of miR-137 according to Target Scan shows that this miRNA has 1305 
predicted target transcripts while the serine palmitoyltransferase is targeted by 18 
miRNAs. Thus, investigation of the total array of target proteins is necessary to 
provide a functional analysis including assessment of overlapping targets between 
miRNAs (70). 
 
An additional important aspect is the probability of a miRNA binding to a 3’ UTR 
mRNA target. Agarwal et al established a scoring system based on 14 features (total 
context score) to permit determination of such a probability, and allows categorization 
of miRNAs into percentiles (63). This score represents the binding affinity of the 
miRNA for the mRNA without considering the number of transcripts or miRNAs. 
Applying this approach to Geekiyanage’s paper and attempting to order the 1305 miR-
137 target transcripts by the total context score, one sees that the targeting of serine 
palmitoyltransferase occupies the 291th position (i.e. in the 78th percentile). In other 
words, miR-137 would have a greater effect on 290 other transcripts thought to have 
higher binding affinities that it, and thus the effects on serine palmitoyltransferase may 
relate to those other transcripts. It has to be acknowledged that the number of genes 
expressed amongst these 1305 candidates will likely vary from tissue to tissue and cell 
type to cell type, so it is conceivable that serine palmitoyltransferase may indeed rank 
higher than the 291st position predicted, yet it also highlights that there is still likely to 
be significant competition between some targets for specific miRNAs. 
 
Finally, the copy number of a miRNA expressed is important. MiR-124 and miR-128 
are examples of highly expressed miRNAs (30,000 – 50,000 copies per neuron), whereas 
other miRNAs have been reported to be very low, e.g. 1 - 2 copies per neuron (52). 
Thus, in addition to the affinity of miRNAs for different target transcripts, the copy 
number is likely to have a modifying effect. It is rarely the case that all of these factors 
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are considered in the numerous studies of miRNAs in dementia to date, and most 
studies have assumed the rationale of single miRNA-protein interaction effect. 
 
I propose a novel approach for the study of miRNAs in dementia considering multiple 
targets, previously reported number of copies of miRNAs, and the affinity for their 
targets in an attempt to overcome proposed caveats in miRNA research, previously 
described. Given that miRNAs are autocrine, paracrine and endocrine molecules 
necessary for physiological processes, I hypothesize that dysregulation of certain 
miRNAs might simultaneously affect different transcripts involved in the development 
of the two most common forms of dementia, AD and VaD. 
 
Based on this approach, in Chapter 3, I have considered 35 gene transcripts suggested 
to be involved in some of the ‘traditional’ neuropathological processes thought to be 
important in the development of dementia. These transcripts were chosen on the basis 
of their participation in one or more of the following AD-related processes: amyloid 
production, transport of amyloid across the blood brain barrier and amyloid degrading 
enzymes, tau phosphorylation, BBB integrity and the glymphatic system. 
 
In Chapter 6, a similar analysis was performed considering multiple transcripts 
involved in processes that are less commonly studied. These include transcripts 
involved in the renin angiotensin system (RAS), as well as vascular dysfunction and 
hypoxia inducible factors. This second analysis was modified in a way looking for 
functional or physiological impact. In this analysis, 164 combinations of overlapping 
targets were examined for miRNAs that were in common, and 14 of which were 
selected on the assumption that they might have a functional impact on the RAS by 
influencing vasoconstriction or vasodilation(45). 
 
For both the first and second analyses, I also propose new approaches towards the 
measurement of these miRNAs and the selection of appropriate calibrators (Chapter 4), 
as well as an exploratory investigation of their presence in a cell culture model 
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(Chapter 7) to test the future viability of this as an experimental model for the future 
study of miRNAs. 
 
While, the approach in this thesis argues the benefits for a broader approach to the 
study of miRNAs, I have also explored the possibility that single miRNA-protein 
relations could exist under certain restricted conditions (Chapter 6). For this analysis, I 
have chosen instances where polymorphisms in single nucleotides exist and have 
reported to increase the risk for dementia. In this regard, I have investigated if these 
variants could have a direct effect on miRNAs (e.g. either by creating or abolishing 
miRNA binding sites), which in turn trigger changes to proteins that could ultimately 
contribute to the pathogenesis of AD. Analysis of data from genome wide association 




















Chapter 2.- Materials and methods 
 
 
2.1 Study cohort 
 
Human post-mortem brain tissue from controls, AD and VaD patients was obtained 
from the Human Tissue Authority (HTA) licensed South West Dementia Brain Bank 
(SWDBB), Southmead Hospital with approval from the local research ethics committee 
(REC reference number 08/H0106/28+5) and was handled according to good laboratory 
practice techniques. The cohort was increased from 66 to 84 cases in the second year of 
this project and is summarised in Table 2.1. 
 
Diagnostic criteria was based on the National Institute on Aging and Reagan Institute 
(NIA-RI) consensus that combine the Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD) score of neuritic plaques and the Braak and Braak (72) 
staging of neurofibrillary tangles (NFTs). The latter was used to distinguish three AD 
categories: I) AD with frequent neuritic plaques (CERAD definite) and abundant 
isocortical NFTs, Braak stage 5 and 6; II) intermediate probability with moderate 
neuritic plaques (CERAD probable) and NFTs in limbic regions, Braak 3 and 4, and III) 
low probability associated with infrequent neuritic plaques (CERAD possible) and 
NFTs restricted to the entorhinal cortex and/or hippocampus, Braak 1 and 2 (5). 
 
The cases were matched where possible for gender, age at death (years) and post-
mortem interval delay (hours – i.e. the time between time of death and the freezing of 
tissue following tissue processing of the brain donation). Cases with a post-mortem 
interval delay of below 48 hours were preferred; however 7 cases are between 48 and 
68 hours. In addition, every effort was made to keep a proportion of cases with and 
without the presence of APOE ε4 allele given its status as a risk factor in AD. However, 
this was more challenging for controls given the normal lower prevalence of APOE ε4 
compared to AD cases. Statistical analysis of the demographic data is included in 
Appendix 1. No statistically significant differences were found with respect to gender 
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or age. A significant difference was found in post-mortem interval delay between 
groups, ANOVA F=3.7 and p=0.01. Post hoc analysis with Tukey’s test showed a 
significant difference between the AD group and controls (p<0.05) and EAC (p<0.05). 
Similarly, a significant difference was found in the proportion of cases with the 
presence of an ApoE4 allele, x2=30.7 and p<0.0001. 
 
Table 2.1 Demographic information of the cohort. 
Diagnosis Gender 
(Male/Female) 
Age (σ) PMI (σ) ApoE4 
(No/Yes) 
Total 
Control 11/13 80 (9.7) 35.4 (16.2) 21/1 24 
Early Alzheimer Changes 11/9 85 (6) 36.5 (15) 14/4 20 
Alzheimer’s Disease 11/11 78 (7.2) 23.7 (13.4) 3/16 22 
Vascular Dementia 9/9 83 (7.9) 34.7 (12.3) 9/4 18 
Total 42/42 81.2 (8.1) 32.5 (15.1) 47/25 84 
Demographic information of the cohort, age in years, post-mortem interval delay (PMI) 
in hours, standard deviation (σ). 
 
2.2 Brain tissue dissection and homogenisation 
 
Post-mortem brain tissue was dissected from frozen brain slices in collaboration with 
Dr. Taya Thomas of SWDBB. 300 mg of the posterior cingulate cortex (Brodmann areas 
23, 31) was dissected from frozen samples using appropriate sterile techniques. The 
brain areas were identified with reference to the corpus callosum and ventricles. Tissue 
was homogenised in a Precellys 24 Homogeniser in 2 separate procedures for isolation 
of RNA and protein. 
 
2.3 RNA isolation, quantification and standardisation 
 
90-100 mg of frozen tissue were collected in 2 mL homogenate tubes and kept on ice 
during the process. MiRvana miRNA isolation kit (AmbionTM AM1560) was then used 
for RNA extraction and isolation. Manufacturer’s instructions were followed and 
precautions were taken against RNAse contamination. Briefly, 900 µl of lysis/binding 
buffer were placed into the 2 mL homogenate tube on ice and 8 ceramic/silica beads 
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(2.3 mm) were added. Tissue was homogenised in a Precellys 24 Homogeniser using 2 
cycles of 15 seconds bursts at 6,000 rpm. After homogenisation, samples were 
centrifuged at 4°C for 15 minutes at 12,470 g. 900 µl of supernatant from the 
homogenate were transferred to another 2 mL homogenate tube and the pellet was 
kept separate. 
 
MiRNA homogenate additive (90 µl) was combined with the supernatant from the 
homogenate, then vortexed and stored on ice for 10 minutes. 900 µl of acid-
phenol:chloroform was added and vortexed for 40 seconds to mix. The mixture was 
centrifuged at room temperature for 15 minutes at 12,470 g to separate the solution and 
the aqueous/upper phase and about 800 µl of the upper phase was transferred to a new 
tube without disturbing the lower phase. 
 
Elution solution and nuclease free water were heated to 95°C to elute the RNA from 
the filter at the end of the procedure. 1 mL of 100% ethanol at room temperature was 
added to the aqueous phase. A filter cartridge was placed into a collection tube 
(included in the kit) and 700 µl of the lysate/ethanol mixture were pipetted onto the 
filter and centrifuged at 7,378 g for 15 seconds. The filtrate was discarded, and the 
procedure repeated with more lysate/ethanol mixture using 700 µl at a time until all 
the lysate/ethanol mixture passed through the filter. 
 
MiRNA wash solution 1 mixed with ethanol (700 µl) was then applied to the filter 
cartridge and centrifuged for 10 seconds at 7,378 g. The filtrate from the collection tube 
was discarded and the filter reinserted into the same tube. 500 µl of the miRNA wash 
solution 2/3 was then applied and drawn through the filter by centrifugation as 
previously. Once completed, a further 500 µl of the miRNA wash solution 2/3 was 
applied, centrifuged, the filter carefully removed to allow the filtrate to be discarded. 
The filter was again replaced into the centrifuged for a final time for 1 minute at 7,378 g 




The filter cartridge was transferred into a new collection tube (supplied with the kit), 
100 µl of pre-heated (95°C) elution solution was applied to the centre of the filter and 
centrifuged for 30 seconds at 7,378 g to recover the RNA. Similarly, 400 µl of pre-
heated RNAse free water (95°C) was applied twice (200 µl each) and centrifuged as 
previously. The filtrate was collected (approximately 500 µl) and stored at -80°C for 
further use. 
 
The RNA isolation procedure was modified for extractions from cell culture. After cells 
were detached and centrifuged, 500 µl of lysis/binding buffer were placed into the 2 
mL homogenate tubes on ice and 8 ceramic/silica beads were added. The cells were 
homogenised and centrifuged as previously described. MiRNA homogenate additive 
(50 µl) was combined with the homogenate, then vortexed and stored on ice for 10 
minutes. 500 µl of acid-phenol:chloroform were added and filtration steps were 
followed as described for brain tissue. 
 
Quant-iT RiboGreen assay (InvitrogenTM R11490) was used for RNA quantification. 
Quant-iT RiboGreen RNA reagent was diluted in a 1:200 proportion. For a 96-well 
plate (Nunc™ F96 MicroWell™ Black Polystyrene Plate 237105) 50 µl of RNA reagent 
was diluted in 9,950 µl of RNAse free water (working solution A). To prepare the 
working solution B, 1 mL of 20X Tris EDTA (TE) buffer (200 mM Tris-HCl, 20 mM 
EDTA, pH 7.5 in DEPC-treated water) was diluted in 19 mL of RNAse free water to 
obtain a 1:20 dilution. 
 
For the standard, ribosomal RNA standard was diluted in working solution B at 
different concentrations, the first measurement was based on a 10-fold serial dilution 
over 4 standards, i.e. 1000, 100, 10 and 1 ng/mL. Given the variability of low 
concentrations (1 and 10 ng/mL) over different plates, an extra standard was included 





Samples were prepared in triplicate at a 1:100 dilution at first instance i.e. 1 µl of RNA 
concentrate in 99 µl of RNAse free water. Similarly, the measurements were not 
reproducible and were highly variable across the initial plates. Thus, 5 µl of the RNA 
concentrate was diluted in 995 µl of RNAse free water and then different dilutions for 
RNA quantification were used to compare the reproducibility of the measurements 
1:200, 1:100, 1:66.66 and 1:50. The latter two dilutions showed a coefficient of variability 
between replicates within a plate of 2.1% (σ=1.6) and the variability between plates 
using standards and sample repeats across all the plates was 2.9% (σ=1.8). 
Homogenate samples were therefore diluted 1:66 and 1:50 in RNAse free water on a 96 
well plate in triplicate, blanks were comprised of 100 µl of working solution B and 
standards were diluted as described in working solution B. 100 µl of working solution 
A was added to each well (samples, blanks and standards) and absorbance was read on 
a multi-detection plate reader (FLUOstar Optima, BMG Labtech). The absorbance of 
the standard and samples was measured compared to the blank at 485 nm excitation 
and 520 nm emission. RNA concentration was determined by the following formula 










All samples were standardised to a concentration of 400 ng/mL ± 10% in order to 
ensure 10 ng of RNA was present in 5 µl as recommended for the qRT-PCR test. The 
amount of RNA needed to reach a 400 ng/mL concentration was calculated according 
to this formula: 
 
𝑅𝑁𝐴 𝑡𝑜 𝑎𝑑𝑑 (µ𝑙) =  
(𝑅𝑁𝐴 𝑎𝑑𝑑𝑒𝑑 µ𝑙)(400 𝑛𝑔/𝑚𝐿)
𝑅𝑁𝐴 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑛𝑔/𝑚𝐿)
 −  𝑅𝑁𝐴 𝑎𝑑𝑑𝑒𝑑 (µ𝑙) 
 
Once the RNA was added, all samples were again quantified, and the process was 
repeated until all samples were at a concentration of 400 ng/mL ± 10%. Where the RNA 
concentration increased more than calculated, RNAse free water was added and 
quantification was re-done until the appropriate concentration was obtained. 
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2.4 Homogenates and protein quantification 
 
100 mg ± 10% of tissue were collected in 2 mL homogenate tubes and kept on ice 
during the process. Lysis buffer was prepared beforehand as follows: 0.1 M of NaCl, 
0.01 M Tris-HCl pH 7.6, 1 µg/mL aprotinin (Sigma A6279), 10% SDS, 1 µM PMSF 
(Sigma 93482) and 43.42 ml of dH2O. Proteinase inhibitors (aprotinin and PMSF) were 
added to the lysis buffer immediately before use and the buffer was added within 30 
minutes. 1 mL of lysis buffer and 6 silica beads (2.3 mm) were added and the brain 
tissue was homogenised in a Precellys 24 Homogeniser using 2 cycles of 15 second 
bursts at 6,000 rpm. After homogenisation, samples were centrifuged at 4°C for 15 
minutes at 12,470 g and the supernatant was separated and stored at -80°C. 
 
Protein quantification was performed using a Coomasie protein assay kit 
(ThermoFisher 23200). All samples were diluted in a 1:20 proportion in 0.85% NaCl 
prior to protein quantification. Standards were made using bovine serum albumin and 
diluted at 9 different concentrations for the standard curve: 2 mg/mL, 1.5 mg/mL, 1 
mg/mL, 0.75 mg/mL, 0.5 mg/mL, 0.25 mg/mL, 0.125 mg/mL, 0.025 mg/mL. From each 
diluted sample and standard, 5 µL were loaded into the plate in triplicate. Then, 250 
µL of Coomasie reagent were added to all wells and the plate was read for absorbance 
on a multi-detection plate reader (Fluostar Optima, BMG Labtech) at 595 nm. Total 
protein was obtained by extrapolating data from the standard curve and then 
multiplied by the dilution factor of 20. 
 
2.5 Simulation of postmortem delay 
 
Previously dissected tissue was sourced from two human brain donations with the 
lowest post-mortem delay (5 hours) were selected, one with a definite diagnosis of AD 
and the other a non-demented control. From the already dissected tissue, 12 aliquots of 
5 mg were taken for assessment of simulated post mortem delay on RNA. Individual 
aliquots were incubated for 0, 6, 12, 24, 48 or 72 hours at room temperature and at 4°C 
(intended to simulate with the average time window in which most brain donations 
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are received post-mortem). After incubation, samples were stored at -80°C. For 
experimentation, samples were retrieved; 5 mg samples were used for RNA isolation, 
quantification and standardisation. 
 
2.6 Quantitative real time polymerase chain reaction 
 
Quantitative real time polymerase chain reaction (qRT-PCR) was performed using 
TaqMan® microRNA assays. First, cDNA was reverse transcribed from total RNA 
samples using specific miRNA primers (stem-looped reverse transcriptase primers). 
PCR products were then amplified from cDNA samples and CT (cycle threshold) 
values established (i.e. the number of cycles required for the signal to cross the 
threshold for detection). This allows quantitative determination of the number of initial 
DNA molecules by use of a standard curve of absolute concentration. Each cycle 
represents a 2-fold change in expression. 
 
First the reverse transcription (RT) reaction was performed to generate cDNA. Each 15 
µl RT reaction assay consisted of 7 µl of master mix, 3 µl of RT primer and 5 µl of RNA 
(10 ng). First, in a 500 µl polypropylene tube the master mix was prepared as follows: 
 
Table 2.2 Constituents of the reverse transcription reaction assay. 
Component Master mix volume 
(µl) 
Volume 24 reactions + 
10% (µl) 
Nuclease free water 4.16 109.8 
10 X RT buffer 1.5 39.6 
RNase inhibitor (20 U/µl) 0.19 5 
dNTP mix (100 mM total) 0.15 3.96 
Multiscribe RT enzyme (50 U/µl) 1 26.4 
Total 7 µl 184.8 µl 
 
The master mix was centrifuged briefly without exceeding 295 g or 5 minutes as 
recommended by manufacturer. Eppendorf® PCR tubes (Sigma Z316121) were 
labelled and 7 µl of master mix was mixed with 5 µl of RNA. 3 µl of RT primer from 
each assay (8 assays) was transferred into the corresponding tubes as described. 
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Figure 2. 1 Example layout of qRT-PCR plates. 
 
Example layout of qRT-PCR plates, miRNAs included are just examples of the 27 
miRNAs investigated in this project. 
 
Tubes were incubated on ice for at least 5 minutes. Using 9,600 emulation mode, the 
thermal cycler was programmed to hold steps of 30 minutes at 16°C, followed by 30 
minutes at 42°C, 5 minutes at 85°C and finishing at 4°C. The reaction volume was set to 
15 µl in the thermal cycler, tubes were loaded and the program was run. 
 
For the PCR amplification step of the qRT-PCR, individual reactions were prepared for 
32 polypropylene tubes on ice (8 assays for each of 3 cases and a blank-negative 
control). Volumes were scaled according to the following proportions and number of 
PCR reactions on a plate. 
 





Nuclease-free water 7.67 25.31 
TaqMan 2X Universal PCR master mix, No AmpErase 10 33 
TaqMan microRNA assay (20X) 1 3.3 
Product from RT reaction (minimum 1:15 dilution) 1.33 4.39 
Total 20 µl 66 µl 
 
For all 32 reactions, a total volume of 683.39 µl nuclease free water was transferred into 
a tube with 891 µl of TaqMan 2X Universal PCR master mix, No AmpErase Uracil-
DNA glycosylase (UNG) (Applied Biosystems™ 4326614) were added, mixed and 
centrifuged. From the PCR master mix/water mixture, 58.3 µl was added into each of 
the 32 polypropylene tubes. 3.3 µl of each TaqMan microRNA assay was added into 
the corresponding tube as previously described. Subsequently, 4.4 µl of the RT product 
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was combined with the master mix and microRNA assay into the corresponding tube 
and RNAse free water for the blanks. A few samples were assayed in a higher dilution 
(1:20) but the CT values for miR-132 and miR-212 were higher than the recommended 
36 cycles and thus not appropriate for analysis. Therefore, the minimum dilution (as 
recommended by manufacturer) of 1:15 was used. 
 
Once all of the components for the PCR amplification were combined and mixed, a 
Fast Optical 96-Well Reaction Plate of 0.1 mL (Applied Biosystems™ 4346907) was 
prepared by dispensing 20 µl of the complete PCR mix into each of the wells. The plate 
was sealed with an optical adhesive cover and centrifuged briefly to spin down the 
content and eliminate air bubbles. 
 
On a Viia7 PCR machine (Applied Biosystems™), the PCR plate was read using the 
following parameters: 
 
Table 2. 4 PCR program used. 
Parameter Value 
Run mode 9600 emulation (Default) 




Step AmpliTaq Gold 
enzyme activation 
PCR 
Cycle (40 cycles) 
HOLD Denature Anneal/extend 
Time 10 min 15 sec 60 sec 
Temp (˚C) 95 ˚C 95 ˚C 60 ˚C 
Auto increment 
settings 
Accept default values (Default is 0) 
Ramp rate 
settings 
Accept default values (Default is Standard) 




Results from the Viia7 PCR machine were exported to Microsoft Excel and CT values 
were analysed to calculate variability within triplicates and to select samples to be 
repeated. Samples were repeated when the standard deviation of triplicates was higher 
than 0.1. In addition, given the similar sequence of some miRNAs assayed the 
specificity of the miRNA probes was also confirmed by interchanging probes for 
different amplimers (e.g. miR-29a quencher dye used with miR-29b RT products and 
vice versa) where no amplification would be expected. 
 












miR-9-5p 000583 UCUUUGGUUAUCUAGCUGUAUGA 
miR-9-3p 002231 AUAAAGCUAGAUAACCGAAAGU 
miR-15a-5p 000389 UAGCAGCACAUAAUGGUUUGUG 
miR-15b-5p 000390 UAGCAGCACAUCAUGGUUUACA 
miR-16-5p 000391 UAGCAGCACGUAAAUAUUGGCG 
miR-195-5p 000494 UAGCAGCACAGAAAUAUUGGC 
miR-424-5p 000604 CAGCAGCAAUUCAUGUUUUGAA 
miR-497-5p 001043 CAGCAGCACACUGUGGUUUGU 
miR-29a-3p 002112 UAGCACCAUCUGAAAUCGGUUA 
miR-29b-3p 000413 UAGCACCAUUUGAAAUCAGUGUU 
miR-29c-3p 000587 UAGCACCAUUUGAAAUCGGUUA 
miR-34a-5p 000426 UGGCAGUGUCUUAGCUGGUUGU 
miR-34b-5p 000427 UAGGCAGUGUCAUUAGCUGAUUG 
miR-34c-5p 000428 AGGCAGUGUAGUUAGCUGAUUGC 
miR-449-5p 001030 UGGCAGUGUAUUGUUAGCUGGU 
miR-125a-5p 002198 UCCCUGAGACCCUUUAACCUGUGA 
miR-125b-5p 000449 UCCCUGAGACCCUAACUUGUGA 
miR-132-3p 000457 UAACAGUCUACAGCCAUGGUCG 
miR-212-3p 000515 UAACAGUCUCCAGUCACGGCC 
miR-17-5p 002308 CAAAGUGCUUACAGUGCAGGUAG 
miR-20a-5p 000580 UAAAGUGCUUAUAGUGCAGGUAG 
miR-20b-5p 001014 CAAAGUGCUCAUAGUGCAGGUAG 
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miR-93-5p 001090 CAAAGUGCUGUUCGUGCAGGUAG 
miR-106a-5p 002169 AAAAGUGCUUACAGUGCAGGUAG 
miR-106b-5p 000442 UAAAGUGCUGACAGUGCAGAU 
 
2.7 Analysis of qPCR using the 2(-ΔΔCT) method 
 
The analytical method represents the relative quantity or fold-change of an expression 
target (in this case target miRNAs) in cases compared to a control, and normalised to a 
calibrator (i.e. a reference standard marker that is ordinarily thought to not be affected 
by disease pathology). The average CT of triplicate reactions was obtained for miRNAs 
of interest and calibrators. 
 
First, the delta CT (ΔCT) value was obtained by subtracting the mean CT of the 
calibrator from the mean CT of the miRNA of interest. Then, the delta delta CT (ΔΔCT) 
value was calculated with respect to controls, ΔCT of sample minus ΔCT of controls. 
The fold change in the expression was calculated as 2(-ΔΔCT) (73). 
 
Although this method has been widely used, its creators acknowledged in a 
subsequent paper that it is not appropriate to use when using patient samples, as 
compared to experimental treated versus untreated samples (74). In addition, given 
that the fold change is the result of an exponential equation, 2 to the power of –ΔΔCT 
(i.e. 2-ΔΔCT), any value higher than one would increase to infinity and in contrast, any 
value lower than one would never decrease below zero, therefore it would affect its 
comparison to the control represented as one. 
 
To validate the statement that any value higher than one would increase towards 
infinity and in contrast, any value lower than one would never decrease below zero, all 











For example, 2 points were selected (blue arrows), both with a ΔΔCT of ±2. Given that 
one cycle of PCR represents a 2-fold change, both of them should represent a 4-fold 
change, which is not what the 2-ΔΔCT value shows. This exponential equation produces a 
multiplicative effect rather than an additive effect. 
 
A new method using absolute values is proposed, referred as Delta (Δ) and 
represented as percentage of difference. By using absolute values, higher and lower 
values than zero will be exponentially elevated in a similar way (Figure 2.3). However, 
relative quantities of 2 and 0.5 (original 2(-ΔΔCT)) would be expressed as +2 rather than +2 
and -2. Thus, relative quantity was multiplied by its original symbol (+/-). Then, the 
percentage of difference with respect to -1 or +1 (2(-ΔΔCT) of zero) was calculated. 
 
 
Delta = (2|(CTis−CTrs)−(CTic−CTrc)| − 1) (−
(CTis − CTrs) − (CTic − CTrc)










Δ = Delta (percentage of difference) 
CTic = Cycle threshold of interest in controls 
CTrc = Cycle threshold of reference in controls 
CTis = Cycle threshold of interest in samples 
CTrs = Cycle threshold of reference in samples 
 
Figure 2. 3 Resulting values using the new formula termed Δ. 
A) B)  
Resulting values using the new formula termed Δ. By using absolute values, values 
higher and lower than zero are proportional but it creates a disjunction from -1 to +1 
(A). By subtracting 1 and presenting the data as a percentage of difference, results are 
continuous with no points of inflection or disjunction (B). 
 
Furthermore, a new formula is proposed to replace the use of geometric mean when 
calculating the reference CT from different calibrator genes. Vandesompele et al 
proposed the use of the geometric mean of calibrator genes for normalization of PCR 
results (75). However, the geometric mean does not consider some principles of PCR. 
First, the geometric mean does not consider that values derived from PCR are based on 
log2. Second, CT values obtained from PCR should be interpreted in an inverse 
manner, i.e. high values represent low quantities and vice versa. When using the 
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geometric mean, high values will have a contrary effect on the result of the geometric 
mean. The geometric mean might be applicable when a high number of CT values are 
used, however when using a few of them, high values can affect the result. The 
formula of geometric mean and a new formula are presented. 
 
𝐺𝑒𝑜𝑚𝑒𝑡𝑟𝑖𝑐 𝑚𝑒𝑎𝑛 =  √𝑎1𝑎2𝑎3 … 𝑎𝑛
𝑛  
 
A formula is proposed considering the logarithmical base of the PCR method and the 
total cycles of the reaction. 
 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑇 𝑜𝑓 𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑜𝑟 𝑔𝑒𝑛𝑒𝑠 = 40 − log2 (






CT= Cycle threshold of calibrator genes 
n = Number of calibrator genes 
 
 
2.8 miRNA repositories (miRbase, mirgeneDB and miRbase tracker) 
 
Training was undertaken at the European Bioinformatics Institute with respect to data 
repositories available for research into miRNAs. Since miRNAs are still an emerging 
field, with hundreds still being discovered, it is therefore necessary to distinguish 
between authentic miRNA sequences from short RNA sequences, which are likely to 
be products of RNA degradation. Different online repositories exist to capture 
information on miRNA and each focuses on specific criteria. MiRbase and mirgeneDB 
were used in this project as the chosen miRNA repositories, whilst miRbase tracker 
was used for comparison and tracking of changes in miRNA nomenclature and 




MiRbase (http://www.mirbase.org) is a widely used resource for miRNA cataloguing 
and nomenclature. It allows browsing and searching of miRNA sequences. In order to 
be recognized as a high confidence miRNA, a locus must meet the following criteria 
(76): 
1. At least 10 reads must map to the two mature miRNAs derived from their 
precursor with no mismatches. 
2. The most abundant reads must match the miRNA duplex with 0–4 nucleotides 
overhanging at the 3′ end. 
3. At least 50% of reads of both mature miRNAs must have the same 5′ end. 
4. The predicted hairpin structure (miRNA precursor) must have a folding free 
energy of <−0.2 kcal/mol/nt. 
5. At least 60% of the bases in the mature sequences must be paired in the 
predicted hairpin structure. 
 
Some changes have been made to these criteria over time. For instance, the first criteria 
in 2003 required a miRNA gene to be phylogenetically conserved; now it is known that 
different organisms present a wide range of miRNAs. However, only 20% of human 
miRNAs passed all these criteria when it was formulated in 2014. 
 
Fromm et al (77) developed mirgeneDB (http://mirgenedb.org/) with different criteria 
for inclusion of bona fide miRNAs. Like miRbase, mirgeneDB allows browsing and 
searching of miRNAs but also includes the option to search for seed regions of 
miRNAs. To be recognized as a high confidence miRNA by mirgeneDB, a locus must 
meet the following criteria: 
1. An RNA stem-loop consisting of two mature miRNAs with a median length of 
22–23 nucleotides (range size from 20 - 26 nucleotides). 
2. Complementary base pairing of both mature miRNAs in at least 16 nucleotides 
separated by a single-stranded loop of 8-40 nucleotides. 
 
An average precursor miRNA forms a 22–23-nt duplex with 2-nucleotide offsets, a loop 
of 16-nucleotides in average and complementarity between the two mature miRNAs. 
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Although Fromm et al suggested that utilization of miRbase is problematic for both 
functional and evolutionary studies; both repositories were used. 
 
Finally, miRbase tracker (http://www.mirbasetracker.org/) was used for tracking of 
changes made to miRNA annotation and as a comparative point for both repositories. 
miRbasetracker allows search of historical and current miRNA annotation in miRbase. 
 
2.9 Genomic mapping (RNA central) 
 
The online resource RNA central (https://rnacentral.org/) from the European 
Bioinformatics Institute and the Genome Browser (https://genome.ucsc.edu/) from the 
University of California Santa Cruz were used for verification of miRNA sequences, 
validation of binding sites and corroboration of single nucleotide polymorphisms (SNP 
rs6857 in Chapter 6). RNA central is a collection of 28 databases of non-coding RNA 
sequences, thus allowing a search and browse of RNA sequences and mapping to their 
genome localization. 
 
2.10 miRNA-target predicting software 
 
TargetScan (www.targetscan.org) and miRanda (www.microrna.org) are software that 
allow users to obtain predicted miRNAs binding at those transcripts and miRNAs with 
the highest number of overlapping transcripts were included. Official international 
gene symbol of transcripts and miRbase nomenclature of miRNAs are used in this 
thesis. miRNA selection was performed in 2 different approaches that are described in 
more detail in Chapters 3 and 6. 
 
2.11 GWAS Catalog NHGRI-EBI 
 
GWAS Catalog National Human Genome Research Institute (NHGRI) Catalog of 
Published Genome-Wide Association Studies (GWAS) European Molecular Biology 
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Laboratory-European Bioinformatics Institute (EMBL-EBI) (NHGRI-EBI). Training was 
undertaken from online courses from the European Bioinformatics Institute. The 
GWAS catalogue is a publicly available, manually curated resource of published 
GWAS and association results (7). For inclusion in the catalogue, studies and 
associations must meet certain criteria. Studies must include an array-based GWAS 
and analysis of >100 000 single nucleotide polymorphisms (SNPs) with genome-wide 
coverage and SNP-trait associations must have a p-value <1×10−5. The database was 
retrieved using the words ‘‘Alzheimer’’, ‘‘Alzheimer’s disease’’, ‘‘Alzheimer’s’’, 
‘’vascular dementia’’ and ‘‘vascular cognitive impairment’’. Initially, all SNP’s reported 
were scrutinised, however, given the constraints on time, it was decided that there 
should be a concentration on 3’UTRs. 
 
2.12 R software 
 
Training was undertaken from an introductory course on R at the University of Bristol 
and subsequently using online courses from Johns Hopkins University. R is a free 
software and computational language developed for statistical computing and 
graphics. It also allows other functions such as data handling and storage, a set of 
operators for calculations, tools for data analysis, graphical facilities for data analysis 
and display, and programming language. 
 
2.13 Software for analysis of target proteins (DAVID and PANTHER) 
 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) 
software (www.david.ncifcrf.gov/) version 6.8 was used for analysis of predicted target 
proteins of the selected miRNAs. This most recent version of DAVID software 
provides a comprehensive set of functional annotation tools to enable the 
understanding of the biological function behind a large list of genes. It facilitates 
discovery of enriched functional-related gene groups, by making clusters redundant 
annotation terms and correlating with gene ontology or BioCarta & Kyoto 
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Encyclopedia of Genes and Genomes (KEGG) pathway maps (78). Disease, gene 
ontology and pathways were considered for analysis. 
 
Use of DAVID software in this study was carried out by initially uploading a list of 
predicted targets using the official internationally agreed gene symbol nomenclature 
for each target gene. The background was selected to be exclusive for genes specific for 
Homo sapiens. DAVID uses 5 predefined levels of stringency (lowest, low, medium, 
high and highest) for user selection. The default setting is medium; which was changed 
to the highest in this work. A higher level specificity (high stringency) is recommended 
for tight, clean and reduced number of clusters. For wider scope and larger number of 
clusters stringency can be lowered. 
 
The Protein ANalysis THrough Evolutionary Relationships (PANTHER) software 
(www.pantherdb.org/) allows to analyse gene lists combining gene function, ontology, 
pathways and statistical analysis tools. The last version of PANTHER (v. 14) includes 
enrichment analysis using pathway classifications similar to KEGG pathway maps 
used in DAVID software (79). 
 
Similar to DAVID software, lists of predicted target genes were uploaded using their 
official gene symbols, with selection of organism as Homo sapiens. Analysis was then 
performed using statistical overrepresentation test with PANTHER pathways, Fisher’s 
exact test and Bonferroni correction for multiple testing. 
 
2.14 Western blotting 
 
Western blotting was used for measurement of the proteins RORA (retinoic acid 
related orphan receptor alpha) and MAP2 (microtubule associated protein 2) covered 
in Chapter 3 and 5. Running buffer and sample buffer were prepared beforehand. A 
dilution of 50 ml of 10x running buffer (30.3 g 0.25M Tris Base, 144 g 1.92M glycine, 900 
ml distilled water and 10 g sodium dodecylsulfate (SDS)) was diluted in 450 ml of 
distilled water. Samples from homogenates were prepared with a concentration of 30 
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µg total protein per well and were incubated at 95°C for 5 minutes. Recombinant 
proteins for MAP2 and RORA were prepared at concentrations of 10, 1, 0.1 and 0.01 ng. 
 
A Bio-Rad gel was assembled (4-20% Mini-PROTEAN TGX Gel, 10 well, 8.6 x 6.7 cm) 
for sample loading at 150V for 1 hour. After electrophoresis was complete, the gel was 
removed from the assembled cassette and placed into blotting buffer prepared as 
follows: 200 ml methanol, 700 ml distilled water and 100 ml of 10x blotting buffer (30.3 
g 0.25M Tris Base, 144 g 1.92M glycine, 1 L distilled water) for 10-20 minutes prior to 
blot assembly. Concurrently, a nitrocellulose membrane (8.6 x 6.7 cm) and 2 filter 
papers (10 x 7.5 cm) were cut and soaked in blotting buffer for 15-20 minutes. 
 
The gel sandwich cassette was assembled in the following order starting at the black 
side of the cassette: pre-wetted fibre pad, a filter paper on the base of the cassette, 
followed by the gel and nitrocellulose membrane, then a second filter paper and finally 
a second fibre pad at the clear side of the cassette. Any air bubbles between the layers 
were removed with a roller. Once the cassette was assembled, it was closed and placed 
into the tank with an ice pack, magnetic stir bar and the tank was filled with blotting 
buffer (as described above). The tank assembly was placed on a magnetic stirrer and 
connected to a power supply to blot for 1 hour at 100V. After transfer, the cassette was 
disassembled, and the membrane was placed in Tris-buffered saline with 0.05% Tween 
20 (TTBS). 
 
The membrane was blocked in blocking buffer (10% milk powder in TTBS) for 1 hour 
at room temperature prior to antibody incubation, the membrane was subsequently 
washed 3 times for 10 minutes in TTBS at room temperature. Antibody buffer was 
prepared using 5% milk powder in TTBS and antibodies were diluted in this at the 
concentrations shown in Table 2.6. The membrane was incubated with the antibody, 






Table 2. 6 Antibodies, requisition ID’s, concentration and dilutions used. 
Antibody Concentration Dilutions 
Monoclonal mouse antibody IgG2A to human 
ROR alpha (RORA) 





Polyclonal rabbit antibody to human RORA 
Abcam Cat no. ab70061 
1 µg/µL 1:500 
Monoclonal mouse antibody [MT-08] to 
(cow/human) MAP2 
Abcam Cat no. ab118898 
1 µg/µL 1:2000 
Monoclonal mouse antibody to purified 
recombinant fragment of human MAP2 (AA: 
24-123) expressed in E. Coli 
Novus Bio Cat no. NBP2-37734 
1 µg/µL 1:500 
 
The following day, the membrane was washed and incubated with a secondary 
antibody (anti-rabbit IgG–Peroxidase antibody produced in goat (Sigma Aldrich, 
A0545-1 mL)) at a concentration of 1:5000 and incubated for 1 hour at room 
temperature on shaker. After incubation the membrane was washed 6 times for 10 
minutes each in TTBS at room temperature on shaker. 
 
The membrane was incubated in Immobilon chemiluminescence horse radish 
peroxidase (HRP) substrate (Millipore, WBKL30500), a mixture of equal volumes of 
luminol reagent and peroxide solution in a clean container for 5 minutes. Finally, the 
membrane was placed in ChemiDoc XRS+ machine (BioRad) and an image of the 







2.15 Cell culture 
 
Cell culture work is undertaken in Chapter 7 to evaluate the suitability of cell culture 
for the study of miRNAs in dementia. Protocols for handling, subculture routine and 
culture media were obtained from the European Collection of Authenticated Cell 
Cultures (ECACC), a Culture Collection of Public Health England (PHE). Training was 
supervised by Mrs. Saranna Chipper-Keating (Translational Health Sciences, 
University of Bristol). Frozen SH-SY5Y cells were (ECACC 94030304) at passage 12 and 
were resuscitated in a water bath for 1 minute at 37°C until thawed. 
 
Culture medium was prepared beforehand as follows, Ham's F12 (Sigma-Aldrich® 
N4888) : Eagle’s Minimum Essential Medium (MEM) (Sigma-Aldrich® M2279) (1:1) 
plus 2mM Glutamine (Sigma-Aldrich® G7513), 1% Non Essential Amino Acids 
(NEAA) (Sigma-Aldrich® M7145) and 15% Foetal Bovine Serum (FBS) (Gibco® 
A31608-01). Resuscitated cells were incorporated into 5 ml of prepared culture medium 
and resuspended. A further 5 ml of culture medium were added to the resuspended 
cells in the solution and placed into a 75 cm2 cell culture flask (Sigma-Aldrich® 
CLS3290) in the incubator at 37°C and 5% CO2. 
 
Subculture was performed at a confluency of 70-80% and cells were detached using 
trypsin-ethylenediaminetetraacetic acid (EDTA) (Lonza® CC-5012) and re-seeded at a 
concentration of 1,000 - 10,000 cells/cm2. Once the first flask reached the determined 
confluency, 2 further flasks were seeded from this, and the rest of the cells were stored 
in -150 °C freezer in aliquots using DMSO (Sigma-Aldrich® D2650). Aliquots were 
labelled with the number of cells, passage, cell line and date of storage. 
 
Cell counting was performed using a haemocytometer and 0.4% trypan blue stain in 
PBS. 100 µl of resuspended cells were combined with 100 µl of trypan blue (Sigma 
T8154 0.4%). An inverted microscope was used to observe and count cells, live cells 




Retinoic acid (Sigma-Aldrich® R2625) was used at a concentration of 10 µM in culture 
media prepared with 98% Neurobasal® medium (Gibco® 21103-049) and 2% B27® 
supplement (Gibco® 17504-044). Treatment with retinoic acid was for 9 days with a 
change of medium on days 1, 4 and 7. Both treated and untreated cells were harvested 
at day 10. The number of samples considered for analysis are six samples for untreated 
cells and six samples for treated cells. 
 
2.16 Statistical package Graph Pad Prism 
 
Data was analysed with GraphPad Prism software version 5 for descriptive statistics 
(Shapiro Wilk and D'Agostino & Pearson omnibus normality tests) and based on the 
characteristics of the variables, unpaired t test and Mann-Whitney tests were 
performed for comparison of two groups and ANOVA and Kruskal Wallis for more 
than two groups. Correction for multiple testing was performed exclusively for 

























MiRNAs are posttranscriptional regulators of gene expression by repressing protein 
synthesis. Changes in several proteins have been implicated in the development of AD. 
Thus, proteins involved in processes relevant in AD pathology and their associated 
miRNAs are a primary research question in this project. miRNAs are able to target 
hundreds of proteins. This property can be used as an advantage in such a way that as 
increasing the number of proteins, miRNAs in common would be restricted. In other 
words, the number of miRNAs in common for a set of proteins will be lower than the 
number of miRNAs of each protein within the set. 
 
In this Chapter, an investigation of miRNAs associated with 35 proteins (see Table 3.1) 
that have been proposed to be relevant in dementia are presented. The proteins 
described are mentioned in relation to biochemical processes they are linked to and 
with their corresponding gene name. 
 
3.1. Alzheimer’s disease-related proteins and their associated miRNAs 
 
3.1.1. Amyloid and its production 
 
Amyloid plaques and cerebral amyloid angiopathy (CAA) are caused by deposits of 
two isoforms of amyloid beta (Aβ) of different lengths (Aβ42 and Aβ40 respectively). 
Cleavage and processing of the amyloid precursor peptide (APP) can be performed 
either by α-secretase or by β-secretase (BACE), resulting in the secretion of two large 
soluble ectodomains, APPsα and APPsβ, respectively. α‐secretases are members of the 
ADAM (A Disintegrin And Metalloprotease) family, including ADAM9, ADAM10 
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(Table 3.1) and ADAM17. Reduced levels of APPsα and ADAM10 in cerebrospinal 
fluid (CSF) are characteristic of AD (80). Similarly, β-secretase is comprised of either 
BACE1 or BACE2 (included in Table 3.1) which cleave APP to yield the precursor to 
Aβ peptide formation as part of the amyloidogenic pathway (80). 
 
The production of APPsα is part of a non-amyloidogenic pathway, with growth 
promoting and neurotrophic properties. APPsβ is thought to have opposing effects, 
and subsequent cleavage of APPsβ by ɣ-secretase results in the production of Aβ, p3, 
and the APP intracellular domain (AICD) (80). ɣ-secretase is a complex composed by 
four different proteins, presenilin PSEN1 (included in Table 3.1) or PSEN2, nicastrin, 
APH-1 (anterior pharynx-defective phenotype) and PEN-2 (presenilin enhancer) (39). 
The site of cleavage on APPsβ by ɣ-secretase determines the length of resultant 
neurotoxic Aβ isoforms to complete the amyloidogenic pathway (19). 
 
Presenilins are also important for development, differentiation of immune cells, 
intestinal goblet cells, and others by regulating Notch signalling (39). Some studies 
have shown that mutations in Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2), which 
cause familial AD, can reduce Notch signalling (81). However, other studies have 
found that Notch1 expression is increased in sporadic AD (81). Dysregulation of 
Notch1 might play a role in AD (NOTCH1 is included in Table 3.1) (81). 
 
3.1.2. ApoE, ApoE receptors and lipidation of Aβ 
 
Aβ metabolism is greatly influenced by apolipoprotein E (ApoE) (82). ApoE is a 
component of lipoprotein particles acting as a ligand in receptor-mediated endocytosis 
of lipoprotein particles, thus supporting lipid transport and injury repair in the brain.  
The gene that encodes for ApoE (APOE) has polymorphic alleles (ɛ2, ɛ3 and ɛ4) that 
give rise to the ApoE isoforms ɛ2, ɛ3 and ɛ4 respectively. APOE ɛ4 is the greatest 
genetic risk factor for development of sporadic AD and VaD and will be covered in 
Chapter 6. The presence of the ApoE ɛ4 allele is also linked with increased risk of CAA 
and age-related cognitive decline in normal ageing (40). 
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ApoE is expressed throughout different organs in the body with a higher expression in 
the liver and the brain, mainly in astrocytes and to some extent in microglia (40,83), 
where ApoE is the most abundant lipoprotein and where it is secreted by astrocytes in 
high density lipoprotein (HDL) molecules (82). A related protein that works in 
conjunction with ApoE is the ATP Binding Cassette 1 protein (ABCA1 – Table 3.1). This 
is a cholesterol transporter protein that mediates the transport of phospholipids, 
cholesterol and is involved in the biogenesis of HDL (84). 
 
Once produced by astrocytes, ApoE is lipidated by ABCA1 to form lipoprotein 
particles that promotes the binding of soluble Aβ in an allele-dependent manner and 
also in relation to lipidated levels of ApoE. ApoE E2 has the highest Aβ-binding 
efficiency, followed by E3 and lastly by E4. ApoE lipidation also appears to influence 
Aβ transport and Aβ plaque formation. When APP transgenic mice were crossed with 
ABCA1 knockout mice, ApoE lipidation was decreased whilst amyloid deposition was 
increased (83). 
 
ApoE is endocytosed into different cell types within the brain and by various members 
of the low density lipoprotein (LDL) receptor family, including LDLR, SORL1 and 
LRP1 (Table 3.1) (83). The low density lipoprotein receptor (LDLR) is a cell surface 
receptor that controls the amount of ApoE in the brain but may also be important in 
relation to Aβ. Basak et al found that overexpression of LDLR in cell cultured primary 
astrocytes enabled Aβ transport into lysosomes and increased intracellular Aβ 
degradation whereas deletion of LDLR caused a decrease in Aβ uptake (85). 
 
Another ApoE receptor is the Sortilin Related Receptor 1 (SORL1 – Table 3.1) is a 
neuronal endocytic receptor of ApoE, which also mediates cellular uptake of Aβ in an 
ApoE isoform dependant manner (86). SORL1 also participates in the processing and 
trafficking of APP; retaining it to prevent Aβ production. Notably SORL1 and APP are 
expressed in nearly equimolar ratio (83). SORL1 levels have been found to be 
significantly decreased in AD brain with a positive correlation with Aβ accumulation 
(87). In agreement with this, a knockout mouse model for SORL1 showed higher 
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concentrations of Aβ (83). Inherited variants of SORL1 have been associated with a 
higher risk to develop AD (83). Shen et al investigated the effects of genetic variants of 
APOE and SORL1 on hippocampal resting-state functional connectivity (88). APOE ε4 
patients had decreased hippocampal connectivity with the precuneus/posterior 
cingulate cortex and subgenual anterior cingulate cortex. Risk associated G-allele 
carriers of SORL1 showed decreased connectivity between the hippocampus and 
middle temporal gyrus (88). Andersen et al suggested that reduced levels of SORL1 in 
AD is probably due to loss of protection of APP from processing (89), however, as 
some studies show, the loss of APP could similarly be suggested to be due to loss of 
SORL1 and thus the nature of the interaction between both still needs further 
clarification. 
 
Similarly to LDLR, the Lipoprotein Receptor-related Protein 1 (LRP1 – Table 3.1) is a 
cell surface receptor that binds soluble Aβ and transports it from the interstitial fluid 
into the bloodstream at the abluminal side of the blood brain barrier (82). There is some 
evidence showing that LRP1 is reduced in brain capillaries of AD brains (83). Halliday 
et al found reduced LRP1 levels in pericytes and endothelial cells from AD brains (90). 
They also found a positive correlation between pericyte coverage and LRP1 levels. A 
conditional knockdown mouse model for LRP1 showed that reduction of LRP1 in 
astrocytes resulted in an increase in Aβ deposition by affecting Aβ clearance with no 
effect on Aβ production (91). 
 
Whilst the efflux of cerebral Aβ into the circulation is thought to be performed mostly 
by LRP1, the Receptor for Advanced Glycation End products (RAGE – Table 3.1) also 
plays an important opposing role in Aβ clearance at the BBB. RAGE works as an 
important transporter by regulating influx of peripheral Aβ into the brain (92). RAGE 
is a cell surface receptor that binds to Aβ and increased levels of RAGE have been 
found in endothelial cells from AD brain and mice models (93). Donahue et al observed 
a stronger expression of RAGE in neurons compared to vascular cells in non-demented 
elderly; however, neuronal RAGE was significantly decreased in AD cases with an 
unexpected stronger RAGE immunoreactivity in vascular cells (94). 
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Other ApoE receptor members of the LDLR family, such as ApoER2 and VLDLR, are 
also thought to be involved in Aβ clearance and tau phosphorylation. ApoER2 and 
VLDLR are also receptors for Reelin (RELN – Table 3.1) (83). RELN is a signalling 
protein important in neurodevelopment, neuronal connectivity and synaptic function. 
RELN induces the cleavage of ApoER2 through processing of α- and γ-secretases, 
however, there is contradictory evidence about RELN levels in AD brain (95). 
Repression of RELN, ApoER2 or VLDLR in mice was associated with reduced 
phosphorylation of the Glycogen Synthase Kinase 3β (GSK3B), which leads to 
disinhibition of this enzyme and subsequent hyperphosphorylation of tau (83). 
 
Similar to LRP1, other important proteins at the BBB are the platelet-derived growth 
factor B (PDGFB), its receptors (PDGFRA and PDGFRB) and aquaporin 4 (AQP4 – all 
in Table 3.1). The platelet-derived growth factor (PDGF) family is composed of four 
ligands (A, B, C and D) that bind to two receptors (PDGFR-α and PDGFR-β). PDGF 
receptors are tyrosine kinases that can form three different conformations of dimers: 
αα, ββ and αβ (96). 
 
Platelet-derived growth factor B (PDGFB) derived from endothelial cells interacts with 
PDGFRB in pericytes, inducing pericyte recruitment. Pericytes and the end-feet of 
astrocytes are essential for a stable and impermeable BBB. PDGFB binds to heparan 
sulfate proteoglycans in the basement membrane, and regulates pericyte proliferation, 
migration, and recruitment to the vessel wall through PDGFRB in pericytes (97). 
 
As mentioned, the end-feet of astrocytes, which express AQP4, contribute to the 
stability of the BBB. The glymphatic system allows clearance of interstitial solutes, 
including Aβ. Within the glymphatic system, the CSF flows through para-arterial 
spaces, and is then transported into the interstitial space by astrocytic AQP4 to be 
drained into the para-venous spaces, and finally diffuses into the subarachnoid CSF or 
enters the bloodstream through the vasculature (98). An AQP4 knockout mice model 
showed a reduction in the clearance of Aβ by approximately 55% (99). Furthermore, 
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the association of function with pericytes is itself notable given the increasing evidence 
of pericyte loss in AD (100). 
 
In addition to Aβ clearance through the glymphatic system, phagocytosis and further 
degradation of Aβ occurs by astrocytes, macrophages and microglia (24,25). Toll-like 
receptors (TLRs) expressed in microglia are necessary for recognition of the immune 
response and further phagocytosis. Aβ binds to the TLR4 co-receptor CD14 (Table 3.1) 
and can induce microglia to produce nitric oxide, interleukin 6, and other 
inflammatory factors (25). Repression of CD14 in microglia impedes phagocytosis in 
response to Aβ, increases Aβ deposition and causes cognitive impairment (25). 
 
Microglia interact with other cell types, including neurons through ligand–receptor 
pairs that support their interaction, including CD200 and its receptor CD200R. CD200 
is expressed on several cell types including neurons whereas the CD200 receptor is 
particularly expressed in cells of the myeloid lineage, such as microglia and 
macrophages (101). Notably, Walker et al found a reduction in the levels of CD200 and 
CD200R in AD brain but the neuronal expression of CD200 was heterogeneous (102). 
 
3.1.3. Proteolytic degradation of amyloid 
 
Aβ clearance, besides being removed by phagocytosis, is due to proteolytic 
degradation that is a substantial determinant of cerebral Aβ levels (103). These include 
neprilysin (MME), endothelin converting enzyme 1/2 (ECE1, ECE2), angiotensin 
converting enzyme 1/2 (ACE1, ACE2), insulin degrading enzyme (IDE), several 
extracellular matrix metalloproteases (including MMP2, MMP14) and the extracellular 
matrix metalloproteinase inducer EMMPRIN (CD147) (all in Table 3.1). 
 
Indeed there are more than 20 proteases reported to degrade Aβ, a number still to be 
fully elucidated and many with differing affinities for Aβ, according to different 
optimal pH conditions for function, as well as regional, cellular, and subcellular 
localizations. A number of these enzymes have been postulated as important 
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determinants of AD pathology, yet some Aβ degrading enzymes work cooperatively 
with each other. Some of these enzymes (e.g. ACE1, ACE2, ECE1, ECE2, and NEP) all 
have important functions in the production or cleavage of vasoactive peptides, and 
thus blood pressure regulation, which is in itself an important factor and pathological 
hallmark of AD. This collection of enzymes also works alongside other catabolic 
mechanisms to eliminate Aβ, and thus collectively influence total Aβ levels (103). 
 
3.1.4. Tau phosphorylation 
 
In addition to amyloid plaques and CAA; neurofibrillary tangles are a classical 
hallmark of AD. Neurofibrillary tangles are composed of hyperphosphorylated tau 
protein (MAPT in Table 3.1). The normal phosphorylation state of a protein occurs 
from the interplay between kinases and phosphatases. Thus imbalance between these 
systems can result in hyperphosphorylation of tau. Glycogen synthase kinase 3 (GSK3) 
proteins are serine/threonine kinases that function as regulatory enzymes in glucose 
metabolism. There are two isoforms, GSK3A and GSK3β (GSK3B in Table 3.1) (104). 
 
The GSK3β isoform is abundant in the central nervous system and is able to 
phosphorylate tau. GSK3β phosphorylates tau in serine/threonine residues and its 
overactivity contributes to Aβ production and Aβ-mediated neuronal death (105). 
Similar to GSK3β, the Mitogen Activated Protein Kinase 1 (MAPK1) is also thought to 
play a role in tau hyperphosphorylation and has been found to be increased in the 
hippocampus of AD brains (106). 
 
Protein phosphatase 2A (PP2A) enzyme family is composed of 96 serine/threonine 
phosphatases. This large family of enzymes is involved in tau phosphorylation as these 
enzymes are responsible for the majority of brain serine/threonine phosphatase 
activity, where tau phosphorylation occurs at serine/threonine residues. PP2A is a 
heterotrimeric complex composed by the catalytic C subunit (PPP2CA in Table 3.1), a 




Changes in PP2A regulators and PP2A catalytic activity, PP2A methylation and/or 
phosphorylation, have been reported in AD (107). PP2A catalytic activity is regulated 
by endogenous ligands, such as metal cations, ceramides and polyamines that enhance 
the activity of PP2A enzymes. In contrast, PP2A phosphatase activity can be inhibited 
by endogenous nuclear inhibitors, such as I1PP2A (ANP32A in Table 3.1) and I2PP2A 
(SET in Table 3.1). PP2A enzymes can also associate with other protein kinases that 
have been linked to AD, such as glycogen synthase kinase 3B (in Table 3.1) (107). 
 
Similar to PP2A, calcineurin is a serine/threonine phosphatase that phosphorylates tau. 
Calcineurin calmodulin-binding catalytic subunit A-beta (PPP3CB) is included in Table 
3.1. Changes in calcineurin have been proposed to contribute to AD pathology by 
inhibiting synaptic function, modifying learning and memory affecting long-term 
potentiation and altering dendritic spine density and dendritic arbor branching. Karch 
et al observed that calcineurin protein levels inversely correlated with Braak stage in 
AD brains and that calcineurin activity is globally reduced in AD brains (108). 
 
Finally, O-GlcNAc glycosylation is a posttranslational modification produced by O-
GlcNAc transferase (OGT in Table 3.1) that has been associated in protein changes of 
neurodegenerative disorders such as α-synuclein, amyloid precursor protein, and tau.  
Knockout mice of OGT showed progressive neurodegeneration, loss of neurons, 
gliosis, an increase in hyperphosphorylated tau and Aβ−peptides and memory 
impairment (109). 
 
This study recognises and explores one of the major challenges in miRNA research, 
which is that a miRNA has the potential to affect the production of hundreds of 
proteins. This property allows the possibility that some miRNAs could be involved in 
several pathways at the same time by affecting numerous proteins such as those 
described above. Selection of miRNAs of interest was therefore performed with 







The null hypothesis is that there is no significant difference in the levels of selected 






3.3.1. Choice of miRNAs 
 
A number of proteins were chosen on the basis that they have been implicated in 
amyloid production or clearance including transport of Aβ across the BBB, Aβ 
degrading enzymes, BBB integrity, proteins involved in the glymphatic system, 
immune response and tau phosphorylation. The software applications TargetScan 
(www.targetscan.org) and miRanda (www.microrna.org) were used to obtain 
predicted miRNAs binding to the transcripts of these genes and the miRNAs that 
appeared relevant to the highest number of target gene transcripts were included. 
 
Table 3.1 lists the number of binding sites of each miRNA family that was predicted to 
bind to the target protein transcripts according to TargetScan. The probability with 
which they bind to the transcripts was also taken into account and all miRNAs selected 
were within the 15% with the highest ‘‘total context score’’, i.e. percentile 85 or higher. 
Only high confidence miRNAs (i.e. according to miRbase criteria) were further 
investigated, according to the average number of reads previously reported in miRbase 
(as produced by NGS data) and the number of predicted transcripts they bind to (Table 
3.2). Ratios between the number of reads and the number of transcripts were 
calculated. Only miRNAs with a ratio higher than 1 were selected for actual screening, 




Table 3. 1 Transcripts related to classical hallmarks of AD. 
Gene name miR-16 miR-29 miR-34 miR-125 miR-132/212 miR-216 
ADAM10 2  2    
BACE1 2 2  1 2 1 
BACE2 1   1  1 
PSEN1  1 1 1  2 
NOTCH1   2 1   
ABCA1   1  1  
LDLR   1  1  
LRP1    1 2  
AGER     2  
SORL1      1 
RELN 2  1    
PDGFB  1 1    
PDGFRA  1 2  1  
PDGFRB  1 1    
AQP4 2 2    4 
CD200   1   1 
CD14   1    
CD200R1   1   5 
MME 1    2 3 
ECE1   2 2   
ECE2      1 
ACE 1 2 3 1   
MMP2  1 1 1   
MMP14   1 1   
CD147    1   
IDE  1  2 1 1 
GSK3B  1   2  
MAPK1  1 2  3  
MAPT   3  1  
PPP2CA 2 1  1  3 
PPP2R1A  1  3   
ANP32A   1  1  
SET  2  1   
OGT 1    2  
PPP3CB 1     3 
Transcripts involved in one or more of the following: amyloid production, transport 
across the blood brain barrier (BBB) and degradation enzymes; tau phosphorylation; 
BBB integrity; glymphatic system or immune response are listed with the 






Table 3. 2 Preselected miRNA families. 
miRNA family Confidence Targets Reads per million Ratio reads/targets 
miR-15 High 1508 3930 2.61 
miR-29 High 1256 17090 13.61 
miR-34 High 751 1130 1.50 
miR-125 High 927 7470 8.06 
miR-132/212 High 474 901 1.90 
miR-216 High 372 195 0.52 
Preselected miRNA families with confidence level (according to MiRbase criteria), 
number of predicted targets (according to miRanda), average reads per million and the 
ratio of the latter two. 
 
3.3.2. Study cohort 
 
The study cohort, as described in detail in Chapter 2 (Section 2.1) comprised brain 
tissue from 19 AD, 10 EAC, 18 VaD and 19 controls. 
 
Table 3. 3 Demographic information of the cohort used in Chapter 3. 
Diagnosis Gender 
(Male/Female) 
Age (σ) PMI (σ) ApoE4 
(No/Yes) 
Total 
Control 10/9 80 (7.4) 30 (12) 19/0 19 
Early AD changes 6/4 85 (6.2) 32 (13) 6/4 10 
AD 8/11 76.6 (6.1) 23 (13.3) 3/16 19 
VaD 9/9 82.6 (7.7) 34.8 (12) 9/4 18 
Total 33/33 81 (7.6) 30 (13) 37/24 66 
Demographic information of the cohort, post-mortem interval (PMI), standard 
deviation (σ). 
 
3.3.3. Brain tissue dissection and homogenization 
 
Brain tissue dissection and homogenization was undertaken on the cohort as described 





3.3.4. RNA isolation, quantification and standardization 
 
RNA isolation, quantification and standardization were performed as described in 
detail in Chapter 2 section 2.3. 
 
3.3.5. Software for analysis of target proteins (DAVID and PANTHER) 
 
DAVID and PANTHER software were used for analysis of predicted target proteins of 
the selected miRNAs as described in detail in Chapter 2 section 2.13. 
 
3.3.6. Data collection and analysis 
 
Data on selected calibrator genes was generated by quantitative polymerase chain 
reaction (qPCR) as described in Chapter 2 section 2.6. The analysis of the resultant data 
was undertaken using the new formula proposed in Chapter 2 section 2.7. Statistical 








D’Agostino & Pearson normality test showed that miR-16 levels were normally 
distributed across the whole cohort. However, Bartlett’s test (p=0.0124) for 
homogeneity of variances found that the groups variances differed significantly. Thus, 
one-way ANOVA was inappropriate for analysis. Kruskal-Wallis test was used for 
analysis of the data. On comparison, the expression of miR-16 was significantly 
different across the groups (Figure 3.1), Kruskal-Wallis statistic H=21.62 and p<0.0001. 
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Dunn’s multiple comparison test showed a significant increase in the AD group 
compared to controls (p=0.03), EAC (p=0.0051) and VaD (p<0.0001). 
 
Figure 3. 1 Percentage of difference for miR-16. 
 
Figure shows the percentage of difference for miR-16 compared to controls, error bars 
show the 95% confidence interval and the average is depicted, * p<0.05, ** p<0.01 and 
*** p<0.001. 
 
Analysis using DAVID software to further explore the potential impact of miR-16 
changes was then undertaken. MiR-16 maps to an intron on chromosome 13q14.2 and 
it is part of the miR-15 gene family (with miR-15, miR-195, miR-424 and miR-497). 
According to TargetScan, 1508 transcripts are predicted to be targeted by miR-16. 
Significant enrichment scores were found with respect to Rho GTPase-activating 
protein domain (enrichment score of 2.72 and p=0.0014); voltage gated sodium channel 
and sodium ion transport (enrichment score of 1.68 and p=0.035); and regulation of 




Both miR-29a and miR-29b are part of the miR-29 family in addition to miR-29c. miR-
29a is encoded in an intron on chromosome 7q32.3. MiR-29b can be derived from two 
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precursors, 29b-1 and 29b-2 that are co-transcribed with miR-29a and miR-29c 
respectively. miR-29b-2 and miR-29c are mapped to chromosome 1. D’Agostino & 
Pearson normality test showed that both miR-29a and miR-29b levels were normally 
distributed across the whole cohort. However, Bartlett’s test found that the variances 
between the groups were significantly non homogeneous (p=0.0050 for miR-29a and 
p=0.048 for miR-29b). Thus the data was analysed by Kruskal-Wallis test. Both miR-29a 
and miR-29b were significantly different across the groups (Kruskal-Wallis statistic 
H=11.86 and p=0.0079 for miR-29a; Kruskal-Wallis statistic of 12.33 and p=0.0063 for 
miR-29b). Dunn’s post hoc test showed that miR-29a was significantly increase in AD 
versus EAC (p=0.033) and VaD (p=0.0189); whilst miR-29b was also significantly 
increased in AD versus EAC (p=0.0281) and VaD (p=0.0183).  
 
Figure 3. 2 Percentage of difference for miR-29a. 
 
Figure show the percentage of difference for miR-29a compared to controls, error bars 









Figure 3. 3 Percentage of difference for miR-29b. 
 
Figure show the percentage of difference for miR-29b compared to controls, error bars 
show the 95% confidence interval and the average is depictured, * p<0.05. 
 
Analysis of the miR-29 family by TargetScan and DAVID revealed it to have 1256 
predicted targets and significant enrichment scores in the angiotensin-converting 
enzyme 2 pathway (enrichment score of 3.53 and p=0.0027); platelet amyloid precursor 
protein pathway (enrichment score of 3.53 and p=0.0054); acute myocardial infarction 
(enrichment score of 3.53 and p=0.024); intrinsic prothrombin activation pathway 
(enrichment score of 3.53 and p=0.035); and apoptosis regulator BCL-2 (enrichment 




The miR-34 family is composed of four miRNAs, miR-34a/34b/34c/449. miR-34a is 
transcribed from chromosome 1p36.22. D’Agostino & Pearson normality test showed 
that miR-34a was normally distributed across the whole cohort and this was confirmed 
by Bartlett’s test (p=0.1196). Thus, the parametric tests one-way ANOVA and Tukey’s 
post hoc were used. miR-34a was found to be differentially expressed between 
diagnostic groups, one-way ANOVA F=7.089 and p=0.0004. Tukey’s post hoc testing 
showed an increase in AD versus EAC (p=0.03) and VaD (p=0.0002).  
76 
 
Figure 3. 4 Percentage of difference for miR-34a. 
 
Figure shows the percentage of difference for miR-34a compared to controls, error bars 
show the 95% confidence interval and the average is depicted, * p<0.05 and *** p<0.001. 
 
DAVID-assisted analysis showed that this miR-34 family has 751 predicted targets and 
significant enrichment scores were found in Notch signalling (enrichment score of 1.2 
and p=0.046). Other clusters were identified with a possible relevance but were not 
significant, with respect to fatty acid transport (enrichment score of 0.68 and p=0.078); 
Rho GTPase-activating protein domain (enrichment score of 0.58 and p=0.23); gamma-
aminobutyric acid A receptor (enrichment score of 0.35 and p= 0.22) and PPAR 




miR-125b is transcribed from chromosome 11q24.1, along with miR-125a both of them 
belong to the miR-125 family. D’Agostino & Pearson normality test showed that miR-
125b was normally distributed, which was confirmed by Bartlett’s test (p=0.0624). One-
way ANOVA showed that miR-125b expression was significantly different between the 
groups (F=10.69 and p<0.0001) with Tukey’s post hoc showing significant increases in 
AD compared to controls (p=0.0114), EAC (p=0.0006) and VaD (p<0.0001). 
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Figure 3. 5 Percentage of difference for miR-125b. 
 
Figure shows the percentage of difference for miR-125b compared to controls, error 
bars show the 95% confidence interval and the average is depicted, * p<0.05 and *** 
p<0.001. 
 
927 transcripts were predicted to be targeted by this miRNA family according to 
DAVID analysis and high enrichment scores were found in a number of pathways. 
These included the apoptosis regulator BCL-2 pathway (enrichment score of 2.09 and 
p=0.0046); fatty acid elongation, saturated, monounsaturated and polyunsaturated 
fatty acids (enrichment score of 1.34 and p=0.041); tyrosine protein kinase 
EGF/ERB/XmrK receptor (enrichment score of 1.34 and p=0.012); and furin-like 




This miRNA family is composed of miR-132 and miR-212, both genes are transcribed 
from chromosome 17p13.3. D’Agostino & Pearson normality test showed that both 
miR-132 and miR-212 were normally distributed, which was confirmed by Bartlett’s 
test (p=0.47 for miR-132 and p=0.2993 for miR-212). Both miRNAs showed differences 
between diagnostic groups, for miR-132 (one-way ANOVA F=5.321 and p=0.0025) and 
miR-212 (one-way ANOVA F=5.645 and p=0.0017). Tukey’s post hoc showed a 
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significant reduction of miR-132 in controls compared to AD (p=0.0396) and VaD 
(p=0.0014). Similarly, for miR-212, Tukey’s post hoc showed a significant reduction in 
controls compared to AD (p=0.0189) and VaD (p=0.0014). 
 
Figure 3. 6 Percentage of difference for miR-132. 
 
Figure represents the percentage of difference for miR-132 compared to controls, error 

















Figure 3. 7 Percentage of difference for miR-212. 
 
Figure 3.7 represents the percentage of difference for miR-212 compared to controls, 
error bars show the 95% confidence interval and the average is depicted, * p<0.05 and 
** p<0.01. 
 
This miRNA family has 474 predicted transcripts associated with it. According to 
DAVID significant enrichment scores were observed for TGF-beta receptor/activin 
receptor pathway (enrichment score of 2.12 and p=0.001); Rho GTPase pathway 
(enrichment score of 1.56 and p=0.024); voltage gated sodium channel and sodium ion 
transport (enrichment score of 1.19 and p= 0.023); and insulin/IGF-1 signalling pathway 
(enrichment score of 1.15 and p=0.05). 
 
3.4.6. Analysis of miRNAs with comparable patterns 
 
MiR-16, miR-29a/b, miR-34a and miR-125b were found to have a similar pattern of 
expression across groups, and in contrast to miR-132 and miR-212. Although not all 
demonstrated significant differences with respect to controls, it should be noted that a 
significant increase was found in Braak stage II that is considered as part of the 
controls. Examination of the expression pattern of the various miRNAs, in relation to 
Braak stage showed increases in these miRNAs in AD in Braak II and VI (miR-16, miR-
29a, miR-34a, miR-125b with p<0.001 and miR-29b p=0.002), but no difference in VaD 
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(Figure 3.8). Thus, the baseline for controls might be increased by those cases 
corresponding to Braak stage II. 
 
Figure 3. 8 Expression pattern of miRNAs according to Braak stage and VaD. 
 
Figure shows patterns of expression for the different miRNAs across AD Braak stage 




A further examination of the four miRNA families, with apparently similar behaviour 
were examined further to the extent in which they may have had similar targets, and 
these are represented in Figure 3.9. Analysis of the transcripts targeted by at least four 
of the miRNAs by DAVID software showed significant clusters  that were involved in 
zinc, zinc metal binding and zinc-finger (enrichment score of 3.83 and p=0.00005); stem 
cell maintenance and development (enrichment score of 2.88 and p=0.0048); 
serine/threonine kinases and phosphatases (enrichment score of 0.99 and p=0.035); and 
another cluster, although not significant, was the neurotrophin signalling pathway 




Figure 3. 9 Overlapping targets of miRNA families. 
 
Figure shows miRNA families that showed a similar expression pattern according to 
Braak stage and their overlapping targets. Only those numbers in red circles were 
considered for further examination. 
 
From this four-way comparison of shared targets, the four miRNA families were all 
found to have 3 transcripts in common. These were ELMSAN1 (ELM2 And Myb/SANT 
Domain Containing 1), RORA (Retinoic acid receptor-related orphan receptor alpha) 
and ONECUT2 (One cut homeobox 2). 
 
Of the three targets shared across the four families, the most information is available 
on RORA, the retinoic acid receptor-related orphan receptor alpha. RORA is thought to 
regulate genes involved in lipid metabolism such as apolipoproteins (110) particularly 
apolipoprotein J, which is a second major lipoprotein in the brain that, unlike 
apolipoprotein E, easily transverses the blood-brain barrier and associates with HDL in 
the periphery (84). This is interesting given that previous pathway analyses of AD 
point to the important of lipid metabolism and cholesterol in AD (42) not to mention 
the long-standing and considerable body literature that points to the important of 
APOE in AD risk and aspects of pathology. 
 
RORA is also involved in hypoxia, another pathway receiving increasing attention as a 
contributor to the early development and progression of dementia (111). In this case 
RORA promotes hypoxia-related changes in cell signalling by interacting with, and 
activating the transcriptional activity of, hypoxia-inducible factor 1-alpha (HIF1A). 
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RORA was also found to participates in peroxisome proliferator-activated receptor 
gamma (PPARγ) dependent adipogenesis through competition for DNA-binding (112). 
The association with PPARγ is also noteworthy for other reasons because of its 
association with Aβ and also that some drugs that reduce angiotensin II signalling and 
which are protective against AD-related pathology in animal models have partial 
PPARγ agonist properties (113). Moreover, the expression of RORA and the α-
secretase ADAM10 (A disintegrin and metalloproteinase domain-containing protein 
10) were significantly (p<0.05) correlated with both fractional anisotropy and gray 
matter thickness, measurements for water diffusion in the brain and white matter 
cerebral atrophy (114). 
 
Other functions that have been attributed to RORA function is that it is also a negative 
regulator of the inflammatory response and regulates interleukin 6 in resting and 
reactive astrocytes (115,116). Finally, in genome-wide association studies (GWAS), a 
significant association was observed for the rs2456930 polymorphism and increased 
risk of AD (119). Other SNPs in RORA have also been implicated with increased risk of 
depression and a relationship between depression and AD has also been observed 
(117,118). A finding also more recently replicated by Baker et al were RORA was one of 
three genes found to be associated with AD, alongside PPARGC1A (a PPARγ related 
gene), and ZNF423 (a zinc finger gene) (119). While there is a limited, but very 
interesting literature related to RORA and a number of related mechanisms in AD, 
there is no literature thus far, describing any role or association between ELMSAN1 
and ONECUT2 with AD. 
 
 
3.5. Discussion and conclusions 
 
These initial results suggest that miRNAs might act in a co-ordinated manner in some 
forms of dementia. While there is already studies reporting the role of single miRNAs 
in dementia (71,120,121), based on the current findings, it is reasonable to suggest that 
such associations are perhaps an over simplification of the possible involvement of 
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these molecules in AD. More likely, it is conceivable that combinations of miRNAs, 
given that some can share the same targets, will have a substantive physiological role 
in the development and/or progression of neurodegeneration. The findings here 
around the identification of changes to miRNAs that all share a property of the 
capacity to target the RORA gene may be one such example. Furthermore, this 
collection of miRNAs also have additional shared functions that are relevant to zinc 
metabolism, serine/threonine protein kinases and phosphatases, stem cell maintenance 
and development. 
 
Zinc metabolism has been linked to the development of AD and several amyloid 
degrading enzymes are metalloproteinases dependant on zinc (122–124). 
Serine/threonine kinases and phosphatases are similarly particularly important due to 
the importance of phosphorylation of tau protein at serine/threonine residues and the 
contribution of this towards the formation of neurofibrillary tangles. 
 
RORA represents an attractive candidate protein that participates in numerous 
processes linked to dementia, however empirical measurement of RORA levels in AD 
or VaD brains have not yet been described. Only one study has directly linked RORA 
to AD by analysis with computational node networks of the insulin pathway and brain 
derived neurotrophic factor (BDNF) (125). RORA also represents an intersection of 
changes observed in AD and VaD, in hypoxia, cholesterol metabolism and energy 
deficiency. 
 
MiRNA expression fluctuates as the disease progresses and thus might represent 
compensatory mechanisms that under non-physiological conditions will affect other 
pathways. MiRNAs might target some transcripts that contribute to the development 
of dementia but at the same time target other transcripts that may act as counter-
regulators. Therefore, under normal physiological conditions certain miRNAs, such as 
the miR-29 family, are able to repress the formation of Aβ by downregulating BACE1 
or favouring vasodilation (and potentially aiding amyloid clearance) by repressing 
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angiotensin converting enzyme (ACE) expression and thus its role in the formation of 
the vasoconstrictor angiotensin II. 
 
However, if a pathology-induced increased expression of miR-29 exceeds a given 
concentration threshold, the ‘excess’ miR-29, unless regulated might begin to affect 
other transcripts through low affinity binding to targets such as the platelet derived 
growth factor (PDGF) and its receptors, and aquaporin 4, important for BBB integrity 
and glymphatic clearance of amyloid. 
 
Similarly, the very nature of how miRNAs function, particularly their sometimes wide 
substrate specificity, could explain why what appears to be non-linked processes tend 
to occur during the development of AD, or how there is some variation that gives rise 
to variable neuropathology for AD and VaD, or indeed even the variable extent to 
which some age-related pathologies accumulate. That miRNAs are autocrine, paracrine 
and endocrine molecules, which can be transported via exosomes poses a possibility 
that they could mediate their effects following a concentration gradient, where there 
might be a higher impact in the cells in which they are being produced, but with a 
reduced effect in neighbouring cells or in other organs. 
 
From the seven miRNAs assessed in this chapter, five of them (miR-16, miR-29a, miR-
29b, miR-34a and miR-125b) followed a similar pattern with differences between AD 
and VaD. Two of them (miR-132 and miR-212) decreased according to Braak stage and 
a similar reduction was found in both AD and VaD suggesting that although there 
might be specific pathways pathognomonic of AD, they also share other characteristics 
in common such as vascular changes. Analysis of a miRNA signature based on hypoxia 
inducible factors, responsive genes and the MTHFR (methylene tetrahydrofolate 
reductase) gene, variation in which is a risk factor for VaD (126), could help to identify 
more similarities between AD and VaD, for instance miR-132 and miR-212. 
 
In studies of disease, in particular in post-mortem tissue, the pathological stage of the 
disease, the duration of post mortem delay prior to the availability of tissue and the 
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agonal state prior to death are also important factors to consider in the study of 
miRNAs, especially since the multi-functional functions of miRNAs measured could 
represent causal and/or responsive mechanisms. Indeed, during the natural history of a 
disease, miRNAs will likely fluctuate and their final expression signature might 
represent a retrospective picture of various attempts at protective mechanisms as well 
as the cause of various detrimental dysregulations. As observed, dysregulation of those 
miRNAs in Braak stage II (Figure 3.8) could support an early diagnosis before the 
manifestation of symptoms. 
 
Analysis of the samples studied here by Braak stage also highlighted the importance of 
using adequate calibrators for the measurement of miRNAs (e.g. calibrators that are 
unlikely to be affected by disease status). RNU6B was found to be relatively stable 
from Braak stage 0 to V but then was observed to have a 3-fold reduction in Braak 
stage VI. The use of more stable calibrators, that would be unaffected by disease for 
any stage of the disease would provide more reliable results. Moreover, there was also 
a low number of cases in Braak stage 0-I as controls (5 cases), perhaps reflecting the 
rarity of the absence of some age-related pathology, even in controls. However, 
increasing the number of cases in Braak 0-I would be beneficial in provide a larger 
number of samples across the spectrum of Braak stages and in doing so allow 
strengthening of statistical power. 
 
All of the seven miRNAs studied here were found to be significantly different between 
diagnostic groups. Of the seven studied, five (miR-16, miR-29a, miR-29b, miR-34a and 
miR-125b) were found to be increased and two (miR-132 and miR-212) found to be 
decreased. With these findings the null hypothesis proposed that there is no significant 
difference in the levels of selected miRNAs between diagnostic groups, can be rejected. 
However, given the observations of a lack of consistent expression across all Braak 
stages for the calibrator RNU6B, which has been a widely used calibrator in the study 
of miRNAs in AD to date, it does shed some doubt as to the reliability of my 
observations. This therefore prompted the need for a more thorough evaluation of 
commonly used calibrator genes, which will be described in Chapter 4, as a way to 
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progress this area and highlight if there are unreliable calibrators that have not been 
extensively studied for their robustness and reliability in the context of AD. This will 
provide a more robust footing on which to re-visit and investigate again whether the 
observations described in this chapter indeed have merit and strengthen the case for 



























Chapter 4.- Advancing the reliability of miRNA measurement 
 
 
4.1. A critical appraisal of techniques for miRNA measurement 
 
4.1.1. Challenges in the measurement of miRNAs 
 
As previously described, miRNAs are small non-coding RNA sequences of about 22 
nucleotides in length, with a range from 16 to 27 nucleotides (127). The structure of 
which present a number of challenges that have a bearing on how they are researched. 
One of the first considerations in the characterization and measurement of miRNAs, is 
that the miRNA sequence is present in three contexts: the primary miRNA transcript, 
the miRNA precursor and the mature miRNA. Another consideration is that miRNAs 
are highly variable in the proportion of guanine/cytosine bases they contain. This 
results in a wide array of melting temperatures and this may in turn affect specificity 
and sensitivity of an assay. 
 
Third, some miRNAs within the same family differ by just a single nucleotide. Thus, 
some methods, such as hybridization methods, may have limited specificity, which is 
notable given that early research in the miRNA field used the northern blot method. 
Given the various challenges summarized above, it is perhaps not surprising that the 
signals obtained from such earlier work could have inaccuracies, or a lack of precision, 
given that these signals could have been derived from each of the three forms in which 
the miRNA sequence exists (66,128). 
 
The important need to distinguish between specific miRNAs will depend on the 
sequence of the mature miRNA. A mature miRNA sequence that is more enriched in 
guanine cytosine bases will bind more efficiently and with greater affinity to the 
detection probe. This interaction can also be manipulated further to increase binding 
affinity and specificity for probes by using Locked Nucleic Acids (LNA) (129). These 
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developments, contribute to why northern blots are less utilized, as well as other less 
satisfactory properties of northern blots that are time consuming and require larger 
amounts of RNA compared to other newer methods. 
 
4.1.2. Newer approaches for measurement of miRNAs 
 
miRNA detection with high sensitivity and specificity remains a challenge; however in 
more recent years three different methods have emerged that are used to varying 
extents to achieve this. The first is the amplification of miRNAs, allowing its 
measurement, using quantitative real time polymerase chain reaction (qPCR). The 
second is the use of microarrays and thirdly, sequencing by Next Generation 
Sequencing (NGS) technologies (66,129). Microarrays have the advantage of highest 
throughput allowing measurement of multiple miRNAs simultaneously. However, 
due to the different and critical binding affinities of miRNAs summarised, microarrays 
can be less specific in differentiating between individual miRNAs, and thus less suited 
where accurate and specific quantification is needed. 
 
Recent NGS technologies have enabled considerable advances in miRNA research by 
allowing the specific detection of low copy number miRNAs. This has helped to 
identify new miRNAs and their relative abundance, and the collection of data that has 
emerged from various NGS experiments has helped to provide new criteria for the 
RNA sequences to be recognized as miRNAs. Despite these great advances of NGS 
experiments, it is recommended that the results derived from NGS experiments are 
also supported by an additional validation method, such as qPCR. Although there is 
still no formal consensus, qPCR has been extensively cited by many researchers as the 
‘gold standard’ approach for miRNA research. This is due to its quantitative 
properties, the specificity it offers towards the differentiation between isomirs, and due 
to the use of stem-loop primers, also helps to discriminate between primary miRNAs, 




Perhaps the most comprehensive study of approaches to miRNA measurement was 
undertaken by Mestdagh et al. They compared 12 different technical platforms for the 
measurement of miRNAs in terms of reproducibility, sensitivity, accuracy, specificity 
and similarity of expression (130). They found that low reproducibility was associated 
with low-copy miRNAs and that such low-copy miRNAs differed in frequency among 
platforms. The low reproducibility observed is also potentiated by the low number of 
copies and proportion of mismatches. In terms of sensitivity, they found lower 
sensitivity for platforms using hybridization approaches. Accuracy was assessed by 
measuring certain miRNAs in specific samples and by measuring the detectability after 
miRNAs were ‘‘spiked’’ into reactions. Overall, they found that in general, qPCR 
generally accurately quantified low-abundant miRNAs. 
 
Mestdagh et al also observed that most platforms showed high specificity between 
miRNAs that differed by only 3-4 nucleotides but there was higher cross-reactivity (i.e. 
lower specificity) between miRNAs when they differed from each other by only 1-2 
nucleotides. Finally, with respect to their evaluation of the similarity of expression, 
they investigated into 66 miRNAs differentially expressed between 2 sample groups 
(130). Of the 66 miRNAs studied, only two were found to be differentially expressed by 
all platforms. Other studies evaluating similar characteristics of different assays have 
found that observed miRNA levels were dependent on the technical approach and also 
with differences between commercial kits of the same technique (i.e. amplification, 
hybridization or NGS) (128,131,132). Yet, qPCR appeared to perform the best overall 
with the widest dynamic range and highest accuracy and it has been on this basis that 
the method has been proposed as the gold standard for miRNA profiling (66,68). 
 
4.2. A closer look at quantitative reverse transcription polymerase chain reaction 
 
Polymerase chain reaction (PCR) is an enzymatic assay that allows the amplification of 
a specific sequence of nucleotides from a pool of DNA, or from RNA that has been 
produced through the use of reverse transcription (RT), also known as RT-PCR (133). 
‘Qualitative’ PCR is another application where the method is used simply to detect the 
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absence or presence of a specific sequence. This is useful when PCR is performed with 
respect to checking the specificity of a PCR reaction for a target, or with respect to 
cloning purposes and validation of the existence of a cloned target or insert, or to 
identify or confirm the presence of a pathogen in a sample (e.g. in forensic or medical 
microbiological applications). 
 
Quantitative real-time PCR (qPCR) provides more information than just specific 
detection of specific sequences (133). This accurately measures the amount of a specific 
DNA or RNA sequence present in a sample and allows for both detection and 
quantification of the PCR product in real-time, while it is being synthesized (133). 
Although qPCR has been recognized as the best technique for miRNA measurement 
(as outlined in 4.1.2), it still requires normalization to a reference (i.e also called 
calibrator) gene that is considered to have a constant level of expression for the sample 
type being investigated, and in the case of applications where disease association is 
being investigated, appears to be unchanged in the presence of the disease. 
 
Unfortunately, there is currently no consensus nor systemic evaluation of the most 
commonly used and cited calibrator genes for miRNA profiling in human post-mortem 
brain tissue. This is because most studies have not investigated brain tissue. However, 
there is an important need to have robust calibrators unaffected by disease. With this in 
mind, there is a risk that calibrator genes previously tested and reported, for instance 
in cultured cell lines, or blood-derived samples (e.g. serum) or other peripheral tissues, 
are not appropriate for use universally or other tissue types (e.g. the brain). 
 
Small nuclear/nucleolar RNAs (snRNAs) have been commonly used for miRNA 
normalization. This is because that have similar properties to miRNAs, they have 
comparable RNA-like stability, are of similar size, and are often abundantly expressed 
(134). The abundant expression of these small RNAs in different cell types, is attractive 
when being considered as a possible calibrator because they provide some flexibility 
for the measurement of miRNAs, and would be subject to similar cell-type specific 
expression (135,136). Yet, surprisingly these small RNAs, and their appropriateness as 
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calibrator genes, have not been investigated in any robust manner with respect to brain 
tissue, where their study is arguably most relevant with the development and 
progression of AD. 
 
The importance of studying these snRNAs in a disease specific manner has been 
shown in other diseases. Gee et al showed that the commonly used snRNAs correlated 
with tumour pathology, breast cancer and head and neck squamous cell carcinoma. 
They also reported that low expression of these snRNAs correlated with markers of 
aggressive pathology, suggesting the importance of their evaluation in other specific 
pathologies (136). Similarly, Benz et al demonstrated that the most commonly used 
snRNA calibrator gene RNU6B was upregulated in patients with sepsis, but 
downregulated in patients with liver fibrosis, highlighting how the behaviour of 
snRNAs have both disease- and tissue-specific profiles of activity (135). Thus, if they 
are to be used as calibrator genes it is important to evaluate whether these small RNAs 
are affected by disease state in dementia. 
 
In doing so, there is also a need to acknowledge that the size of such snRNAs is 
variable. The sequence length of commonly used and commercially available snRNAs 
was investigated (Table 4.1.) using manufacturer catalogue and the National Center for 
Biotechnology Information (https://www.ncbi.nlm.nih.gov/). 
 






Table shows examples of commercially available 
assays for various snRNAs used for normalization 
with summary information regarding their size. 















RNU6B has, thus far, been the most commonly used calibrator in miRNA screenings in 
dementia (137). However, it is important to note that its length is almost five times that 
of a more typical miRNA (22 nucleotides) which immediately raises questions 
regarding potential issues around comparability of assay kinetics with those for 
snRNAs. Furthermore, as per the findings in the previous chapter (3.5. Discussion and 
conclusions), despite its widespread use in dementia, its expression in human brain 
tissue was not uniform according to disease severity. I observed that in brain tissue 
determined to be Braak stage VI, the levels of RNU6B had a significant three-fold 
reduction compared to other less severe Braak stages, suggesting changes in the most 
severe cases of AD. 
 
Another notable gene that has been used for calibrating miRNA expression is, miR-9-
5p. This was used as calibrator gene in the largest study of miRNAs in AD (138). 
However, this study lacked information justifying its selection for this function and 
there was no information regarding the evaluation of its stability to support its validity 
for this function (138). 
 
To explore the possible relevance of amplimer length with respect to chosen calibrator 
genes, I selected three snRNAs (RNU43, RNU44 and RNU48) with the shortest lengths 
(Table 4.1). RNU6B as the most commonly used, miR-9-5p as used in the largest study 
to-date (138) and its counterpart miR-9-3p, to evaluate their suitability as calibrator 
genes for the measurement of miRNAs in dementia. To do this I investigated them in 
two ways. 
 
First, in terms of their potential variability with respect to disease state in dementia. 
Second, I was also interested to explore the potential impact, if any, of post-mortem 
delay, on their measured expression levels. For the latter, I undertook an experiment 
that simulated post-mortem delay (further details provided in the methods section 2.5 
Simulation of postmortem delay) as a way to determine if levels of the proposed 
calibrators changed under different temperature and time conditions. This would 
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allow better contextualization and interpretations of further human tissue-based 
studies, particularly in dementia and where post-mortem delay is likely. 
 
Different methods for selecting appropriate calibrator genes have been proposed in the 
literature but which have differences between them. A search was performed in 
Pubmed using the words ‘‘qPCR microRNA’’, ‘‘normalization microRNA PCR’’, 
‘‘calibrator gene microRNA PCR’’ and combinations thereof. Twenty papers published 
to date were also examined closely in terms of the experimental methodology used. 
Similarly the various mathematical and analytical approaches used were scrutinized 
and will be summarised. 
 
Chen et al compared the stability of 9 commonly used calibrator genes in human 
umbilical vein endothelial cells. This was using four widely used analytical methods 
involving the software applications Genorm, NormFinder and BestKeeper in addition to 
the comparative ΔCT method (139). Their results showed some consistency between 
conclusions drawn from Genorm, NormFinder and the ΔCT method with some minor 
differences between them; however BestKeeper was found to be less consistent with 
respect to the other methods. NormFinder, which performed the best, relies on the 
variation of the calibrator genes within the same group and between groups (intra and 
intergroup variation) which is the same principle of the statistical test analysis of 
variance, ANOVA (140). 
 
The inventors of NormFinder have stated that the generally accepted criterion for 
selecting a calibrator gene is too simple (140). The criteria is that a gene should show no 
variation across the sample set, and that analysis of subgroups should be performed. 
On the basis of my initial results (Chapter 3), no significant differences were observed 
in the calibrator RNU6B between diagnostic groups. Yet, a three-fold reduction was 
observed in Braak stage VI compared to all the other Braak stages where no change 
was observed. Given that calibrator genes are used to standardize the measurement of 
target miRNAs within each individual sample, analysis of their stability by groups 




Genorm relies on pairwise analysis of calibrator genes and subsequent normalization to 
the geometric mean of calibrator genes that showed higher correlation between them 
(75). The authors also suggested that normalization by multiple calibrator genes is 
required for accurate measurement. Nevertheless, the fact that a subset of calibrator 
genes shows good correlation between each other does not necessarily prove that this 
is indicative of wider changes in miRNA expression overall. Such subsets could be 
involved in and very specific to certain pathologies, as could be represented by the two 
groups of miRNAs with similar patterns of expression across Braak stage. The three 
most stable calibrators identified in this chapter will be used for further normalisation 
of the miRNAs I am interested in. 
 
BestKeeper showed less consistency than Genorm, Normfinder and the comparative ΔCT 
method (139). First described by Pfaffl et al and freely available, BestKeeper is an Excel-
based tool that considers pair-wise correlations to the geometric mean of all evaluated 
calibrator genes. This comparative approach is to some extent, similar to Genorm but 
differs in that BestKeeper focuses in the standard deviation while the others consider 
other factors such as mean and coefficient of variation (141). Pfaffl et al showed that the 
reference value (derived from evaluation of all calibrator genes collectively) obtained 
with their tool performed better than individual calibrator genes. 
 
However, it is conceivable that this approach could be subject to artefacts created by 
the mean of different calibrator genes regardless of its stable expression across all 
samples. For instance, one cycle of qPCR represents a two-fold difference in gene 
expression, thus the exponential nature of the method might affect the resultant 
geometric mean when a few but highly variable samples are included within the 
dataset. This might explain why BestKeeper was reported to be less consistent than the 
other methods evaluated by Chen et al. 
 
Other methods have also been described in the literature. ReadqPCR and NormqPCR are 
packages based on the software ‘R’ for normalisation of qPCR (142). Software R is 
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further described in the methods section 2.12 R software. Both ReadqPCR and 
NormqPCR were explored for use in this work, however, on further exploration it was 
found that both methods rely on the same algorithm used by (and thus are in effect 
derivatives of) Genorm and thus were not further explored. 
 
Finally, the comparative ΔCT method was also evaluated in this project. Whilst doing 
so it revealed that any ΔCT value higher than one would increase towards infinity, 
whilst in contrast, any ΔCT value lower than one would never decrease below zero. 
This exponential equation therefore produces a multiplicative effect rather than an 
additive effect. With this in mind, and these limitations, a modification of this method 
is proposed and described in the methods section. In summary, analysis of the 
variability of calibrator genes will be performed by the comparative ΔCT method using 
absolute values and plots of the data. In additional work to validate the calibrators for 
the current investigative context, the effect of a simulation of postmortem delay on 
brain tissue was explored to explore the stability of the qPCR signal of these calibrator 





The null hypothesis states that there is no significant difference in the levels of these 











4.4.1 Study cohort 
 
The study cohort comprised brain tissue from 22 AD, 20 EAC, 18 VaD and 24 controls, 
as described in Chapter 2.1. 
 
Table 4. 2 Demographic information of the cohort used in Chapter 4. 
Diagnosis Gender 
(Male/Female) 
Age (σ) PMI (σ) ApoE4 
(No/Yes) 
Total 
Control 11/13 80 (9.7) 35.4 (16.2) 21/1 24 
Early Alzheimer Changes 11/9 85 (6) 36.5 (15) 14/4 20 
Alzheimer’s Disease 11/11 78 (7.2) 23.7 (13.4) 3/16 22 
Vascular Dementia 9/9 83 (7.9) 34.7 (12.3) 9/4 18 
Total 42/42 81.2 (8.1) 32.5 (15.1) 47/25 84 
Table shows the demographic information of the cohort, post-mortem interval (PMI), 
standard deviation (σ). 
 
4.4.2. Brain tissue dissection and homogenization 
 
Brain tissue dissection and homogenization was undertaken on the cohort as described 
in Chapter 2.2. 
 
4.4.3. RNA isolation, quantification and standardization 
 
RNA isolation, quantification and standardization were similarly performed as 
described in Chapter 2.3. 
 
4.4.5. Simulation of postmortem delay. 
 
Two cases with the lowest postmortem delay (5 hours) were selected, one with a 
definite diagnosis of AD and the other a non-demented control. From already dissected 
tissue, 60 mg of tissue were taken and divided into 12 aliquots of 5 mg. These aliquots 
were incubated for 0, 6, 12, 24, 48 or 72 hours at room temperature and at 4°C 
(resonating with the typical time window in which most brain banking seeks to recruit 
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within). After incubation, samples were stored at -80°C and once all samples were 
retrieved, RNA isolation, quantification and standardisation were performed as 
described. For RNA isolation, specific quantities were modified according to the 
proportion of tissue. 
 
4.4.6 Data collection and analysis. 
 
Data on selected calibrator genes was generated by quantitative polymerase chain 
reaction (qPCR) as described in Chapter 2.6. The analysis of the resultant data was 
undertaken using the new formula proposed in section 2.7. The 2(-ΔΔCT) method. 
Statistical analysis was performed using the statistical package Graph Pad Prism 









Figure 4.1 shows the variability of expression of RNU43 across the whole cohort (n=84) 
with differences in  CT values from a maximum CT difference value (from the 
geometric mean) of 2.27 to a minimum difference of -1.69. The average percentage 













Figure 4.2 shows the highly variable expression of RNU44 across the whole cohort 
(n=84) between a maximum CT difference of 4.27 and a minimum of -2.45. The average 
percentage of difference to the geometric mean was 188.62%. 
 







































































The lesser variability of expression of RNU48 across the cohort (n=84) is shown in 
Figure 4.3, with values ranging from a maximum CT difference of 2.83 to a minimum 
of -1.57. The average percentage of difference to the geometric mean was 71.23%. 
 





In addition to the significant differences in the levels of expression of RNU6B between 
states of neuropathology observed in Chapter 3, Figure 4.4 shows in more detail the 
variable expression of RNU6B across the cohort (n=84) with differences in the CT 
values from the geometric mean ranging from a maximum of 4.28 to a minimum of -













































The variability in the expression of miR-9-5p across the cohort (n=84) is plotted in 
Figure 4.5, ranging from a maximum CT difference of 1.63 to a minimum of -0.87. The 
average percentage of difference to the geometric mean for miR-9-5p was 29.86%. 
 






































































The variability in the expression of miR-9-3p across the cohort (n=84) is plotted in 
Figure 4.6, ranging from a maximum CT difference of 0.895 to a minimum of -1.019. 
The average percentage of difference to the geometric mean of miR-9-3p was 23.99%. 
 
Figure 4. 6 Plot of CT differences for miR-9-3p in individual samples of the cohort. 
 
 
4.5.1.7 Rank-ordering of the calibrator genes related to CT value differences from 
the geometric mean. 
 
Based on the above data, the rank order of the performance of calibrator genes studied, 
based on the size of average differences observed in CT values from the geometric 
means is as follows: 
 






































4.5.2 Simulation of post-mortem delay 
 
This experiment is to test the stability of the expression of all proposed calibrators in 
post mortem brain tissue. Given that most research using post mortem tissue may be 
subject to the effects on assays of unavoidable post mortem delays and possible 
changes to the tissue, it is important to try and assess if there are any changes to the 
levels of expression that can be measured in such samples. As described in the 
methods, this experiment, which is conducted in brain tissue with an initial short post-
mortem delay from an AD patient and a control (no VaD brain tissue was available) 
tests the performance of each calibrator gene over a series of time points and 




RNU43 showed an approximate CT difference of 2 in the simulation of post-mortem 
delay (Figure 4.7). This CT difference suggests about a four-fold reduction in the levels 
of RNU43 for both samples (AD and control) at both temperatures (4°C and room 
temperature). After six hours, the four samples appeared to continue to degrade until 
72 hours, resulting in an approximate 32 fold reduction in RNU43. 
 


























In Figure 4.8, a CT difference of approximately 1.5 is observed after leaving the 
samples for six hours. This represents an almost three-fold reduction in RNU44 in the 
samples. A similar CT difference is observed for three of the four samples after 12 
hours with the deviation being from the control room temperature (CTRL RT) sample. 
After this point, samples showed greater degradation with more heterogenous results. 
At 72 hours, two samples displayed a CT difference of three indicative of an eight-fold 
reduction in transcript levels whilst two other samples showed CT differences of 4.5 
and around 6 suggesting a decrease of 22 and 64 folds respectively. 
 





As can be observed in Figure 4.9, RNU48 demonstrated reasonable similar and stable 
levels for the 2 tissue samples stored at 4°C until 24 hours. Some difference is later 
perceptible at 48 hours and 72 hours for these samples with CT differences between 0.5 
and 1. A CT difference of 1 at 72 hours indicates a two-fold reduction for the calibrator 
gene RNU48. In contrast, the two samples stored at room temperature started to show 




















CTRL RT CTRL 4°C AD RT AD 4°C
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from 1 to 3.5 up to 72 hours. This represents a reduction from a two-fold at 24 hours to 
an 11 fold decline in measurable RNU48 transcripts at 72 hours. 
 





RNU6B shows a CT difference of nearly 1.5 for both samples stored at 4°C and 
approximately 2.5 for samples stored at room temperature (RT). This corresponds to a 
three-fold and almost six-fold drop in measurable transcript levels respectively (Figure 
4.10). From 12 until 72 hours CT differences varied between 2.5 and 3.5 with some 
minor discrepancies. This represents a diminution in RNU6B transcript levels from six-




























CTRL RT CTRL 4°C AD RT AD 4°C
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Samples stored at 4°C demonstrated steady transcript levels for miR-9-5p up to 72 
hours in the simulation of post-mortem delay as observed in Figure 4.11. In the case of 
samples stored at room temperature, a CT difference of 2 is observable at 72 hours. 
This represents a four-fold drop for miR-9-5p at 72 hours. 
 














































As observed in Figure 4.12, miR-9-3p shows very steady values for both samples at 
both temperatures. All CT differences are within a range of -0.5 to 0.5 to the geometric 
mean. This miRNA, along to its counterpart miR-9-3p are stable up to 72 hours. 
 
Figure 4. 12 CT difference of individual samples to the 0 hours sample for miR-9-3p. 
 
 
4.5.2.7 Comparison and rank-ordering of observed transcript stabilities for 
investigated calibrators. 
 
For the 4°C incubation experiments, based on variations of CT value differences from 
the geometric mean, the performance of the various calibrators, in terms of highest to 
lowest apparent stability of transcripts over time are: 
 























CTRL RT CTRL 4°C AD RT AD 4°C
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For the RT incubation experiments, based on variations of CT value differences from 
the geometric mean, the performance of the various calibrators, in terms of highest to 
lowest apparent stability of transcripts over time are: 
 
miR-9-3p > miR-9-5p > RNU48 > RNU44 > RNU6B > RNU43 
 
4.5.3. Evaluation of calibrator genes according to disease pathology 
 
In addition to the need to assess general patterns of expression of each of the 
calibrators across all individual samples, and to investigate the stability of calibrator 
transcripts under various simulated storage conditions, the final assessment needed to 
verify the suitability of a calibrator is to assess whether the expression of the calibrator 
genes is changed according to any phenotype or level of disease severity, as was noted 
in Chapter 3 for RNU6B highlighting its lack of suitability as a calibrator gene for the 




The small nucleolar RNU43 (Official symbol SNORD43) is transcribed from 
chromosome 22q13.1. The average CT standard deviation between triplicates was 0.052 
(252 triplicates in total) suggesting a good estimate for results (143). D’Agostino & 
Pearson normality test showed that RNU43 doesn’t have a normal distribution. The 
expression of RNU43 with Braak stage score was not significantly different, as assessed 
by Kruskal-Wallis test H=5.09 and significance of p=0.4049 (Figure 4.13). The 
expression of RNU43 between diagnostic groups was not significantly different, as 







Figure 4. 13 Percentage of difference for RNU43 by Braak stages. 
 
Figure shows the percentage of difference for RNU43 in Braak-related disease stages 
compared to samples with Braak stage 0 and I, error bars show the 95% confidence 
interval and average is depicted. 
 
 
Figure 4. 14 Percentage of difference for RNU43 by diagnostic groups. 
 
Figure shows the percentage of difference for RNU43 by diagnostic groups, error bars 






The small nucleolar RNU44 (Official symbol SNORD44) is transcribed from 
chromosome 1q25.1. The average CT standard deviation between triplicates was 0.042 
(255 triplicates in total) suggesting a good estimate for results (143). D’Agostino & 
Pearson normality test showed that RNU44 was not normally distributed. The 
expression of RNU44 with Braak stage score was significantly different, as assessed by 
Kruskal-Wallis test H=14.37 and significance of p=0.0134 (Figure 4.15). Dunn’s post hoc 
test showed a significant difference between Braak stage VI and Braak stage 0-1 
(p<0.05) and Braak stage III (p<0.05) (Figure 4.15). The expression of RNU44 between 
diagnostic groups was significantly different, as assessed by Kruskal-Wallis test H=15.4 
and significance of p=0.0015 (Figure 4.16). Dunn’s post hoc test showed a significant 
difference between AD and VaD (p<0.01) (Figure 4.16). 
 
Figure 4. 15 Percentage of difference for RNU44 by Braak stages. 
 
Figure 4.15 shows the percentage of difference for RNU44 in Braak-related disease 
stages compared to samples with Braak stage 0 and I, error bars show the 95% 







Figure 4. 16 Percentage of difference for RNU44 by diagnostic groups. 
 
Figure shows the percentage of difference for RNU44 between diagnostic groups, error 




The small nucleolar RNU48 (Official symbol SNORD48) is transcribed from 
chromosome 6p21.33. The average CT standard deviation between triplicates was 0.032 
(258 triplicates in total). D’Agostino & Pearson normality test showed that RNU48 was 
not normally distributed. The expression of RNU48 between Braak stages was not 
significantly different, Kruskal-Wallis statistic of H=4.43 and p=0.4893 (Figure 4.17). 
The expression of RNU48 between diagnostic groups was not significantly different, as 










Figure 4. 17 Percentage of difference for RNU48 by Braak stages. 
 
Figure shows the percentage of difference for RNU48 in Braak-related disease stages 
compared to samples with Braak stage 0 and I, error bars show the 95% confidence 
interval and average is depicted. 
 
Figure 4. 18 Percentage of difference for RNU48 by diagnostic groups. 
 
Figure shows the percentage of difference for RNU48 between diagnostic groups, error 






The small nuclear RNU6B (Official symbol RNU6-6P) maps from a pseudogene in 
chromosome 10p13. The average CT standard deviation between triplicates was 0.031 
(252 triplicates in total). D’Agostino & Pearson normality test showed that RNU6B was 
not normally distributed. The expression of RNU6B across Braak stage and VaD was 
significantly different, Kruskal-Wallis statistic of 12.42 and p=0.0294. Dunn’s multiple 
comparison test showed a significant difference between Braak stage VI and Braak 
stage III (p<0.05) (Figure 4.19). The expression of RNU6B between diagnostic groups 
was significantly different, as assessed by Kruskal-Wallis test H=12.37 and significance 
of p=0.0062 (Figure 4.20). Dunn’s multiple comparison test showed a significant 
difference between AD and VaD (p<0.05) (Figure 4.20). 
 
Figure 4. 19 Percentage of difference for RNU6B by Braak stages. 
 
Figure shows the percentage of difference for RNU6B in Braak-related disease stages 
compared to samples with Braak stage 0 and I, error bars show the 95% confidence 







Figure 4. 20 Percentage of difference for RNU6B by diagnostic groups. 
 
Figure shows the percentage of difference for RNU6B between diagnostic groups, error 




miR-9-5p derives from the miR-9 gene along with miR-9-3p located on chromosome 
1q22. The average CT standard deviation between triplicates was 0.036 (252 triplicates 
in total). D’Agostino & Pearson normality test showed that miR-9-5p was not normally 
distributed. The expression of miR-9-5p across Braak stage and VaD was not 
significantly different, Kruskal-Wallis statistic of 7.284 and p=0.2003 (Figure 4.21). The 
expression of miR-9-5p between diagnostic groups was not significantly different, as 










Figure 4. 21 Percentage of difference for miR-9-5p by Braak stages. 
 
Figure shows the percentage of difference for miR-9-5p in Braak-related disease stages 
compared to samples with Braak stage 0 and I, error bars show the 95% confidence 
interval and average is depicted. 
 
Figure 4. 22 Percentage of difference for miR-9-5p by diagnostic groups. 
 
Figure shows the percentage of difference for miR-9-5p between diagnostic groups, 








Similar to its counterpart (miR-9-5p), miR-9-3p derives from the miR-9 gene located on 
chromosome 1q22. The average CT standard deviation between triplicates was 0.042 
(255 triplicates in total). D’Agostino & Pearson normality test showed that miR-9-3p 
was not normally distributed. The expression of miR-9-3p across Braak stage was not 
significantly different, Kruskal-Wallis statistic of 5.104 and p=0.4034 (Figure 4.23). The 
expression of miR-9-3p between diagnostic groups was not significantly different, as 
assessed by Kruskal-Wallis test H=1.581 and p=0.6637 (Figure 4.24). 
 
Figure 4. 23 Percentage of difference for miR-9-3p by Braak stages. 
 
Figure shows the percentage of difference for miR-9-3p in Braak-related disease stages 
compared to samples with Braak stage 0 and I, error bars show the 95% confidence 










Figure 4. 24 Percentage of difference for miR-9-3p by diagnostic groups. 
 
Figure shows the percentage of difference for miR-9-3p between diagnostic groups, 
error bars show the 95% confidence interval and average is depicted. 
 
4.5.3.7. Ranking of calibrators according to expression in relation to 
neurodegenerative pathology and disease group 
 
According to the comparisons of each of the calibrators in relation to markers of 
neurodegenerative pathology and diagnostic group, all but 2 of the calibrators showed 
no significant differences. As a calibrator no differences would be what is expected to 
be suited as a calibrator gene. 
 
4.5.4. Overall ranking of small RNAs as calibrator gene 
 
It is important to assess the performance of all the calibrators across all of the criteria in 
which they were tested in this chapter. This includes assessment of expression 
according to plots of the data across all the individual samples studied and the 
percentage of difference proposed previously. It also includes performance for their 
stability against the simulated post-mortem delay experiments, and the comparisons 




A good calibrator gene should be one with low variance between individual samples, 
show little or no loss of stability according to post-mortem delay time and temperature 
conditions, and not be altered according to the disease phenotypes it is to be used in to 
measure changes of other target miRNAs. 
 
Overall, miR-9-3p appeared to be the most consistent performer across all of these 
investigative tests and would appear to be the highest performing calibrator gene 
tested. On balance the second best performing calibrator was miR-9-5p. The third most 
stable calibrator gene found was RNU48, followed by RNU43 and RNU6B. Finally, 
RNU44 is the least stable calibrator gene evaluated. 
 
 
4.6. Discussion and conclusions 
 
4.6.1 Summary of findings 
 
As stated, the null hypothesis posits that there would be no significant difference in the 
levels of these snRNAs between stages of neuropathology and disease, nominated by 
Braak stage and by type of dementia when compared to VaD. A statistically significant 
difference in the expression of RNU6B and RNU44 was found. Thus, the null 
hypothesis is rejected for these two calibrator genes. Although, the null hypothesis 
cannot be rejected for the rest of snRNAs evaluated, analysis of their stability by 
groups might disguise specific differences. 
 
The alternative analysis using general plots of the data across all samples and the 
percentage of difference using absolute values showed equivalent results. These data 
showed that the most stable, and least variable of the snRNAs were miR-9-3p and miR-
9-5p with only minor differences between them. There were greater levels of variance 
observed for RNU48, RNU43, RNU6B and RNU44 in that order. 
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Similar standardised testing of all the calibrators under simulated conditions of post-
mortem delay showed a similar pattern of results, where the best performing 
calibrators were miR-9-3p and miR-9-5p with the other snRNAs performing less well 
and not to standards that might be deemed acceptable for use in post-mortem tissue 
studies. Finally, from comparisons with neurodegenerative pathology (according to 
Braak stage) and with disease type, there were no significant differences found for 
miR-9-3p, miR-9-5p, RNU48 and RNU43. 
 
4.6.2. Next steps 
 
miRNAs are much more resistant to RNA degradation than longer RNA sequences (66) 
and thus this chapter sought to test more appropriate snRNAs that were of more 
equivalent size to miRNAs as well as test the possible effect of sequence length as a 
variable in its own right with respect to being a calibrator gene. 
 
My results showed that RNU48, miR-9-3p and miR-9-5p are all stable at 4°C in the 
period of 72 hours. This is in accordance to others reports in the literature, in related 
work, Ma et al analysed the effect of post-mortem delay on RNA degradation in rat 
brain tissue (144). They analysed the stability of 9 commonly used calibrators 
(including RNU6B, miR-9 and miR-125b) over a period of 144 hours with 12-time 
points and at different temperatures, including 4, 15, 25, and 35°C. They concluded, in 
this non-human, non-diseased tissue that miR-9 and miR-125b were not degraded up 
to 144 hours post-mortem even at 35°C and that the commonly used RNU6B is not 
suitable as an endogenous control. This is consistent with my findings where miR-9-5p 
and miR-9-3p were the best performing calibrators and RNU6B one of the worst 
performers. 
 
In a subsequent publication, by the same group, they analysed the extent of RNA 
degradation in rat and human tissues from myocardium and liver, but not brain tissue 
(145). They showed in this study that miR-1 and miR-133a were stable over 5 days, 
even at 35°C. Similarly, Peiro-Chova et al analysed samples from patients with breast 
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cancer obtained after tumor resection that were stored using cryopreservation, frozen 
samples with several thawing processes and formalin-fixed paraffin-embedded 
samples (146). They studied the stability of several calibrators, including miR-21, miR-
125b, miR-191 and like in this study, RNU6B. They concluded that miRNAs are 
strongly preserved irrespective of the quality of the tissue sample and that their levels 
were similar between different samples and with RNA integrity values ranging from 
1.3 to 9.7 (147). 
 
From my data, which has been validated against the tissue type and the disease context 
I am investigating, I have concluded that the best choice of calibrators for this work, 
miR-9-3p, miR-9-5p and RNU48, will be used henceforth as calibrator genes for the 
reinvestigation of the panel of miRNAs investigated in Chapter 3 and also to 




















Chapter 5.- Evidence-based re-evaluation of examining miRNAs related to classical 





A number of proteins postulated to play a role in the development of AD have been 
investigated and miRNAs predicted to target those proteins, have been considered as 
miRNAs of interest in the studies outlined in this thesis. Details of experiments to 
determine the involvement of miRNAs findings related to those proteins can be found 
in Chapter 3. Seven miRNAs from five miRNA families of interest were examined in 
Chapter 3, and some thought-provoking results were obtained. 
 
A pattern of expression for five of the seven miRNAs was found to be associated with 
disease progression and significant differences were observed between the diagnostic 
groups EAC, AD, VaD and control. However, it was also found that such 
measurements lacked some precision. The calibrator gene used was not appropriate 
and this questioned preliminary results. 
 
Thus, in Chapter 4, I evaluated six calibrator genes to explore their suitability as 
alternative calibrator genes that would be better suited to the study of miRNAs in AD. 
In doing so, I also scrutinised several methods in order to find the best way of 
analysing the variability of the reference genes. The intention of these studies was to 
identify the best performing calibrator genes to allow a more accurate re-evaluation of 
the miRNAs of interest in relation to the development of classical histopathological 
hallmarks of AD, first described in Chapter 3. 
 
From the six calibrator genes analysed, two of them showed significant differences 
between subgroups. Whilst statistical analysis was undertaken between subgroups, it 
is possible that the use of subgroups can disguise specific differences and thus, I also 
examined variability of expression for each calibrator gene by plots of the data and a 
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proposed percentage of difference method using absolute values (described in 
Methods section 2.7). 
 
To aid with the re-evaluation, the three best performing calibrator genes selected from 
Chapter 4 (miR-9-3p, miR-9-5p and RNU48) were used to re-examine previous miRNA 
families of interest but this time with the total number of miRNAs comprising such 
miRNA families. A summary of the miRNAs and the proteins previously described in 
Chapter 3 are presented in Table 5.1 for convenience. This re-evaluation is the central 

























Table 5. 1 Transcripts and miRNAs related to classical hallmarks of AD. 
Gene name miR-16 miR-29 miR-34 miR-125 miR-132/212 miR-216 
ADAM10 2  2    
BACE1 2 2  1 2 1 
BACE2 1   1  1 
PSEN1  1 1 1  2 
NOTCH1   2 1   
ABCA1   1  1  
LDLR   1  1  
LRP1    1 2  
AGER     2  
SORL1      1 
RELN 2  1    
PDGFB  1 1    
PDGFRA  1 2  1  
PDGFRB  1 1    
AQP4 2 2    4 
CD200   1   1 
CD14   1    
CD200R1   1   5 
MME 1    2 3 
ECE1   2 2   
ECE2      1 
ACE 1 2 3 1   
MMP2  1 1 1   
MMP14   1 1   
CD147    1   
IDE  1  2 1 1 
GSK3B  1   2  
MAPK1  1 2  3  
MAPT   3  1  
PPP2CA 2 1  1  3 
PPP2R1A  1  3   
ANP32A   1  1  
SET  2  1   
OGT 1    2  
PPP3CB 1     3 
Table shows transcripts involved in one or more of the following: amyloid production, 
transport across the blood brain barrier (BBB) and degradation enzymes; tau 
phosphorylation; BBB integrity; glymphatic system or immune response are listed with 







The null hypothesis is that there is no significant difference in the levels of these 






5.3.1. Study cohort 
 
The study cohort, as described in detail in Chapter 2 (Section 2.1) comprised brain 
tissue from 22 AD, 20 EAC, 18 VaD and 24 controls. 
 
Table 5. 2 Demographic information of the cohort used in Chapter 5. 
Diagnosis Gender 
(Male/Female) 
Age (σ) PMI (σ) ApoE4 
(No/Yes) 
Total 
Control 11/13 80 (9.7) 35.4 (16.2) 21/1 24 
Early Alzheimer Changes 11/9 85 (6) 36.5 (15) 14/4 20 
Alzheimer’s Disease 11/11 78 (7.2) 23.7 (13.4) 3/16 22 
Vascular Dementia 9/9 83 (7.9) 34.7 (12.3) 9/4 18 
Total 42/42 81.2 (8.1) 32.5 (15.1) 47/25 84 
Table shows demographic information of the cohort, post-mortem interval (PMI), 
standard deviation (σ). 
 
5.3.2. Brain tissue dissection and homogenization 
 
Brain tissue dissection and homogenization was undertaken on the cohort as described 






5.3.3. RNA isolation, quantification and standardization 
 
RNA isolation, quantification and standardization were performed as described in 
detail in Chapter 2 section 2.3. 
 
5.3.4. Software for analysis of target proteins (DAVID and PANTHER) 
 
DAVID and PANTHER software were used for analysis of predicted target proteins of 
the selected miRNAs as described in detail in Chapter 2 section 2.13. 
 
5.3.5. Data collection and analysis 
 
Data on selected calibrator genes was generated by quantitative polymerase chain 
reaction (qPCR) as described in Chapter 2 section 2.6. The analysis of the resultant data 
was undertaken using the new formula proposed in Chapter 2 section 2.7. Statistical 






This section will include the re-evaluation of all the miRNAs studied in Chapter 3, as 
well as the study of additional miRNAs that represent additional members of the main 
miRNA families that have been attributed to the characteristic hallmarks of AD 
pathology. Table 5.3 summarises the list of miRNAs studied here, according to the 
families they relate to and to highlight those that have been examined in Chapter 3 and 






Table 5. 3 miRNA families studied in Chapter 5. 






Table shows miRNA families studied in this chapter and their corresponding miRNA 
members. 
 
5.4.1. miR-16 family 
 
This miRNA family is composed by miR-15a/15b/16/195/424/497, all of which, as 




miR-15a is encoded on chromosome 13q14.2 (MIR15A gene). After the measurement of 
expression it was revealed by the D’Agostino & Pearson normality test that the miR-
15a measurements were not normally distributed and thus the Kruskal-Wallis test was 
used. This revealed that there was a significant percentage of difference for miR-15a 
between diagnostic groups, Kruskal-Wallis test H=9.55 and p=0.0228 (Figure 5.1). 
Further analysis by Dunn’s multiple comparison test showed a significant difference 
between EAC and AD (p<0.05), whereby there was a higher level of miR-15a 











Figure 5. 1 Percentage of difference for miR-15a. 
 
Figure shows the percentage of difference for miR-15a in different diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 




miR-15b is encoded in chromosome 3q25.33 (MIR15B gene). The D’Agostino & Pearson 
normality test applied to the data showed that, like miR-15a, that the expression for 
miR-15b was not normally distributed and thus the Kruskal-Wallis test was used. This 
then showed the percentage of difference for miR-15b expression was significantly 
different between diagnostic groups, Kruskal-Wallis test H=16.10 and p=0.0011 (Figure 
5.2). Dunn’s multiple comparison test then revealed significant increases in miR-15b 










Figure 5. 2 Percentage of difference for miR-15b. 
 
Figure shows the percentage of difference for miR-15b of all diagnostic groups 
compared to controls. Error bars show the average and the 95% confidence interval, * 




Similar to miR-15a, miR-16 maps to chromosome 13q14.2 (MIR16 gene), both genes are 
clustered within 0.5 kb. Application of the D’Agostino & Pearson normality test to the 
data showed that miR-16 was similarly not normally distributed (as with previous 
family members) and thus, the Kruskal-Wallis test was used. The Kruskal-Wallis test 
on miR-16 (Figure 5.3) revealed significant difference between diagnostic groups, 
(Kruskal-Wallis test H=28.21 and p=0.0001). Furthermore, application of Dunn’s 
multiple comparison test showed a significant increase in miR-16 expression in AD 









Figure 5. 3 Percentage of difference for miR-16. 
 
Figure 5.3 shows the percentage of difference for miR-16 of all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 




miR-195 is transcribed from chromosome 17p13.1 (MIR195 gene). The D’Agostino & 
Pearson normality test, as for the other miRs in this family, showed that miR-195 was 
not normally distributed and thus, the Kruskal-Wallis test was used. In this analysis it 
revealed that the percentage of difference for miR-195 expression (Figure 5.4) was 
significantly different between diagnostic groups (Kruskal-Wallis test H=23.76 and 
p<0.0001). Moreover, Dunn’s multiple comparison test found a significant increase in 










Figure 5. 4 Percentage of difference for miR-195. 
 
Figure shows the percentage of difference for miR-195 for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 




miR-424 is derived from chromosome Xq26.3 (MIR424 gene). As with the previous 
miRNAs, the D’Agostino & Pearson normality test showed that miR-424 was not 
normally distributed and thus, the Kruskal-Wallis test was used. As seen for the other 
family members, miR-424 measurements were significantly different (Figure 5.5) 
between diagnostic groups (Kruskal-Wallis test H=10.42 and p=0.0153). Dunn’s 
multiple comparison test similarly showed a significant difference between AD and 










Figure 5. 5 Percentage of difference for miR-424. 
 
Figure shows the percentage of difference for miR-424 for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 




Similar to miR-195, miR-497 is also transcribed from chromosome 17p13.1 (MIR497 
gene). In contrast to all of the other family members, miR-497 expression was found to 
be normally distributed, which was confirmed by Bartlett’s test (p=0.269). miR-497 was 
significantly different between diagnostic groups (Figure 5.6) ANOVA F=3.01 and 
p=0.0347. Furthermore, Tukey’s multiple comparison test showed a significant increase 











Figure 5. 6 Percentage of difference for miR-497. 
 
Figure shows the percentage of difference for miR-497 for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 
depicted, * p<0.05. 
 
5.4.1.5. Summary of miR-16 family results 
 
All of the individual miRNA members of the miR-16 family showed relatively similar 
results. For some of them (miR-15b, miR-16 and miR-195) significant differences in 
their expression across all diagnostic groups with the greatest expression consistently 
shown in the AD group. For the remainder (miR-15a, miR-424 and 497) despite 
apparent significant differences across all groups, it was later found by Dunn’s 
multiple comparison test, that the greatest effect appeared to be between the AD and 
EAC group. 
 
5.4.1.6. Analysis of miR-16 family predicted target proteins 
 
As these miRNAs share the seed region and predicted targets, and if they have 
influential effects on classical neuropathological hallmarks of AD, perhaps it is not 
unusual for all members of this family to demonstrate similar levels of expression. 
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With this in mind, it was deemed prudent for the predicted targets of these miRNAs to 
be analysed further. 
 
Overall, this miRNA family has 1515 predicted targets according to TargetScan. 
Analysis of these predicted targets with DAVID software (May 2019) found 9 clusters 
that encapsulate particular pathways as defined by gene ontology terms. The clusters 
are annotated with their corresponding number of proteins involved in the pathway 
and the significance (p value) are shown in Table 5.4. The Benjamini value corresponds 
to the normal p-value (significance) adjusted to control for false discovery rate. 
 
Table 5. 4 Analysis of predicted targets for miR-16 family by DAVID software. 




Cluster 1 enrichment score: 2.74   
 Dicer pathway 4 0.48 
 RISC-loading complex 4 0.21 
 miRNA loading onto RISC involved in gene silencing by 
miRNA 
4 0.5 
Cluster 2 enrichment score: 1.3   
 mRNA cleavage involved in gene silencing by siRNA 3 0.68 
 mRNA cleavage involved in gene silencing by miRNA 3 0.78 
 micro-ribonucleoprotein complex 3 0.51 
Cluster 3 enrichment score: 1.18   
 Phosphatidylinositol-5-phosphate binding 5 0.39 
 Phosphatidylinositol-3,5-bisphosphate binding 5 0.81 
 Phosphatidylinositol-3-phosphate binding 5 0.95 
Cluster 4 enrichment score: 0.94   
 Inositol-1,4,5-trisphosphate 5-phosphatase activity 3 0.76 
 Phosphatidylinositol-4,5-bisphosphate 5-phosphatase 
activity 
3 0.85 
 Inositol-1,3,4,5-tetrakisphosphate 5-phosphatase activity 3 0.88 
Cluster 5 enrichment score: 0.73   
 Ubiquitin-like protein binding 3 0.76 
 Protein neddylation 3 0.99 
 Cullin family protein binding 3 0.97 
Cluster 6 enrichment score: 0.51   
 Voltage-gated chloride channel activity 3 0.95 
 Chloride ion binding 3 0.97 
 Regulation of anion transmembrane transport 3 1 
Cluster 7 enrichment score: 0.3   
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 Inorganic anion transport 3 1 
 Inorganic anion exchanger activity 3 0.99 
 Anion transmembrane transport 3 1 
Cluster 8 enrichment score: 0.28   
 Nerve growth factor pathway 4 0.89 
 Epidermal growth factor signalling pathway 4 0.95 
 Platelet derived growth factor signalling pathway 4 0.96 
Cluster 9 enrichment score: 0.04   
 Proteasome 3 0.97 
 Regulation of cellular amino acid metabolic process 3 0.99 
 Antigen processing and presentation of exogenous 
peptide antigen via MHC class I, TAP-dependent 
3 0.97 
Table shows gene ontology and pathways related to proteins predicted to be targeted 
by the miR-16 family according to DAVID software analysis. The number of proteins 
that correspond to each pathway and the significance value (Benjamini value) are 
specified. 
 
To further understand the possible biological relevance of changes observed in miR-16 
family results, predicted targets for various miR-16 members were also analysed with 
PANTHER software (May 2019) and the summary results of these are shown in Table 
5.5. 
 
Table 5. 5 Analysis of predicted targets for miR-16 family by PANTHER software. 





Cell cycle 9 5.65 0.0229 
Insulin/insulin growth factor pathway-mitogen 
activated protein kinase cascade 
13 5.28 0.0014 
Alzheimer disease-amyloid secretase pathway 22 3.49 0.0004 
Alzheimer disease-presenilin pathway 54 3.36 1.72 e-10 
Fibroblast growth factor signalling pathway 26 2.99 0.0008 
Cadherin signalling pathway 28 2.45 0.0133 
Angiogenesis 30 2.28 0.0222 
Wnt signalling pathway 49 2.13 0.0007 
Gonadotropin-releasing hormone receptor 
pathway 
45 2.09 0.0027 
Table shows biological pathways related to proteins predicted to be targeted by miR-16 
family members according to PANTHER software and presented in order of fold 
enrichment. The individual Panther pathways that were identified, the number of 
proteins targeted within that pathway, the corresponding fold enrichment and the 




According to the analysis done by PANTHER, nine pathways were identified that were 
statistically significant. These pathways involved variable numbers of predicted target 
proteins that ranged from 9 to 54 target proteins in any one pathway. These also had a 
range of fold enrichment scores that ranged from 5.65 to 2.09. On further examination 
of the pathways identified, it is evident that the Alzheimer-disease presenilin pathway 
has the highest target protein count and was the most highly significant (p=1.72 e-10), 
with an enrichment score of 3.36. Other pathways that were highly significant included 
the insulin/insulin growth factor pathway-mitogen activated protein kinase cascade 
(p=0.0014); Alzheimer disease-amyloid secretase pathway (p=0.0005); fibroblast growth 
factor signalling pathway (p=0.0008); Wnt signalling pathway (p=0.0007) and 
gonadotropin-releasing hormone receptor pathway (p=0.0027). There were also 
significant effects, although to a lesser extent for cell cycle (p=0.0229); cadherin 
signalling pathway (p=0.0133), and angiogenesis (p=0.0222). 
 
5.4.2. miR-29 family 
 
The miR-29 family is composed of the three members miR-29a/29b/29c, all of which 




miR-29a is encoded on chromosome 7q32.3 (MIR29A gene). miR-29a expression when  
analysed by the D’Agostino & Pearson normality test showed that miR-29a was not 
normally distributed and thus, Kruskal-Wallis test was necessary. Application of the 
Kruskal-Wallis test showed that the percentage of difference for miR-29a (Figure 5.7) 
was significantly different between diagnostic groups (H=8.79 and p=0.032). 
Subsequent post hoc analysis by Dunn’s multiple comparison test found that the 
previous association between all groups is perhaps due to a significant difference in 
miR-29a expression between the VaD and EAC groups such that the expression of the 
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VaD group was significantly lower than that of the EAC group (p<0.05), but which was 
not significantly different to the AD group. 
 
Figure 5. 7 Percentage of difference for miR-29a. 
 
Figure shows the percentage of difference for miR-29a for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 




MiR-29b can be derived from two precursors, miR-29b-1 (MIR29B1 gene) and miR-29b-
2 (MIR29B2 gene) that are co-transcribed with miR-29a (chromosome 7q32.3) and miR-
29c (chromosome 1q32.2) respectively. As for miR-29a, the D’Agostino & Pearson 
normality test showed that miR-29b was not normally distributed and thus, the 
Kruskal-Wallis test was used. On analysis it was revealed that measurements of miR-
29b (Figure 5.8) were significantly different between diagnostic groups (Kruskal-Wallis 
test H=12.77 and p=0.005). Dunn’s multiple comparison test showed a significant 






Figure 5. 8 Percentage of difference for miR-29b. 
 
Figure shows the percentage of difference for miR-29b for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 




miR-29c is mapped to chromosome 1q32.2 (MIR29C gene). Initial analysis by the 
D’Agostino & Pearson normality test showed that miR-29c was normally distributed, 
which was then confirmed by Bartlett’s test. In contrast to the other miR-29 family 
members, analysis by ANOVA showed that there was no significant difference for 












Figure 5. 9 Percentage of difference for miR-29c. 
 
Figure shows the percentage of difference for miR-29c for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 
depicted. 
 
5.4.2.4. Summary of miR-29 family results 
 
Only miR-29b showed a significant increase in AD cases, whilst miR-29c was found to 
have no statistical differences for AD, and miR-29a only had differences between EAC 
and VaD, but not compared to controls. It would seem that the majority of any 
involvement of the miR-29 family in AD may be reliant on miR-29b, and perhaps with 
some contribution from miR-29a. With this in mind additional pathway analysis was 
still deemed a worthy pursuit, to explore further the mechanisms which might be 
influenced by members of the miR-29 family. 
 
5.4.2.5. Analysis of miR-29 family predicted target proteins 
 
The miR-29 family was found to have 1265 predicted targets, according to TargetScan 
and analysis of them with both DAVID and PANTHER software’s showed that these 
proteins are related to a number of pathways shown in Tables 5.6 and 5.7. 
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Table 5. 6 Analysis of predicted targets for miR-29 family by DAVID software. 




Cluster 1 enrichment score: 2.73   
 Collagen type IV trimer 6 0.0009 
 Regulators of Bone Mineralization 6 0.065 
 Angiotensin-converting enzyme 2 regulates heart 
function 
6 0.13 
 Platelet Amyloid Precursor Protein Pathway 6 0.2 
 Acute Myocardial Infarction 6 0.48 
 Intrinsic Prothrombin Activation Pathway 6 0.53 
Cluster 2 enrichment score 1.45   
 5-methylcytosine catabolic process 3 0.63 
 Sulfonate dioxygenase activity 3 0.54 
 C-19 gibberellin 2-beta-dioxygenase activity 3 0.54 
 C-20 gibberellin 2-beta-dioxygenase activity 3 0.54 
 2,4-dichlorophenoxyacetate alpha-ketoglutarate 
dioxygenase activity 
3 0.54 
 Procollagen-proline dioxygenase activity 3 0.54 
 Methylcytosine dioxygenase activity 3 0.54 
 Hypophosphite dioxygenase activity 3 0.54 
 DNA-N1-methyladenine dioxygenase activity 3 0.72 
 Peptidyl-proline hydroxylation 3 0.97 
 Oxidative demethylation 3 0.98 
Cluster 3 enrichment score 0.77   
 L-alpha-amino acid transmembrane transport 3 0.96 
 L-amino acid transport 3 0.98 
 L-amino acid transmembrane transporter activity 3 0.92 
Table shows gene ontology and pathways related to proteins targeted by miR-29 
family, the number of proteins and Benjamini value are specified. 
 
 
Analysis derived from DAVID software identified three clusters of pathways related to 
proteins predicted to be targeted by the miR-29 family. From them, only one pathway 
(collagen type IV trimer) within the cluster with the highest enrichment score (Cluster 
1 enrichment score: 2.73) was found to be significant. Other pathways within this 






Table 5. 7 Analysis of predicted targets for miR-29 family by PANTHER software. 





Axon guidance mediated by netrin 10 4.58 0.0344 
Insulin/insulin growth factor pathway-protein 
kinase B signalling cascade 
13 4.47 0.0051 
Phosphoinositide 3-kinase pathway 14 3.91 0.0089 
Notch signalling pathway 14 3.85 0.0104 
p53 pathway feedback loops 14 3.72 0.0141 
Integrin signalling pathway 43 3.60 3.31 e-9 
Alzheimer disease-presenilin pathway 40 2.97 2.06 e-6 
Epidermal growth factor receptor signalling 
pathway 
23 2.75 0.0071 
Cadherin signalling pathway 26 2.71 0.0028 
Cholecystokinin receptor signalling map 34 2.18 0.0153 
Gonadotropin-releasing hormone receptor 
pathway 
39 2.17 0.0039 
Wnt signalling pathway 41 2.13 0.0041 
Table shows pathways related to proteins targeted by miR-29 family, number of 
proteins targeted, fold enrichment and p values are specified. 
 
After analysis of the target proteins with PANTHER, it was revealed that 12 pathways 
might be involved in miR-29 family function due to their statistically significant values. 
These 12 pathways include a number of proteins ranging from 10 to 41 target proteins 
in any one pathway. The range of enrichment scores for these pathways went from 2.13 
to 4.58. On further inspection of the pathways identified, two of them presented higher 
significance. These pathways are the integrin signalling pathway (p=3.31 e-9) and the 
Alzheimer disease-presenilin pathway (p=2.06 e-6). Other statistically significant 
pathways include: axon guidance mediated by netrin (p=0.0344), insulin/insulin 
growth factor pathway-protein kinase B signalling cascade (p=0.0051), 
phosphoinositide 3-kinase pathway (p=0.0089), Notch signalling pathway (p=0.0104), 
p53 pathway feedback loops (p=0.0141), epidermal growth factor receptor signalling 
pathway (p=0.0071), cadherin signalling pathway (p=0.0028), cholecystokinin receptor 
signalling (p=0.0153), gonadotropin-releasing hormone receptor pathway (p=0.0039) 




5.4.3. miR-34 family 
 
The miR-34 family is composed of four members miRNAs, miR-34a/34b/34c/449, which 




miR-34a is transcribed from chromosome 1p36.22 (MIR34A gene). Initial analysis by 
the D’Agostino & Pearson normality test showed that miR-34a was not normally 
distributed. Kruskal-Wallis test was therefore applied and showed that the percentage 
of difference for miR-34a was significantly different between diagnostic groups 
(H=20.45 and p=0.0001). Subsequent analysis by Dunn’s multiple comparison test 
showed a reduction in miR-34a expression in VaD compared to EAC (p<0.01) and AD 
(p<0.001), but not between EAC and AD compared to controls (Figure 5.9) 
 
Figure 5. 10 Percentage of difference for miR-34a. 
 
Figure 5.10 shows the percentage of difference for miR-34a for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 






miR-34b is transcribed from chromosome 11q23.1 (MIR34B gene). As for miR-34a, the 
D’Agostino & Pearson normality test showed that miR-34b was not normally 
distributed. The percentage of difference for miR-34b expression was then found to be 
significantly different between diagnostic groups (Figure 5.11) using the Kruskal-
Wallis test (H=11.92 and p=0.0076). A significant difference in miR-34b expression was 
then found between EAC and AD (p<0.01), but not between any of the diagnostic 
groups and controls by Dunn’s multiple comparison test. 
 
Figure 5. 11 Percentage of difference for miR-34b. 
 
Figure shows the percentage of difference for miR-34b for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 




Similar to miR-34b, miR-34c also derives from chromosome 11q23.1 (MIR34C gene). 
Also similar to miR-34a and miR-34b, the D’Agostino & Pearson normality test showed 
that miR-34c was not normally distributed. Application of the Kruskal-Wallis test to 
miR-34c expression (Figure 5.12) revealed that there was significant difference between 
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diagnostic groups (H=12.17 and p=0.0068). Similar to miR-34b, Dunn’s multiple 
comparison test showed a significant difference between EAC and AD (p<0.01), but 
none of the diagnostic groups individually differed from controls. 
 
Figure 5. 12 Percentage of difference for miR-34c. 
 
Figure shows the percentage of difference for miR-34c for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 




miR-449 is encoded in chromosome 5q11.2 (MIR449 gene). Unlike the other family 
members, the D’Agostino & Pearson normality test showed that miR-449 was normally 
distributed. However, Bartlett’s test found that the variances between the groups were 
significantly non homogeneous (p=0.001) and thus, the data was analysed with 
Kruskal-Wallis test. There was no significant difference in miR-449 between diagnostic 







Figure 5. 13 Percentage of difference for miR-449. 
 
Figure shows the percentage of difference for miR-449 for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 
depicted. 
 
5.4.3.5. Summary of miR-34 family results 
 
Neither miR-34a, -34b nor -34c, which did not have normal expression distributions, 
showed a significant difference between AD and controls, but there were some 
significant differences identified between levels of expression between various 
diagnostic groups in post hoc analysis. Similarly, miR-449, which had a normal 
distribution of expression, did not have any differences in expression across all groups. 
Acknowledging that there were no significant differences between various diagnostic 
group cases and controls, but that there were still some differences between diagnostic 
groups, it is worthwhile exploring what pathways this miRNA family is related to, 






5.4.3.6. Analysis of miR-34 family predicted target proteins 
 
An initial examination using TargetScan showed that the miR-34 family has 754 
predicted targets. A further analysis (May 2019) of the pathways related to these 
predicted target proteins is shown according to analysis by DAVID software (Table 5.8) 
and PANTHER software (Table 5.9). 
 
Table 5. 8 Analysis of predicted targets for miR-34 family by DAVID software. 




Cluster 1 enrichment score 1.05   
 Semaphorin receptor binding 4 0.76 
 Negative regulation of axon extension involved in axon 
guidance 
4 0.92 
 Chemorepellent activity 4 0.81 
 Negative chemotaxis 4 0.97 
Cluster 2 enrichment score 0.94   
 Positive regulation of cytoplasmic mRNA processing 
body assembly 
3 0.82 
 Poly (A)-specific ribonuclease activity 3 0.82 
 RNA phosphodiester bond hydrolysis, exonucleolytic 3 1 
 Nuclear-transcribed mRNA poly(A) tail shortening 3 1 
Cluster 3 enrichment score 0.74   
 Fatty acid transport 3 0.91 
 Long chain fatty acid-coA ligase activity 3 0.82 
 Long chain fatty acid metabolic process 3 0.98 
 Peroxisome proliferator activated receptor signalling 
pathway 
3 0.92 
Cluster 4 enrichment score 0.6   
 Diacylglycerol kinase activity 3 0.76 
 Protein kinase C-activating G-protein couple receptor 
signalling pathway 
3 1 
 Glycerolipid metabolism 3 0.88 
Cluster 5 enrichment score 0.58   
 nuRD complex 3 0.71 
 ATP-dependent chromatin remodelling 3 0.99 
 Nucleosomal DNA binding 3 0.99 
Cluster 6 enrichment score 0.19   
 tRNA export from nucleus 3 1 
 Regulation of glucose transport 3 1 
 mRNA export from nucleus 3 1 
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 Viral transcription 3 1 
 Protein sumoylation 3 1 
Table shows gene ontology and pathways related to proteins targeted by miR-34 
family, the number of proteins and Benjamini value are specified. 
 
None of the pathways identified by DAVID software reached levels of significance. 
Nevertheless, when analysed with PANTHER, five pathways were found to be 
statistically significant (Table 5.9). 
 
Table 5. 9 Analysis of predicted targets for miR-34 family by PANTHER software. 





Notch signalling pathway 17 7.94 1.24 e-7 
Metabotropic glutamate receptor group II pathway 9 5.37 0.0179 
5-hydroxytryptamine-2 type receptor mediated 
signalling pathway 
10 4.18 0.0468 
Transforming growth factor-beta signalling 
pathway 
15 3.62 0.0072 
Alzheimer disease-presenilin pathway 25 3.16 0.0002 
Table shows pathways related to proteins targeted by miR-34 family, number of 
proteins targeted, fold enrichment and p values are specified. 
 
According to the analysis done with PANTHER, these five pathways include variable 
number of predicted target proteins that range from 9 to 25 proteins in any one 
pathway. Notably, the pathway with the highest significance (p=1.24 e-7) and fold 
enrichment score (7.94) is the Notch signalling pathway. Other pathways retrieved are 
Metabotropic glutamate receptor group II pathway (p=0.0179), 5-hydroxytryptamine-2 
type receptor mediated signalling pathway (p=0.0468), transforming growth factor-beta 
signalling pathway (p=0.0072), and Alzheimer disease-presenilin pathway (p=0.0002). 
Interestingly presenilins, part of the ɣ-secretase, regulate Notch signalling and are both 






5.4.4. miR-125 family 
 





miR-125a is transcribed from chromosome 19q13.41 (MIR125A gene).  Initial analysis 
by the D’Agostino & Pearson normality test showed that miR-125a was not normally 
distributed. The percentage of difference for miR-125a was significantly different 
between diagnostic groups (Figure 5.14) using the Kruskal-Wallis test (H=7.992 and 
p=0.046). Further analysis was then performed with Dunn’s multiple comparison test 
showing a significant difference in miR-125a expression between EAC and AD 
(p<0.05). 
 
Figure 5. 14 Percentage of difference for miR-125a. 
 
Figure shows the percentage of difference for miR-125a for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 






miR-125b is transcribed from chromosome 11q24.1 (MIR125B gene). The D’Agostino & 
Pearson normality test applied to the data showed that miR-125b was not normally 
distributed and thus the Kruskal-Wallis test was used. This then showed that the 
percentage of difference for miR-125b was significantly different between diagnostic 
groups (Figure 5.15), Kruskal-Wallis test H=27.61 and p<0.0001. Dunn’s multiple 
comparison test then revealed a significant increase in miR-125b expression in AD 
compared to controls (p<0.01), EAC (p<0.001) and VaD (p<0.0001). 
 
Figure 5. 15 Percentage of difference for miR-125b. 
 
Figure shows the percentage of difference for miR-125b for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 
depicted, ** p<0.01, *** p<0.001, **** p<0.0001. 
 
5.4.4.3. Summary of miR-125 family results 
 
Despite the fact that miR-125a did not reach a significant difference between AD and 
controls, miR-125b expression appeared to be more greatly altered between AD cases 
and controls, but also between AD and the other diagnostic groups. In contrast, miR-
125a was only significantly different between EAC and AD. Given these observed 
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differences with controls and between groups for miR-125 family members, it is worth 
exploring what pathways and target proteins have been attributed to miR-125 activity, 
to further explore what effects they may have on AD pathology. 
 
5.4.4.4. Analysis of miR-125 family predicted target proteins 
 
Assessment of this miRNA family on TargetScan shows that it may have 931 predicted 
target proteins. The analysis of the pathways (May 2019) related to these proteins is 
shown for both DAVID software (Table 5.10) and PANTHER software (Table 5.11). 
 
Table 5. 10 Analysis of predicted targets for miR-125 by DAVID software. 




Cluster 1 enrichment score 1.72   
 2,4-dichlorophenoxyacetate alpha-ketoglutarate 
dioxygenase activity 
3 0.35 
 Procollagen-proline dioxygenase activity 3 0.35 
 Hypophosphite dioxygenase activity 3 0.35 
 Sulfonate dioxygenase activity 3 0.35 
 C-19 gibberellin 2-beta-dioxygenase activity 3 0.35 
 C-20 gibberellin 2-beta-dioxygenase activity 3 0.35 
 DNA-N1-methyladenine dioxygenase activity 3 0.58 
 Peptidyl-proline hydroxylation 3 0.94 
Cluster 2 enrichment score 1.32   
 3-oxo-cerotoyl-CoA synthase activity 3 0.58 
 3-oxo-arachidoyl-CoA synthase activity 3 0.58 
 3-oxo-lignoceronyl-CoA synthase activity 3 0.58 
 Fatty acid elongase activity 3 0.58 
 Fatty acid elongation, monounsaturated fatty acid 3 0.86 
 Fatty acid elongation, polyunsaturated fatty acid 3 0.86 
 Fatty acid elongation, saturated fatty acid 3 0.86 
 Very long-chain fatty acid biosynthetic process 3 0.96 
Cluster 3 enrichment score 1.11   
 Dicer pathway 3 0.64 
 RISC-loading complex 3 0.51 
 miRNA loading onto RISC involved in gene silencing by 
miRNA 
3 0.86 





 RISC complex 3 0.67 
 Double-stranded RNA binding 3 1 
Cluster 4 enrichment score 1.06   
 Neuropilin binding 4 0.53 
 Semaphorin receptor binding 4 0.8 
 Semaphorin-plexin signalling pathway 4 0.99 
Cluster 5 enrichment score 0.91   
 Voltage-gated sodium channel activity involved in 
cardiac muscle cell action potential 
3 0.44 
 Voltage-gated sodium channel complex 3 0.71 
 Cardiac muscle cell action potential involved in 
contraction 
3 0.98 
 Sodium channel regulator activity 3 0.98 
Cluster 6 enrichment score 0.79   
 Magnesium ion transport 3 0.96 
 Magnesium ion transmembrane transport 3 0.98 
 Magnesium ion transmembrane transporter activity 3 0.90 
Cluster 7 enrichment score 0.72   
 Inorganic anion exchanger activity 4 0.75 
 Regulation of intracellular pH 4 0.99 
 Bicarbonate transport 4 1 
Cluster 8 enrichment score 0.7   
 G-protein activated inward rectifier potassium channel 
activity 
3 0.76 
 Inward rectifier potassium channel activity 3 0.93 
 Potassium ion import 3 1 
Cluster 9 enrichment score 0.53   
 Antigen Processing and Presentation 3 0.86 
 Proteasome core complex 3 0.83 
 Threonine-type endopeptidase activity 3 0.94 
 Proteolysis involved in cellular protein catabolic process 3 1 
Table shows gene ontology and pathways related to proteins targeted by miR-125 
family, the number of proteins and Benjamini value are specified. 
 
 
Similar to previous miRNA families analysed, none of the pathways identified with 
DAVID software reached levels of significance. Nonetheless, when analysed with 







Table 5. 11 Analysis of predicted targets for miR-125 by PANTHER software. 





p38 mitogen-activated protein kinase pathway 9 4.8 0.0427 
Transforming growth factor-beta signalling 
pathway 
20 3.86 0.0002 
Epidermal growth factor receptor signalling 
pathway 
23 3.73 5.91e-5 
Ras pathway 12 3.63 0.0444 
Fibroblast growth factor signalling pathway 18 3.36 0.0038 
Table 5.10 Pathways related to proteins targeted by miR-125 family, number of 
proteins targeted, fold enrichment and p values are specified. 
 
According to the analysis done by PANTHER, five pathways were identified that were 
statistically significant. These pathways involved variable numbers of predicted target 
proteins that ranged from 9 to 23 target proteins in any one pathway. These also had a 
range of fold enrichment scores that ranged from 3.36 to 4.8. On further examination of 
the pathways identified, the highest significance value was observed for the epidermal 
growth factor receptor signalling pathway with an enrichment score of 3.73 and also 
the highest target protein count. Other pathways that were statistically significant 
included the p38 mitogen-activated protein kinase pathway (p=0.0427), transforming 
growth factor-beta signalling pathway (p=0.0002), Ras pathway (p=0.0444) and 
fibroblast growth factor signalling pathway (p=0.0038). 
 
5.4.5. miR-132/212 family 
 
This miRNA family is composed by miR-132 and miR-212, both genes are clustered 




Application of the D’Agostino & Pearson normality test to the data found that the 
expression of miR-132 was not normally distributed and thus Kruskal-Wallis test was 
used. The percentage of difference for miR-132 expression, as found by Kruskal-Wallis 
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test was significantly different between diagnostic groups (H=30.37 and p<0.0001). 
Furthermore, application of Dunn’s multiple comparison test showed a significant 
decrease in miR-132 expression in AD in comparison with controls (p<0.0001), EAC 
(p<0.01) and VaD (p<0.05), but no differences between EAC and VaD compared to 
controls. 
 
Figure 5. 16 Percentage of difference for miR-132. 
 
Figure shows the percentage of difference for miR-132 for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 




As with previous miRNAs, the percentage of difference for miR-212 was not normally 
distributed according to D’Agostino & Pearson normality test. Then, analysis by the 
Kruskal-Wallis test revealed that miR-212 levels were significantly different between 
diagnostic groups, (H=28.54 and p<0.0001). Furthermore, application of Dunn’s 
multiple comparison test showed a significant decrease in AD in comparison with 
controls (p<0.0001) and EAC (p<0.01), but no differences between EAC and VaD and 




Figure 5. 17 Percentage of difference for miR-212. 
 
Figure shows the percentage of difference for miR-212 for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 
depicted, ** p<0.01 and **** p<0.0001. 
 
5.4.5.3. Summary of miR-132 family results 
 
Both miR-132 and miR-212 demonstrated a significant reduction in AD cases compared 
to controls and also with respect to the EAC group. Whilst miR-132 reached 
significance for a difference between the AD and the VaD groups, this was not 
observed for miR-212. To further understand the possible biological relevance of the 
reduction observed in miR-132 and miR-212 in AD it was prudent to analyse the 
predicted target proteins regulated by this miRNA family. 
 
5.4.5.4. Analysis of miR-132 family predicted target proteins 
 
An initial examination using TargetScan showed that the miR-132 family has 474 
predicted target proteins. A further analysis (May 2019) of the pathways related to 
these predicted target proteins is shown according to analysis by DAVID software 
(Table 5.12) and PANTHER software (Table 5.13). 
153 
 
Table 5. 12 Analysis of predicted targets for miR-132 family by DAVID software. 




Cluster 1 enrichment score 1.15   
 Insulin growth factor-1 signalling pathway 4 0.37 
 Insulin signalling pathway 4 0.37 
 Thrombopoietin signalling pathway 4 0.41 
 Epidermal growth factor signalling pathway 4 0.47 
Cluster 2 enrichment score 0.93   
 Multiple antiapoptotic pathways from IGF-1R signalling 
lead to BAD phosphorylation 
4 0.4 
 Transcription factor CREB and its extracellular signals 4 0.47 
 IL-2 Receptor Beta Chain in T cell Activation 4 0.66 
Cluster 3 enrichment score 0.91   
 Voltage-gated sodium channel complex 3 0.51 
 Voltage-gated sodium channel activity 3 0.67 
 Neuronal action potential 3 0.91 
 Membrane depolarization during action potential 3 0.91 
 Ion channel activity 3 0.91 
Cluster 4 enrichment score 0.72   
 T-cell anergy 3 0.98 
 Dorso-ventral axis formation 3 0.4 
 Links between Pyk2 and Map Kinases 3 0.79 
Table shows gene ontology and pathways related to proteins targeted by miR-132/212 
family, the number of proteins and Benjamini value are specified. 
 
As with previous miRNA families analysed, none of the pathways identified with 
DAVID software reached levels of significance. Nevertheless, when analysed with 
PANTHER, five pathways were found to be statistically significant (Table 5.13). 
 
Table 5. 13 Analysis of predicted targets for miR-132 family by PANTHER software. 





Insulin/insulin growth factor pathway-protein 
kinase B signalling cascade 
8 7.34 0.0048 
p53 pathway feedback loops 2 10 7.10 0.0006 
Transforming growth factor-beta signalling 
pathway 
17 6.45 1.05e-6 
Phosphoinositide 3 kinase pathway 8 5.97 1.79e-2 
B cell activation 9 5.5 1.2e-2 
Epidermal growth factor receptor signalling 
pathway 
17 5.42 1.06e-5 
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p53 pathway 13 5.4 0.0004 
Gonadotropin-releasing hormone receptor 
pathway 
34 5.04 1.9e-11 
Fibroblast growth factor signalling pathway 13 4.77 0.0013 
Parkinson disease 11 4.7 0.0074 
Angiogenesis 16 3.87 0.0015 
Cholecystokinin receptor signalling map 21 3.6 0.0002 
Wnt signalling pathway 22 3.05 0.0013 
Table shows pathways related to proteins targeted by miR-132/212 family, number of 
proteins targeted, fold enrichment and p values are specified. 
 
According to the analysis done by PANTHER, 13 pathways were identified to be 
statistically significant. These pathways involved variable numbers of predicted target 
proteins that ranged from 8 to 34 target proteins in any one pathway. These also had a 
range of fold enrichment scores that ranged from 3.05 to 7.34. On further examination 
of the pathways identified, three of them showed a high significant value, the 
gonadotropin-releasing hormone receptor pathway (p=1.9e-11), the transforming 
growth factor-beta signalling pathway (p=1.05e-6) and the epidermal growth factor 
receptor signalling pathway (p=1.06e-5). Other pathways that were highly significant 
included the insulin/insulin growth factor pathway-protein kinase B signalling cascade 
(p=0.0048), the p53 pathway feedback loops 2 (p=0.0006), the phosphoinositide 3 kinase 
pathway (p=1.79e-2), B cell activation (p=1.2e-2), p53 pathway (p=0.0004), fibroblast 
growth factor signalling pathway (p=0.0013), Parkinson disease (p=0.0074), 
angiogenesis (p=0.0015), cholecystokinin receptor signalling map (p=0.0002) and Wnt 
signalling pathway (p=0.0013). 
 
 
5.5 Discussion and conclusions 
 
The null hypothesis was that there is no significant difference in the levels of these 
miRNAs between diagnostic groups, AD, VaD, early AD changes (EAC) and non-
demented controls. The null hypothesis is rejected for 15 of the 17 miRNAs measured. 
Although some miRNAs showed significant differences between diagnostic groups, 
only seven of them (miR-15b, miR-16, miR-195, miR-29b, miR-125b, miR-132 and miR-
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212) were found to be significantly different in the AD group compared to controls. In 
order to understand the possible impact that miRNAs might have in disease, several 
factors should be considered. 
 
In Chapter 3, a pattern of expression for five miRNAs (miR-16, miR-29a, miR-29b, miR-
34a, miR-125b) was found with respect to Braak stage. The initial interesting finding in 
Chapter 3, that there was apparent increase in some of these miRNAs in AD, not VaD 
in Braak stage II disappeared when the size of the cohort was increased and they were 
re-evaluated with the three unchanging calibrator genes identified in Chapter 4. This 
highlights the importance of sample size and the use of rigorously verified calibrator 
genes. 
 
Indeed, according to the data of re-assessed miRNAs in this chapter, and comparison 
with their corresponding data in Chapter 3 highlights that, the most commonly used 
calibrator gene, RNU6B (137) is questionable as a reliable calibrator for brain tissue 
studies of neurodegenerative disease. Most notable in this conclusion is that RNU6B 
was not stable after only 6 hours in the simulation of post-mortem delay experiment. 
This lack of stability might give rise to high RNU6B variability in various cohorts and 
thus increase the likelihood of false associations. By using three different calibrator 
genes, that have been demonstrated to have low variability and high stability to 
degradation rates, it gives greater confidence as to the accuracy of the results shown in 
this chapter compared to those presented in Chapter 3, which were based on what 
were approaches (using certain calibrators) more regularly used in the scientific 
literature. 
 
From other studies, downregulation of the miR-132/212 family across different brain 
areas has been the only consistent finding so far in AD (64), which the data presented 
here agrees with. Whilst in Chapter 3, using a less reliable calibrator, miR-132/212 was 
found to be significantly reduced in AD and VaD for both miRNAs. In this Chapter, 
similar but statistically more significant (indicating greater confidence) reductions 
were found for both AD and VaD, but also for early AD changes (EAC). Other 
156 
 
miRNAs here examined have been found in the literature with inconsistent results that 
likely relate to the techniques used and brain regions analysed. Similar to the results 
here shown, miR-15a, miR-29b, miR-34a, miR-125a and miR-125b have been found to 
be increased in AD brain (148) whilst contradictorily some of these miRNAs (miR-15a 
and miR-29b) have also been found to be decreased in AD by others in the literature 
(121,149). 
 
In Chapter 3, a similar analysis of predicted targets for the miR-132/212 family was 
undertaken that showed that these proteins are related to the TGF-beta receptor/activin 
receptor pathway, Rho GTPase pathway, voltage gated sodium channel and sodium 
ion transport and insulin/IGF-1 signalling pathway. The Rho GTPase pathway and the 
voltage gated sodium channel pathways in particular might be more relevant in the 
function of this miRNA family as it is highly expressed in dendrites and synapses 
(150). However, in the corresponding pathway analysis performed in this chapter, the 
Rho GTPase pathway was not found by DAVID nor PANTHER software despite prior 
evidence as to its importance in the function of this miRNA family. This highlights 
another important challenge in the study of miRNAs, and potentially in the use of 
bioinformatics in general, whereby similar analyses over a period of time can provide 
differences due to changing availability of data that can be updated, refined and in 
some cases revised or corrected. Thus, as a standard practice, with respect to any 
analyses and publication of results for any analysis using publicly available software 
and databases, the times at which the analyses were performed are strongly advised. 
Another implication of this is with respect to the effect it could give rise to false 
positives findings.  For instance, the miR-29 targets were seen to be related to the 
platelet amyloid precursor protein pathway with a change in the p-value from 0.0052 
(March 2017) as identified for work conducted in Chapter 3 to a non-significant p-value 
of 0.2 (May 2019) as was identified for the work in this chapter. This presents an 
important challenge for miRNA research and demonstrates the need for any ongoing 
project that the rationale by which they have been previously identified may require 





Another consideration and potential limitation, which the use of both DAVID and 
PANTHER here is designed to mitigate against, is that, the use of a single software can 
introduce bias towards the results. For example, using the preliminary data shown in 
Chapter 3 that was only analysed with DAVID software, when two types of software 
were applied to the same family, as was undertaken in this chapter, the results 
obtained from both DAVID and PANTHER software can differ. On one hand, even 
though the data might differ, that they both might yield results that point to related or 
converging pathways can still support the function. For instance, miR-29 target 
proteins relate to angiotensin-converting enzyme 2 regulation of heart function, 
platelet amyloid precursor protein pathway, Notch signalling pathway and Alzheimer 
disease-presenilin pathway, all of them relevant for dementia. However, it may also be 
conceivable, that instead of showing supportive converging results, it could have the 
potential to lead to contradictory information, thereby making interpretation of the role 
of target miRNAs a significant challenge. 
 
Furthermore, several pathways can be found to relate to targets for a particular 
miRNA, however, if such pathways are being represented by a reduced number of 
proteins, for instance three proteins from hundreds of predicted targets, the final effect 
of the miRNA can be minimal and it could be similar to a single miRNA-protein 
relation. In addition, other factors such as the spatiotemporal expression of a miRNA 
should be considered. 
 
No patterns of expression were found in this analysis. Yet, the RORA protein 
represents an attractive target for the multiple points at which intersects with 
characteristics observed in dementia. Similarly, with respect to the miR-132/212, the 
MAP2 protein could provide more information about the role of this miRNA family in 
synaptic loss. Both proteins were attempted to be measured and are presented in 
Appendix 2. This chapter covered classical histopathological hallmarks of AD. A 
slightly different approach and considering proteins that might be relevant to vascular 
factors and hypoxic conditions is presented in Chapter 6. 
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AD is histopathologically characterised by extracellular amyloid plaques, intracellular 
neurofibrillary tangles, astrogliosis and reactive microglia. Similar to VaD, many cases 
of AD also demonstrate varying degrees of vascular changes such as cortical 
microinfarcts, lacunar infarcts in the basal ganglia and cortical petechial microbleeds, 
which are linked to cerebral amyloid angiopathy (CAA) (5). 
 
As mentioned in the introduction of this thesis, cerebral microinfarcts are caused by 
occlusion of cerebral blood flow and microbleeds are caused by extravasation of blood 
into the brain parenchyma. Interestingly, post-mortem microinfarcts have been 
associated with ante-mortem microbleeds in an odds ratio (OR) of 8.6. The authors of 
the study suggested that the 8-fold association of increased risk of microinfarcts in the 
presence of microbleeds could be due to the vascular damage and BBB disruption 
caused by CAA pathology (23). 
 
Both microinfarcts and microbleeds are common findings at postmortem, the 
prevalence of microinfarcts has been reported as 16-48% of all brains studied whilst for 
microbleeds it is around 23.5% (23,151). Microinfarcts and microbleeds are also both 
associated with cognitive decline regardless of the presence or not of dementia (31,32). 
 
Extravasation of blood into the brain parenchyma is neurotoxic. Haemorrhage triggers 
the formation of cerebral oedema in the tissue surrounding the haemorrhage. First, 
cytotoxic oedema is produced by glutamate accumulation. Then, vasogenic oedema is 
produced by exudation of serum proteins, including thrombin. Thrombin activates 
microglia and downregulates tight-junction proteins in endothelial cells through 




This results in BBB disruption and opening. Moreover, haemoglobin (derived from 
blood extravasation) degrades into methaemoglobin and free iron. Methaemoglobin is 
a ligand for the toll like receptor 4 (TLR4) and is able to activate microglial secretion of 
TNF and inflammation. Free iron causes reactive oxygen species production, matrix 
metalloproteinase 9 activation and BBB disruption (152). 
 
Microinfarcts are caused by CAA, arteriolosclerosis, microemboli and hypoperfusion 
(31). Cortical microinfarcts but not subcortical microinfarcts are associated with 
cognitive impairment, in particular amongst individuals with risk factors for dementia 
(32). Arvanitakis et al examined the brains of 1,066 individuals looking at the 
relationship between microinfarcts and cerebral vessel pathology. Atherosclerosis was 
present in 41% of the individuals, arteriosclerosis in 36% and CAA in 35% of them. 
Interestingly, they found that atherosclerosis and arteriosclerosis were associated with 
subcortical microinfarcts whilst CAA was associated with cortical microinfarcts (153). 
 
Although these associations do not necessarily imply a causal relationship, the findings 
highlight the importance of topographical location of vessel pathology that might 
contribute to differences in underlying aetiology. Remarkably, the specific association 
between cortical microinfarcts, CAA and cognitive decline still remains unclear. This 
might be explained by relating the normal physiology of CAA and localization of 
microinfarcts in the cortex. As described in the introduction of this thesis, Aβ 
accumulates directly in relation to the amount of synaptic activity (154).  
 
Further research is necessary to fully elucidate the relationship between microinfarcts, 
microbleeds, CAA and cognitive decline. As suggested by Damasceno (32), the most 
relevant factor for the development of microinfarcts is CAA, where Aβ is deposited in 
the capillaries with subsequent occlusion and decrease in blood flow. This causes 
chronic cerebral hypoperfusion with hypoxia, oxidative stress and inflammation, also 




Poels et al examined the prevalence and determinants of microbleeds in a cohort of 
3,979 individuals. The presence of microbleeds was detectable in middle age and 
strongly increased with age. They also found a robust association between 
cardiovascular factors (such as systolic blood pressure, hypertension and smoking) and 
microbleeds in subcortical regions. Interestingly, they found that strictly lobar 
microbleeds (markers of CAA) were significantly more often present in carriers of the 
APOE ε4 allele (155). 
 
Alongside vascular changes, AD and VaD also present other similarities, such as risk 
factors. The greatest genetic risk factor for the development of dementia is the presence 
of the APOE ε4 allele, which is also associated with increased risk of CAA and CAA-
related haemorrhages, normal aging-related cognitive decline, hyperlipidaemia, 
hypercholesterolemia, atherosclerosis, cardiovascular and cerebrovascular disorders 
(40). 
 
ApoE, which is encoded for by ApoE, is a cholesterol carrier that supports lipid 
metabolism and injury repair in the brain (40). Presence of two copies of the ApoE ε4 
has been reported to increase the risk for dementia up to as much 15-fold (40). 
Furthermore, differences in risk have been observed between different genetic 
backgrounds, for example carriers of ApoE ε4 having an odds ratio (OR) of 5.7 in 
African American individuals, OR 2.2 in Hispanic individuals, OR 33.1 in Japanese 
individuals (40). Yet, the importance of disturbance to pathways associated with 
cholesterol metabolism has been strongly associated with the development of dementia 
in general. Genome wide association studies have also highlighted the involvement of 
multiple genes involved in cholesterol metabolism and immune response (42). 
 
Interestingly, cholesterol derivatives are able to upregulate the brain renin angiotensin 
system, an important system for the control of blood pressure and which is also 
implicated in other cardiovascular and cerebrovascular disorders (156). Hypertension 
(Stage 1: systolic/diastolic blood pressure of ≥ 140/90), and even prehypertension (Stage 
2: blood pressure of 130-139/80-89), considered as a systolic blood pressure <140 mmHg 
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have been widely reported as a risk factor for the development of dementia (22). 
Several studies have shown cognitive decline in late-life (≥70 years) when individuals 
had high blood pressure in middle life. Hypertension induces stiffening of large 
arteries and this in turn reduces cerebral blood flow. Its effect is also observed in small 
vessels where hypertension may result in degenerative changes to the vessel wall that 
can result in haemorrhages which are another risk factor for AD, and also for some 
forms of VaD (22). 
 
Hypertension, which can be induced by excess angiotensin II (Ang II)-mediated 
signalling, causes neurovascular dysfunction, mediated by central and peripheral 
effects on cerebral blood vessels (22). Such effects can include modulation of cerebral 
blood flow by vasoconstrictors such as Ang II, and also endothelin, but also 
vasodilators such as bradykinin and adenosine. Notably, the vasopressor effect of Ang 
II is also counter-regulated by other angiotensin ligands that bind through different 
RAS receptors in the brain (65). 
 
Thus, an analysis of miRNAs involved in the RAS was performed, reviewed in (65), 
where 368 different miRNA families were found that target RAS elements, with the 
majority of these elements sharing gene transcripts. Table 6.1 summarizes the total 
number of miRNAs and unique miRNAs that have thus far been attributed to RAS 
elements, but where some also have other targets outside the RAS. For example, 
Angiotensin IV receptor (also known as AT4R or IRAP) has 252 miRNA families 
associated with it, making it the highest amongst the RAS, but also perhaps not 
surprising because the receptor is also involved in a number of metabolic pathways, 
including insulin transport, as well as oxytocin and vasopressin-related functions, in 
addition to downstream signalling in RAS that has been reported to be important in 
cognitive function. 
 




Figure shows the renin angiotensin system (RAS) and its components. RAS has two 
main axes: the pressor axis (tending towards an increase in blood pressure) comprising 
AngII, ACE and AT1Rs and the counter-regulatory axis comprising Ang(1–7), ACE2 
and MasR. Angiotensin I (AngI), angiotensin II (AngII), angiotensin III (AngIII), 
angiotensin IV (AngIV), aminopeptidase A (APA), aminopeptidase N (APN), 
carboxypeptidase P (CP), prolyl oligopeptidase (PO), angiotensin 3-7 (Ang3-7), 
angiotensin 1-7 (Ang1-7), carboxypeptidase P (CP). 
 
 
In contrast, the MAS receptor (MasR), a receptor involved in Ang-(1-7) signalling has 
only five miRNAs known to be associated, suggesting tightly regulated homeostatic 
expression, although other post-transcriptional modifications are also likely to be 
involved in its regulation. The MAS receptor, activated by the ligand Ang 1-7, 
functions as counterbalance to the angiotensin II type 1 receptor, thus MAS receptor 






Table 6. 1 RAS elements with their total amount of miRNAs. 
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Angiotensin converting enzyme ACE 59 55 4 
Angiotensin converting enzyme 2 ACE2 54 50 4 
Angiotensinogen AGT 85 74 11 
Angiotensin II type 1 receptor AGTR1 46 45 1 
Angiotensin II type 2 receptor AGTR2 78 73 5 
Aminopeptidase N ANPEP 31 27 4 
Dipeptidyl peptidase DPP3 32 32 0 
Aminopeptidase A ENPEP 158 145 13 
Angiotensin IV receptor (IRAP) * LNPEP 252 224 28 
Mas receptor MAS1 5 4 1 
Neprilysin MME 151 143 8 
Renin REN 21 19 2 
Aminopeptidase B RNPEP 29 29 0 
Table shows RAS elements with their total amount of miRNAs, the number of 
overlapping miRNAs with respect to other elements of the RAS and number of unique 
miRNAs for each RAS component. * denotes the fact that the complex molecule IRAP 
has both enzymatic as well as receptor functions, also been referred to in the literature 
by a number of other names such as: Oxytocinase, Vasopressinase, Insulin Regulated 
Aminopeptidase (IRAP), Angiotensin type IV receptor (AT4) (158). 
 
A more detail of RAS-associated miRNAs, according to their functional impact in the 
RAS physiology is shown in Table 6.2. From a total of 164 combinations (Appendix 3) 
of overlapping targets and miRNAs in common, 14 were selected since these might 
have a functional impact in the RAS as they targeted multiple RAS components. Of 
these, 12 of them if increased would promote vasoconstriction and two would increase 
vasodilation. 
 
6.1.1. A brief introduction to multi-functional miRNAs in RAS 
 
miR-125-5p, which is listed, was also notably included in the first panel of miRNAs 
discussed in this thesis that investigated miRNAs involved in amyloid and tau 
processing. miR-670-3p is an interesting miRNA having  550 predicted targets, yet only 
26 copies have been previously reported in miRbase. Based on this apparent 
discrepancy, particularly the low copy number, it is likely that changes in miR-670-3p 
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are unlikely to have any meaningful effect and thus will not be considered further as a 
miRNA of interest. 
 
Table 6. 2 Combinations of RAS components and miRNAs in common. 
RAS components miRNA families in common 
ACE ACE2 ANPEP ENPEP 
LNPEP 
1 miR-125-5p 
ANPEP DPP3 ENPEP LNPEP 1 miR-670-3p 
AGTR2 DPP3 LNPEP MME 1 miR-17-5p/20-5p/93-5p/106-5p/519-3p 
ACE2 ENPEP LNPEP MME 3 miR-9-5p, miR-200-3p/429, miR-942-5p 
AGTR2 LNPEP MAS1 1 miR-23-3p 
ENPEP LNPEP MME 17 miR-26-5p, miR-30-5p, miR-132-3p/212-3p, miR-
194-5p, miR-204-5p/211-5p, miR-216-5p, miR-376-
3p, miR-376c-3p, miR-378-3p, miR-450b-5p, miR-
518d-5p/519-5p, miR-522-3p, miR-580-3p, miR-
653-5p, miR-1269, miR-3942-5p, miR-4766-3p 
ACE2 ENPEP LNPEP 4 miR-374-5p/655-3p, miR-543, miR-4424, miR-
1306-5p 
ACE2 LNPEP MME 3 miR-374a-3p, miR-3194-3p, miR-5691 
DPP3 LNPEP MME 5 miR-146-5p, miR-183-5p.1, miR-589-5p, miR-876-
5p, miR-2355-5p 
ACE2 DPP3 LNPEP 1 miR-329-3p/362-3p 
ACE2 ENPEP MME 1 miR-140-3p.1 
ENPEP LNPEP 17 miR-9-3p, miR-19-3p, miR-29-3p, miR-34b-
5p/449c-5p, miR-105-5p, miR-122-5p, miR-144-3p, 
miR-320, miR-323-3p, miR-323b-3p, miR-382-3p, 
miR-494-3p, miR-514a-5p, miR-515-5p/519e-5p, 
miR-642a-5p, miR-3146, miR-5579-3p 
DPP3 ENPEP 1 let-7-5p/98-5p 
MAS1 1 miR-143-3p 
ACE AGTR1 DPP3 1 miR-34-5p/449-5p 
Table shows a detailed list of miRNAs that have various combinations of RAS 
components in common. 
 
In contrast, the miR-17 family is an abundant miRNA with 7,380 copies reported in 
miRbase and 1,384 predicted targets. Thus, changes in the miR-17 family might have a 
more relevant impact. In addition to the RAS components, miR-17 also targets 
hypoxia-inducible factors and hypoxia-inducible genes such as the genes ANGPT2, 
EPAS1, HIF1A, SERPINE1 and VEGFA (159), which is notable given that hypoxia and 
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oxidative stress are also prominent features of the pathogenesis of AD and VaD, and 
likely some other forms of dementia. 
 
miR-9-5p is another miRNA that was prominent in the examination of RAS miRNAs, it 
has previously been used as a calibrator in the largest screening of miRNAs in 
dementia (138). Furthermore, as is evident from Chapter 4 this miRNA was also 
considered for evaluation as both a calibrator and as a miRNA of interest. miR-9-3p, 
which is processed from the same precursor as miR-9-5p, similarly targets 
aminopeptidase A and the angiotensin IV receptor, as does miR-9-5p and targets a 
similar number of RAS components. 
 
It is assumed that while one of these mature miRNA binds to a 3’UTR, its counterpart 
is degraded, nevertheless there is no report in the literature about the relation between 
these two miRNAs derived from the same precursor. Therefore the novel findings 
presented in Chapter 4 provide some update  on these two miRNAs where they have 
been demonstrated to be robust calibrators for measurements to be undertaken in this 
chapter. 
 
Although I have been critical of single miRNA-protein relationships in this project, 
given that the Mas receptor is regulated by only five miRNAs, it is possible that 
fluctuations in just one of them might have an important effect on MasR protein levels. 
Thus, I have included these as part of the 14 miRNAs of interest and an additional 
assessment of these MasR miRNAs was done. 
 
This assessment was based on criteria previously described, that consider what is 
reported regarding binding affinity, number of copies previously reported, number of 
gene transcripts targeted and the ratio between the latter two referred to as the 






Table 6. 3 Assessment of Mas receptor miRNAs. 
miRNA Confidence Targets Reads per million Ratio reads/targets 
miR-143 High 487 24700 50.72 
miR-23 High 1332 16900 12.69 
miR-224 N/A 440 620 1.41 
miR-448 N/A 685 24.7 0.03 
miR-651 High 3719 168 0.05 
Table shows the assessment of Mas receptor miRNAs. The confidence value is derived 
from miRbase catalogue. The reads/target ratio is an indicator of the number of miRNA 
copies that are likely to bind at each target. 
 
Of the 5 MasR-targeting miRNAs, miR-143 was the miRNA with the highest affinity 
for MasR according to TargetScan. In addition, miR-143 is the most abundant of these 
miRNAs with the highest ratio between targets and previously reported copies (i.e. the 
reads/target ratios suggests that at least 50 miRNA copies are able to bind to each of 
predicted target gene transcripts). Thus, MasR protein levels could be explained by 
changes in miR-143, given its high affinity, abundancy and low number of predicted 
targets. 
 
Moreover, changes in this miRNA might be specific to MasR in terms of the RAS 
system as the other 4 miRNAs targeting the MasR also target other RAS components. 
Following this assumption, it is feasible that an inverse relationship occurs between 
miR-143 and MasR levels. Such an assumption then lends itself to the possibility that 
single miRNA-protein relations could exist under specific conditions, for instance, 
polymorphisms in single nucleotides. 
 
6.1.2. miRNAs and single nucleotide polymorphisms 
 
Numerous single nucleotide polymorphisms (SNPs) have been proposed to increase 
the risk for dementia. Yet, hypothetically, any SNP could still have a direct effect over 
protein levels. That is, if a SNP is not in a coding or promoter region of any gene, a 
SNP could have an effect on a protein, if the SNP altered the sequence of a miRNA that 
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targeted it. This could occur, for example by affecting the seed region by which a 
miRNA binds to the 3’UTR of a gene transcript, by creating miRNA binding sites on 
gene transcripts or by modifying or abolishing a miRNA gene. 
 
I undertook an exploratory examination of SNPs located at 3’UTR of genes reported to 
be associated with AD was performed using the catalogue for genome wide association 
studies (GWAS), updated in June 2019 (Appendix 4). No miRNA binding sites that 
could be abolished by these SNPs were found; however the creation of a miRNA 
binding site for miR-320e at the SNP rs6857 was found using mirgeneDB and manually 
corroborated. 
 
Then, to further evaluate the relevance of this SNP, a search was performed in the 
GWAS catalogue for associated traits to this SNP. This SNP is associated to cerebral 
amyloid angiopathy, verbal declarative memory performance in nondemented older 
people, body fat percentage, type 2 diabetes, age-related macular degeneration and 
frontotemporal dementia. Although this miRNA binding site has been reported by 
others in the literature, its levels in brain tissue remain elusive (160,161). 
 
The PVRL2 gene codes for  Poliovirus receptor-related 2, an endothelial adhesion 
molecule, which was discovered in 1998 (162). This protein is also known as nectin-2 or 
CD112. PVRL2 knockout mice show a tendency to develop atherosclerosis and altered 
trans endothelial migration with infiltration of leukocytes (163). Furthermore, it is a 
cholesterol responsive gene in both humans and mice more strongly expressed in 
endothelial cells and at lower levels in leukocytes (163). 
 
A SNP can act in different ways, affecting the tertiary form of a protein, altering 
function, transport, etc. This particular SNP (rs6857) however, is located in the 3’UTR 
of the PVRL2 gene where miR-320e is able to bind at it, thus possibly affecting protein 
levels of PVRL2. In doing so, it would affect cellular adhesion of endothelial cells and 
thus increase BBB permeability, which in turn might be a risk factor for cerebral 
amyloid angiopathy. Yashin et al suggested that PVRL2 is influenced by APOE (the 
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highest genetic risk factor for AD) and TOMM40 (another AD-associated SNP) (164). 
Thus, PVRL2 not only represents an important risk factor by itself but also as a 
polygenic risk with APOE and TOMM40. This chapter will explore the miR-17 family, 






First, the null hypothesis is that there is no significant difference in the levels of the 
member of the miR-17 family and miR-143 between diagnostic groups, AD, VaD, early 





6.3.1. Study cohort 
 
The study cohort, as described in detail in Chapter 2 (Section 2.1) comprised brain 
tissue from 22 AD, 20 EAC, 18 VaD and 24 controls. 
 
 
Table 6. 4 Demographic information of the cohort used in Chapter 6. 
Diagnosis Gender 
(Male/Female) 
Age (σ) PMI (σ) ApoE4 
(No/Yes) 
Total 
Control 11/13 80 (9.7) 35.4 (16.2) 21/1 24 
Early Alzheimer Changes 11/9 85 (6) 36.5 (15) 14/4 20 
Alzheimer’s Disease 11/11 78 (7.2) 23.7 (13.4) 3/16 22 
Vascular Dementia 9/9 83 (7.9) 34.7 (12.3) 9/4 18 
Total 42/42 81.2 (8.1) 32.5 (15.1) 47/25 84 
Table shows demographic information of the cohort, post-mortem interval (PMI), 




6.3.2. Brain tissue dissection and homogenization 
 
Brain tissue dissection and homogenization was undertaken on the cohort as described 
in Chapter 2 section 2.2. 
 
6.3.3. RNA isolation, quantification and standardization 
 
RNA isolation, quantification and standardization were performed as described in 
detail in Chapter 2 section 2.3. 
 
6.3.4. Software for analysis of target proteins (DAVID and PANTHER) 
 
DAVID and PANTHER software were used for analysis of predicted target proteins of 
the selected miRNAs as described in detail in Chapter 2 section 2.13. 
 
6.3.5. GWAS Catalog NHGRI-EBI 
 
Examination of SNPs located at 3’UTR of genes reported to be associated with AD was 
performed using the GWAS Catalog NHGRI-EBI as described in detail in Chapter 2 
section 2.11. 
 
6.3.6. Data collection and analysis 
 
Data on selected calibrator genes was generated by quantitative polymerase chain 
reaction (qPCR) as described in Chapter 2 section 2.6. The analysis of the resultant data 
was undertaken using the new formula proposed in Chapter 2 section 2.7. Statistical 







6.4.1. miR-17 family 
 
The miR-17 family is composed of six members miR-17/20a/20b/93/106a/106b, all of 




miR-17 is transcribed from chromosome 13q31.3 (MIR17 gene). mir-17 expression 
when analysed by the D’Agostino & Pearson normality test showed that miR-17 was 
not normally distributed and thus, Kruskal-Wallis test was necessary. Application of 
the Kruskal-Wallis test showed that the percentage of difference for miR-17 was 
significantly different (Figure 6.2) between diagnostic groups (H=33.74 and p=0.0001). 
Subsequent post hoc analysis by Dunn’s multiple comparison test  found that the 
previous association  between all groups is perhaps due to a significant increase in the 
















Figure 6. 2 Percentage of difference for miR-17. 
 
Figure shows the percentage of difference for miR-17 for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 




Similar to miR-17, miR-20a is co-transcribed from chromosome 13q31.3 (MIR20A gene). 
Initial analysis by the D’Agostino & Pearson normality test showed that miR-20a was 
normally distributed. However, Bartlett’s test (p=0.0354) for homogeneity of variances 
found that the groups variances differed significantly. Thus, one-way ANOVA was 
inappropriate for analysis. Kruskal-Wallis test showed that the percentage of difference 
for miR-20a was significantly different (Figure 6.3) between diagnostic groups, 
(H=21.93 and p<0.0001). Application of Dunn’s multiple comparison test showed an 









Figure 6. 3 Percentage of difference for miR-20a. 
 
Figure shows the percentage of difference for miR-20a for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 




miR-20b is transcribed from chromosome Xq26.2 (MIR20B gene). As for miR-20a, the 
D’Agostino & Pearson normality test showed that miR-20b was normally distributed, 
which was then confirmed by Bartlett’s test (p=0.25). On analysis it was revealed that 
measurements of miR-20b (Figure 6.4) were significantly different between diagnostic 
groups (ANOVA F=15.41 and p<0.0001).  Further analysis with Tukey’s multiple 
comparison test showed an increase in AD compared to controls (p<0.0001), EAC 










Figure 6. 4 Percentage of difference for miR-20b. 
 
Figure shows the percentage of difference for miR-20b for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 




miR-93 is transcribed from chromosome 7q22.1 (MIR93 gene). miR-93 expression when 
analysed by the D’Agostino & Pearson normality test showed that miR-93 was not 
normally distributed. Therefore, Kruskal-Wallis test was implemented. Application of 
the Kruskal-Wallis test showed that the percentage of difference for miR-93 (Figure 6.5) 
was significantly different between diagnostic groups (H=19.27 and p=0.0002). 
Subsequent post hoc analysis by Dunn’s multiple comparison test found that the 
previous difference between groups is perhaps due to a significant increase in miR-93 









Figure 6. 5 Percentage of difference for miR-93. 
 
Figure shows the percentage of difference for miR-93 for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 




miR-106a is co-transcribed with miR-20b from chromosome Xq26.2 (MIR106A gene). 
D’Agostino & Pearson normality test showed that miR-106a was not normally 
distributed. The percentage of difference for miR-106a was significantly different 
between diagnostic groups, Kruskal Wallis test H=20.69 and p=0.0001 (Figure 6.6). 
Dunn’s multiple comparison test showed an increase in AD compared to controls 











Figure 6. 6 Percentage of difference for miR-106a. 
 
Figure shows the percentage of difference for miR-106a for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 




miR-106b is co-transcribed with miR-93 from chromosome 7q22.1 (MIR106B gene). 
Initial analysis by the D’Agostino & Pearson normality test showed that miR-106b was 
normally distributed, which was then confirmed by Bartlett’s test (p=0.0811). 
Application of the one way ANOVA test found that the percentage of difference for 
miR-106b (Figure 6.7) was significantly different between diagnostic groups (F=7.11 
and p=0.0003). Subsequent analysis by Tukey’s multiple comparison test showed an 
increase in miR-106b expression in AD compared to controls (p<0.05), EAC (p<0.01) 









Figure 6. 7 Percentage of difference for miR-106b. 
 
Figure shows the percentage of difference for miR-106b for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 
depicted, *p<0.05, **p<0.01 and *** p<0.001. 
 
6.4.1.7. Summary of miR-17 family results 
 
All of the individual miRNA members of the miR-17 family showed relatively similar 
results. All of them demonstrated a significant difference between diagnostic groups. 
Further analysis with post hoc tests showed that all members of this miRNA family 
presented higher levels for the AD group in comparison to controls, EAC and VaD. 
 
6.4.1.8. Analysis of miR-17 family predicted target proteins 
 
As these miRNAs share the seed region and predicted targets, perhaps it is not unusual 
for all members of this family to demonstrate similar levels of expression. With this in 
mind, it was deemed prudent for the predicted targets of these miRNAs to be analysed 
further. Overall, this miRNA family has 1385 predicted target proteins according to 




Table 6. 5 Analysis of predicted targets for miR-17 family by DAVID software. 




Cluster 1 enrichment score 1.3   
 5-methylcytosine catabolic process 3 0.48 
 Sulfonate dioxygenase activity 3 0.46 
 C-20 gibberellin 2-beta-dioxygenase activity  3 0.46 
 C-19 gibberellin 2-beta-dioxygenase activity  3 0.46 
 Hypophosphite dioxygenase activity 3 0.46 
 Procollagen-proline dioxygenase activity 3 0.46 
 Methylcytosine dioxygenase activity 3 0.46 
 2,4-dichlorophenoxyacetate alpha-ketoglutarate 
dioxygenase activity 
3 0.46 
 DNA-N1-methyladenine dioxygenase activity 3 0.71 
 Peptidyl-proline hydroxylation 3 0.97 
 Oxidative demethylation 3 0.98 
 DNA demethylation 3 1 
Cluster 2 enrichment score 1.25   
 Ganglioside biosynthetic process 5 0.69 
 Sialyltransferase activity 5 0.55 
 Oligosaccharide metabolic process 5 0.91 
Cluster 3 enrichment score 0.76   
 Histone methyltransferase activity (H3-K4 specific) 4 0.83 
 Histone H3-K4 methylation 4 0.97 
 Histone methyltransferase complex 4 0.78 
Cluster 4 enrichment score 0.53   
 Cytokine Receptors 3 0.88 
 Insulin signalling 3 0.99 
 LAT couples T-cell receptor 3 0.99 
Cluster 5 enrichment score 0.53   
 Semaphorin receptor binding 4 0.93 
 Negative regulation of axon extension involved in axon 
guidance 
4 0.99 
 Semaphorin-plexin signalling pathway 4 1 
Cluster 6 enrichment score 0.34   
 Palmitoyltransferase activity 3 0.98 
 Protein palmitoylation 3 1 
 Protein-cysteine S-palmitoyltransferase activity 3 1 
Table shows gene ontology and pathways related to proteins targeted by miR-17 




None of the pathways identified with DAVID software reached levels of significance. 
However, analysed performed with PANTHER found seven pathways to be 
statistically significant (Table 6.6). 
 
Table 6. 6 Analysis of predicted targets for miR-17 family by PANTHER software. 





Cadherin signalling pathway 31 2.96 0.0001 
Alzheimer disease-amyloid secretase pathway 17 2.94 0.0350 
Transforming growth factor-beta signalling 
pathway 
22 2.86 0.0067 
Platelet derived growth factor signalling pathway 26 2.59 0.0078 
Angiogenesis 28 2.32 0.0211 
Alzheimer disease-presenilin pathway 32 2.17 0.0029 
Wnt signalling pathway 45 2.13 0.0021 
Table shows pathways related to proteins targeted by miR-17 family, number of 
proteins targeted, fold enrichment and p values are specified. 
 
According to the analysis done by PANTHER, nine pathways were identified that were 
statistically significant. These pathways involved variable numbers of predicted target 
proteins that ranged from 17 to 45 target proteins in any one pathway. These also had a 
range of fold enrichment scores that ranged from 2.13 to 2.96. On further examination 
of the pathways identified, the cadherin signalling pathway has the highest enrichment 
score and was the most highly significant (0.0001), with an enrichment score of 2.96. 
Other pathways that were highly significant included the Alzheimer disease-amyloid 
secretase pathway (p=0.035), the transforming growth factor-beta signalling pathway 
(p=0.0067), the platelet derived growth factor signalling pathway (p=0.0078), 
angiogenesis (p=0.0211), the Alzheimer disease-presenilin pathway (p=0.0029) and Wnt 




miR-143 is transcribed from chromosome 5q32 (MIR143 gene). According to the 
D’Agostino & Pearson normality test, measurements of miR-143 were not normally 
distributed. Thus, Kruskal-Wallis test was used for analysis of the data. The percentage 
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of difference for miR-143 was significantly different between diagnostic groups, 
Kruskal-Wallis test H=11.03 and p=0.011 (Figure 6.8). Subsequent post hoc analysis by 
Dunn’s multiple comparison test showed an increase in AD compared to EAC (p<0.05). 
 
Figure 6. 8 Percentage of difference for miR-143. 
 
Figure shows the percentage of difference for miR-143 for all diagnostic groups 




6.4.2.1. Analysis of miR-143 predicted target proteins 
 
In addition to the MAS receptor, miR-143 has another 497 predicted targets according 
to TargetScan; analysis of the pathways related to these proteins with DAVID and 









Table 6. 7 Analysis of predicted targets for miR-143 by DAVID software. 




Cluster 1 enrichment score 0.59   
 Integrin affinity modulation 3 0.45 
 Endometrial cancer 3 0.74 
 Non-small cell lung cancer 3 0.77 
 Fc epsilon RI signalling pathway 3 0.84 
 Hepatitis C 3 0.98 
Cluster 2 enrichment score 0.57   
 fMLP induced chemokine gene expression in HMC-1 
cells 
4 0.98 
 Fc Epsilon Receptor I Signalling in Mast Cells 4 0.98 
 NFAT and Hypertrophy of the heart (Transcription in 
the broken heart) 
4 1 
Cluster 3 enrichment score 0.45   
 Role of MEF2D in T-cell Apoptosis 3 0.98 
 Neuropeptides VIP and PACAP inhibit the apoptosis of 
activated T cells 
3 0.98 
 BCR Signalling Pathway 3 1 
 Signalling Pathway from G-Protein Families 3 1 
 T Cell Receptor Signalling Pathway 3 1 
Table shows gene ontology and pathways related to proteins targeted by miR-143, the 
number of proteins and Benjamini value are specified. 
 
As with previous miRNAs, none of the pathways identified with DAVID software 
obtained significant levels. Nonetheless, when analysed with PANTHER, it revealed 
that only one pathway came up to be statistically significant (Table 6.8). This pathway 
is the gonadotropin-releasing hormone receptor pathway with a protein count of 21, 
fold enrichment score of 2.96 and significance of p=0.0032. 
 
Table 6. 8 Analysis of predicted targets for miR-143 by PANTHER software. 





Gonadotropin-releasing hormone receptor 
pathway 
21 2.96 0.0032 
Table 6.8 Pathway related to proteins targeted by miR-143, number of proteins 






miR-320e is transcribed from chromosome 19q13.32 (MIR320E gene). The D’Agostino 
& Pearson normality test showed that miR-320e was normally distributed. It was not 
possible to perform genotyping of the SNP rs6857, thus analysis was performed using 
diagnostic groups. The percentage of difference for miR-320e was significantly 
different between diagnostic groups, ANOVA F=3.84 and p=0.026 (Figure 6.8). Tukey’s 
multiple comparison test showed an increase in AD compared to controls (p<0.05) and 
EAC (p<0.05). 
 
Figure 6. 9 Percentage of difference for miR-320e. 
 
Figure shows the percentage of difference for miR-320e for all diagnostic groups 
compared to controls. Error bars show the 95% confidence interval and the average is 
depicted, *p<0.05. 
 
6.4.3.1. Analysis of miR-320e predicted target proteins 
 
In addition to the binding site created at the SNP rs6857 at the PVRL2 gene, miR-320e 
has 4219 predicted targets; analysis of the pathways related to these proteins with 




Table 6. 9 Analysis of predicted targets for miR-320e by DAVID software. 




Cluster 1 enrichment score 1.23   
 Actin cortical patch 3 0.82 
 Actin cortical patch localization 3 0.99 
 Actin cortical patch assembly 3 0.99 
Cluster 2 enrichment score 0.66   
 N-formyl peptide receptor activity 3 0.98 
 Complement receptor activity 3 0.99 
 Complement receptor mediated signalling pathway 3 1 
Cluster 3 enrichment score 0.5   
 Glycerol channel activity 4 1 
 Cellular water homeostasis 4 1 
 Glycerol transport 4 1 
 Water channel activity 4 1 
Cluster 4 enrichment score 0.44   
 Proton-transporting two-sector ATPase complex 3 0.91 
 Proton-transporting V-type ATPase, V1 domain 3 0.95 
 Proton-transporting ATPase activity, rotational 
mechanism 
3 1 
Cluster 5 enrichment score 0.36   
 Pointed-end actin filament capping 3 1 
 Striated muscle thin filament 3 0.98 
 Myofibril assembly 3 1 
Cluster 6 enrichment score 0.3   
 Voltage-gated sodium channel complex 3 0.95 
 Voltage-gated sodium channel activity 3 1 
 Regulation of postsynaptic membrane potential 3 1 
Cluster 7 enrichment score 0.25   
 Potassium: proton antiporter activity 3 1 
 Sodium: proton antiporter activity 3 1 
 Sodium ion import across plasma membrane 3 1 
Table shows gene ontology and pathways related to proteins targeted by miR-320e, the 
number of proteins and Benjamini value are specified. 
 
As with previous miRNAs, none of the pathways identified with DAVID software 
reached levels of significance. Nonetheless, when analysed with PANTHER, two 
pathways were found to be statistically significant (Table 6.8). These pathway are the 
cadherin signalling pathway (p=0.0032) with a protein count of 46 and fold enrichment 
score of 2.06, and the Wnt signalling pathway (p=0.0294) with a protein count of 74 and 
fold enrichment score of 1.65. 
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Table 6. 10 Analysis of predicted targets for miR-320e by PANTHER software. 





Cadherin signalling pathway 46 2.06 0.0064 
Wnt signalling pathway 74 1.65 0.0294 
Table shows pathways related to proteins targeted by miR-320e, number of proteins 
targeted, fold enrichment and p values are specified. 
 
 
6.5 Discussion and conclusions 
 
The null hypothesis was that there is no significant difference in the levels of miR-17 
family and miR-143 between diagnostic groups, AD, VaD, early AD changes (EAC) 
and non-demented controls. In the case of miR-320e, the null hypothesis was that there 
is no significant difference between diagnostic groups, AD, early AD changes (EAC) 
and non-demented controls. The null hypothesis is rejected for the eight miRNAs 
measured. Seven of them showed a significant difference between diagnostic groups, 
and specifically a significant increment was found in AD with respect to controls. miR-
143 that targets the MASR was found to be significantly different between the AD 
group and the EAC group. As mentioned previously, it could be possible that such 
miRNAs have an impact in disease; however there are several factors that need to be 
considered. 
 
Unexpectedly, no change was observed in theses miRNAs for the VaD group. The 
transcripts considered were based in elements of the renin angiotensin system and 
others related to hypoxic conditions. However, it should be noted that there is a high 
disparity in the number of considered transcripts compared to the number of 
transcripts targeted by these miRNAs, 1385 target proteins for miR-17 family and 497 
target proteins for miR-143. 
 
In the case of miR-17 family, all miRNAs were found to be significantly increased in 
the AD group compared to other diagnostic groups. Interestingly, PANTHER software 
showed that this miRNA family target proteins related to amyloid secretase and the 
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presenilin pathway, which are implicated in AD, but also to angiogenesis, 
transforming growth factor (TGF), platelet derived growth factor (PDGF) and cadherin 
signalling pathways. However, similar to the results obtained in Chapter 5, there was 
almost no concordance between the results obtained from DAVID and PANTHER 
software. This puts in doubt whether or not these pathways are indeed related to the 
miR-17 family. 
 
Before making any assumptions about the role of any miRNAs examined in this thesis 
some factors such as the location of the miRNA in the brain should be considered. 
Using in situ hybridization, miR-17 family has been found to be expressed at high 
levels in paediatric high-grade gliomas (165). It has also been found to be highly 
expressed in medulloblastoma (166). Unfortunately, the normal expression of the miR-
17 family in the human brain and whether differences exist across brain areas in 
unknown. However, interestingly the authors found a specific miRNA pattern in 
paediatric high-grade glioma, which reinforces the idea that miRNA signatures exist 
(165). 
 
Combinations of miRNAs are likely to have a more relevant role in disease. Although 
single miRNA–protein relations have been criticised in this project, it could be possible 
that under certain restricted conditions such relations exist. The analysis of miRNAs 
for the MAS receptor showed that only five miRNAs are able to bind at it. miR-143 is 
the miRNA with the highest affinity for binding at MAS receptor and also an abundant 
miRNA with respect to the other four miRNAs that bind at this receptor. miR-143 was 
found to be significantly increased in the AD cases in comparison to the early AD 
changes (EAC) group. Nevertheless, the MAS receptor is only one of the 497 predicted 
targets for miR-143. The location of miR-143 should also be investigated and whether it 
co-localizes with the MAS receptor. 
 
Another important factor in miRNA research is to validate the binding site at which 
the miRNA binds and thus, may cause a reduction in protein levels. This has 
exceptionally importance for experiments where the predicted binding site is not 
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supported by target predicting software. For instance, Zhao et al suggested that a 
binding site at the mRNA of TREM2 exists for miR-34 and thus its expression is 
regulated by miR-34a. This was performed using independent bioinformatics 
algorithms (69). However, when analysed by TargetScan and MiRanda miRNA 
binding predicting software, no binding sites are found. 
 
Along these lines, the SNP at rs6857 creates a binding site for miR-320e. Although the 
existence of this binding site has been reported already in the literature, the results 
shown in this thesis suggest that the levels of miR-320e are increased in AD brain 
(160,161). Yet, it would be even more interesting to know the levels of this miRNA in 
relation to the presence of the SNP rs6857. Also, to relate such findings in relation with 
the protein levels of the PVRL2 gene. 
 
The protein levels of PVRL2 are not only relevant for this miRNA but also as a marker 
of blood brain barrier dysfunction. The PVRL2 gene is an endothelial adhesion 
molecule important for cell adhesion and adherens junction (162). Knockout mice of 
this gene has shown a tendency to develop atherosclerosis and altered trans 
endothelial migration with infiltration of leukocytes (163). This is also relevant as the 
most common form of amyloid accumulates in the brain as CAA. 
 
Indeed, individuals who carry the APOE ɛ4 allele are in a higher risk to present CAA-
related microbleeds and age related cognitive decline (40). Where age and the presence 
of the APOE ɛ4 allele are the highest risk factors to develop dementia. The APOE gene 
is located within the AD linkage region at chromosome 19, specifically the cytogenetic 
band 19q13.32. Interestingly, miR-320e is also encoded at 19q13.32 along TOMM40 and 
the PVRL2 genes. Yashin et al suggested the PVRL2 is influenced by APOE and 
TOMM40 and that APOE, APOC1, TOMM40 and NECTIN2 (all encoded at 19q13.32) 
might influence AD acting in concert (164). miR-320e might also work synergistically 




Based on this, a further research question would be the effect of APOE status in 
relation to miR-320e levels. This was not possible to analyse in this cohort given the 
proportions of APOE ɛ4 carriers with respect to other carriers within the diagnostic 
groups. There is only one APOE ɛ4 carrier in the control group (N=24), four carriers in 
the EAC group (N=20) and 16 carriers in the AD group (N=22). Yet, the effect of APOE 
status in miR-320e levels remains an interesting research question. This could also be 
associated with PVRL2 protein levels once the validation of the binding site is 
performed. 
 
Validation of miRNA binding sites is a supportive tool in order to extrapolate results 
from miRNA binding software into functionality. Cell culture is a useful tool for 
experimentation of changes derived from observational studies. Causal versus 
consequential effects can be investigated using cell culture. Validation of miRNA 
binding sites is being performed using luciferase assays. However, luciferase assays 
are not able to differentiate between canonical and non-canonical binding sites, neither 
if the effects are a result of direct miRNA binding to the transcript or via changes in 
other miRNAs that also affect the transcript (65). 
 
In adittion, miRNAS have certain characteristics that should be considered, and it is 
necessary to first evaluate the suitability of cell culture as a model for study of 
dementia. Some miRNAs are cell-type and brain-area specific (167,168). Given the 
cytoarchitectural and functional differences between Brodmann areas of the brain, it is 
possible that different brain areas exhibit cellular populations with characteristic 
miRNA signatures. These properties and the location of miRNAs previously examined 








Chapter 7.- Evaluation of cell culture as an experimental model for the study of 





This part of the study aims to investigate whether there is a cellular association 
between miRNAs of the same family. This is of importance because the origin of the 
miRNAs informs us as to the origin of the changes which are occurring in a disease 
state.  In order to address this question, a cell culture approach has been used to 
determine if, with induced differentiation of SH-SY5Y cells, localisation of certain 
miRNA families develops. 
 
It is important first however, to consider the knowledge we have so far as to the 
cellular location of different miRNA families .As described in Chapter 6, the presence 
of a miRNA is not sufficient to assume its effect, but the location of the miRNA and 
whether it co localizes with its targets is critical. The importance of in situ localization 
of miRNAs and how this differs between cell types, has also been emphasized by Kent 
et al (169). Kent et al reviewed the role of both miR-143 (this miRNA is discussed in 
Chapter 6) and miR-145 as tumour suppressors. These miRNAs have been found to be 
highly expressed in the colon and are consistently reported as being downregulated in 
colorectal and other cancers. 
 
However, it came to light that miR-143 and miR-145 are not expressed in colonic 
epithelial cells; although highly expressed in mesenchymal cells such as fibroblasts and 
smooth muscle cells. Several studies were performed without considering that multiple 
different cell types, each with unique miRNA signatures, make up each tissue. As 
mentioned above, without knowing the origin of the miRNAs it is impossible to 
evaluate why it has changed. The authors also examined other examples of miRNAs 




The localisation of the 25 miRNAs previously measured in this thesis is summarised in 
Table 7.1. Most of them are unknown. Mellios et al performed in situ hybridization of a 
set of miRNAs in the prefrontal cortex of subjects aged 15-84 years (171). They found 
lamina-specific expression patterns for several miRNAs. miR-16 was expressed from 
layer III to layer VI with a stronger expression in layer V whilst miR-195 was expressed 
in layers II to V with strongest expression in layers II and III. Interestingly, miR-103 
was similarly expressed across all layers and also in white matter. miR-103 was not 
considered for analysis in this thesis. However, this finding suggests that this miRNA 
might be important for instance in differentiation of brain cells from the ectoderm. The 
localisation of other members of the miR-16 family in the human brain is unknown. 
 
Similarly, the localisation of miR-29 family is also unknown. Wang et al found this 
miRNA family to be enriched in cultured glial preparations (172). Nevertheless, its 
presence in vitro could be just inherent of the particular cell type. The in situ location of 
miR-29 across brain areas would be necessary in order to relate to the functional 
attributes found previously using pathways software. In the same way, miR-34 family 
localisation in the human brain is also unknown. 
 
Liu et al suggested that miR-34b upregulation was associated with astrocyte apoptosis 
in mice. Yet, this upregulation of miR-34b could be specific for apoptosis regardless of 
the cellular population. It could also be exclusive to mice or specific to the area 
analysed (hippocampus). Interestingly, although the study used mice tissue, Kasai et al 
performed in situ hybridization of miR-34a and found its specific expression in 
GABAergic interneurons across the thalamic reticular nucleus, the globus pallidus and 
the entopeduncular nucleus (173). 
 
Thus, the findings reinforce the idea of the specificity for miRNAs in cellular 
populations, in this case within a neuronal subgroup (GABAergic interneurons). In 
contrast, using laser microdissection and human brain tissue, Rao et al observed that 
miR-34a and miR-449 (both members of the miR-34 family) were expressed in 
astrocytes, together with other miRNAs considered in this project such as miR-125b 
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and miR-143 (174). However, the study focused on astrocytes and it is possible that 
those miRNAs might be expressed at even higher levels in other cell types. 
Determination of the in situ location of the miRNAs is therefore fundamental before 




Table 7. 1 In-situ location of previously measured miRNAs in the human brain. 
miRNA family miRNA Human brain location Cellular population 
miR-16 miR-15a Unknown Unknown 
 miR-15b Unknown Unknown 
 miR-16 Prefrontal cortex 
Layers III-VI 
Pyramidal neurons 
 miR-195 Prefrontal cortex 
Layers II-V 
Pyramidal neurons 
 miR-424 Unknown Unknown 
 miR-497 Unknown Unknown 
miR-29 miR-29a Unknown Unknown 
 miR-29b Unknown Unknown 
 miR-29c Unknown Unknown 
miR-34 miR-34a Unknown Unknown 
 miR-34b Unknown Unknown 
 miR-34c Unknown Unknown 
 miR-449 Unknown Unknown 
miR-125 miR-125a Unknown Unknown 
 miR-125b Unknown Unknown 
miR-132 miR-132 ? Neurons 
Synapses and dendrites 
 miR-212 ? Neurons 
Synapses and dendrites 
miR-17 miR-17 Unknown Unknown 
 miR-20a Unknown Unknown 
 miR-20b Unknown Unknown 
 miR-93 Unknown Unknown 
 miR-106a Unknown Unknown 
 miR-106b Unknown Unknown 
miR-143 miR-143 Unknown Unknown 





Location of the miR-125 family in the human brain is also unknown. Pogue et al found 
miR-125b to be expressed in cell culture of astrocytes (175). Along these lines, Rao et al 
observed that miR-125b was undetected in deeper grey matter astrocytes, whereas 
white matter astrocytes expressed this miRNA. Rao et al focused on analysing 
astrocytic miRNAs, thus it still remains unknown as to whether miR-125b is also 
present in other cellular populations (e.g. like neurons) and how they compare to 
reported levels of astrocytic miR-125b. 
 
In contrast to previously described miRNAs, there is more evidence about the miR-
132/212 family. Downregulation of this miRNA family in different brain areas is the 
only consistent finding according to a meta-analysis of profiling studies in AD (64). 
The miR-132/212 family is highly expressed in dendrites and synapses, and is 
regulated by neuronal activity (150,176). Zhu et al observed the expression of miR-132 
in neurons of the nucleus basalis of Meynert (177). They also found a significant 
positive correlation with choline acetyltransferase (ChAT) expression and that ChAT 
expression showed a significantly negative correlation with hyperphosphorylated tau. 
 
Functional attributes of this miRNA family in the brain have been found by Hansen et 
al (176,178). These studies provided insight into the function of this miRNA family 
using a combination of conditional knockout and transgenic mouse models of miR-
132/212. They corroborated that miR-132 is upregulated by neuronal activity and that 
induction of miR-132 expression was sufficient to modulate cognitive capacity in a 
dose-dependent manner (176). Likewise, miR-132 levels correlated with spine density 
and interestingly, expression of miR-132 over and above physiological levels led  to 
excessive spine density and cognitive deficits (176). 
 
Hansen et al also, used Illumina sequencing to show that miR-132/-212 deletion 
increased the expression of hundreds of genes. Functional gene ontology analysis of 
those genes revealed significant enrichment scores related to synaptic transmission, 
neuronal proliferation and morphogenesis (178). Interestingly, in Chapter 3, the 
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analysis of predicted targets for the miR-132/212 also found significant enrichment 
scores for the Rho GTPase signalling pathway, important for neurogenesis. 
 
Another miRNA family (discussed in Chapter 6) that has been proposed to contribute 
to neurogenesis is the miR-17 family (179). Jin et al suggested that the miR-17 family 
have a significant impact on neurogenesis in mice as well as in depression and anxiety. 
However, the localisation of members of the miR-17 family in the human brain is 
unknown. Similarly, the location of miR-143 and miR-320e is also unknown. As 
described before, several attributes can be suggested from each of the transcripts that a 
miRNA binds to. However, the effect of the miRNA will be related to the number of 
transcripts that it targets and whether they are co-localised in the brain. 
 
miRNAs have an important role in cell fate and differentiation (180,181). Laser 
microdissection of human astrocytes showed miRNA signatures specific to brain 
regions, subcortical astrocytes, cortical astrocytes and differences were even observed 
between layers of the cortex (174). A proportion of their evaluated miRNAs was 
present in all astrocytes suggesting that these miRNAs might be important for 
functions common to all astrocytes. 
 
In addition, this study also found that not only the presence but also the levels of a 
miRNA might be relevant as some changes were observed when a miRNA was present 
in surrounding neuronal and other glial cells. The results suggest that some miRNAs 
might be important for the coordination of a microenvironment between cellular 
populations. In this way, a combination of miRNAs might be determinant in the 
proteome landscape expressed by different cell types and brain areas in order to direct 
specific functions and to respond to external stimuli. 
 
Similarly, the levels of a miRNA might also change during the differentiation of a cell. 
miR-128 and miR-124 are examples of abundant miRNAs in the adult brain (52). miR-
124 expression is undetectable or expressed at low levels during neurogenesis in 
progenitor cells whilst it is upregulated in differentiating and post mitotic neurons 
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(181). Le et al also observed that miR-124 expression increased after differentiation of 
the human neuroblastoma cell line SH-SY5Y into neuronal-like cells. They then 
overexpressed miR-124 in SH-SY5Y cells and found a significant increase in the 
percentage of differentiated cells with neurite outgrowth (182). 
 
Similarly, using HeLa cells (cervical cancer cells), overexpression of miR-124 caused a 
decrease in several non-neuronal genes, showing a gene expression program that 
resembles neuronal cells (181). In accordance with this, it has been shown that 
pluripotent stem cells demonstrate exclusive miRNA patterns, the levels of which 
decrease following differentiation (180). Indeed, an important function of miRNAs in 
human embryonic stem cells is to regulate cell cycle progression (180). If such miRNAs 
are able to modify cellular phenotype, experimentation of miRNAs in cell culture and 
its extrapolation from observational studies should be taken with caution as every 
cellular population will show specific miRNA signatures. 
 
For instance, Sarkar et al observed that miR-34a is increased in brain regions of AD 
patients and that this miRNA was also overexpressed in a mouse model for AD (183). 
The authors postulated miR-34a as a potential therapeutic target for AD. Similarly, 
Zovoilis et al found increased levels of miR-34c in the hippocampus of AD patients and 
also in mouse models for AD. The authors suggested that targeting miR-34c could be 
used as a therapeutic approach (184). 
 
However, despite the promise of an intervention, the complexity of therapeutic 
manipulation of miRNAs in the brain should not be under-estimated. Indeed, miR-34 
and miR-125 have been found to be able to differentiate SH-SY5Y cells into neuronal-
like phenotype (182,185). Le et al overexpressed miR-125b in SH-SY5Y cells and 
observed that miR-125b was both sufficient and necessary to induce neurite and 
dendritic outgrowth and in doing so affected 164 target genes (182). In contradiction to 
this, Zhang et al found that overexpression of miR-125b in the brains of mice resulted 




Zhang et al also observed that overexpression of miR-125b in vitro caused 
hyperphosphorylation of tau. miR-125b has also been associated with cognitive deficits 
in vivo and hyperphosphorylation of tau in vitro by others in the literature (120,187). 
The contradictory evidence might be explained by the fact that some miRNAs are cell-
type and brain-area specific (167,168). Given the cytoarchitectural and functional 
differences between Brodmann areas of the brain, it is possible that different brain 
areas exhibit cellular populations with characteristic miRNA signatures. 
 
Yet, experimentation of miRNAs in cell culture could be used to investigate certain 
properties of miRNAs, such as their regulation. Little is known about expression of 
miRNAs of the same miRNA family in relation to each other. miRNAs within the same 
family share the seed region by which they bind to the mRNAs and eventually 
remodel the proteome. It is known that miRNAs that are clustered within 50 kilobases 
from each other show common expression patterns (52). However, it is also clear, as 
was shown in chapter 6 that different members of the same miRNA family can reside 
on different chromosomes. So it remains the question as to whether miRNAs of the 
same family show similar expression despite their genomic location and similarly 
whether this is altered under circumstances of differentiation of a cell type. The 
research question covered in this chapter is ‘‘Is there an association between miRNAs 





The null hypothesis is that there is no correlation in the expression between miRNAs of 









7.3.1. RNA isolation, quantification and standardization 
 
RNA isolation, quantification and standardization were similarly performed as 
described in Chapter 2.3. 
 
7.3.2. Cell culture 
 
The SH-SY5Y cell line is human-derived. Originally, a bone marrow biopsy was taken 
from a metastatic bone tumour of a four-year-old female and this formed the SK-N-SH 
cell line;  SH-SY5Y was subcloned from this. The cells are epithelial-like but addition of 
retinoic acid causes them to produce dendrites and thus are termed ‘neuron-like’. They 
are adrenergic but can also have markers similar to those found in dopaminergic, 
cholinergic and glutamatergic neurons (188). 
 
Protocols for handling, subculture routine and culture media were obtained from the 
European Collection of Authenticated Cell Cultures (ECACC), a Culture Collection of 
Public Health England and practical training was supervised by Mrs. Saranna Chipper-
Keating. Frozen SHSY5Y cells were acquired (ECACC 94030304) at passage 12 and 
were resuscitated on a water bath until thawed. 
 
Culture medium was prepared beforehand as follows, Ham's F12 (Sigma-Aldrich® 
N4888) : Minimum Essential Medium Eagle (MEM) (Sigma-Aldrich® M2279) (on a 
proportion of 1:1) plus 2mM Glutamine (Sigma-Aldrich® G7513), 1% Non Essential 
Amino Acids (Sigma-Aldrich® M7145) and 15% Foetal Bovine Serum (Gibco® A31608-
01). Resuscitated cells were incorporated into 5 ml of prepared culture medium and 
resuspended. 5 ml of culture medium was added to the resuspended cells in the 
solution and placed into a 75 cm2 cell culture flask (Sigma-Aldrich® CLS3290) in the 
incubator at 37°C and 5% CO2. 
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Subculture was performed at a confluency of 70-80% and cells were detached using 
trypsin-EDTA (ethylenediaminetetraacetic acid) (Lonza® CC-5012) and re-seeded at a 
concentration of 1,000 - 10,000 cells/cm2. Once the first flask reached the determined 
confluency, two flasks were seeded, and the rest of the cells were stored in aliquots 
using DMSO (Sigma-Aldrich® D2650). Aliquots were labelled with the number of cells, 
passage, cell line and date of storage. 
 
Cell counting was performed using a haemocytometer and 0.4% trypan blue stain in 
phosphate buffered saline (PBS). 100 µl of resuspended cells were combined with 100 
µl of trypan blue. An inverted microscope was used to observe and count cells, live 
cells appearance was bright and colourless whilst dead cells stained blue. 
 
Retinoic acid (Sigma-Aldrich® R2625) was used at a concentration of 10 µM in culture 
media prepared with 98% Neurobasal® medium (Gibco® 21103-049) and 2% B27® 
supplement (Gibco® 17504-044). The time period of retinoic acid treatment was nine 
days with three points for medium change at day 1, 4 and 7. Both treated and 
untreated cells were harvested at day 10. The number of samples considered for 
analysis is six samples for untreated cells and six samples for treated cells. 
 
7.3.3. Data collection and analysis. 
 
Data on selected calibrator genes was generated by quantitative polymerase chain 
reaction (qPCR) as described in Chapter 2.6. The analysis of the resultant data was 
undertaken using the new formula proposed in section 2.7. Statistical analysis was 
performed using the statistical package Graph Pad Prism (section 2.16 Statistical 








7.4.1. Selection of calibrator gene 
 
All miRNAs measured in this chapter were evaluated for use as a calibrator gene. Six 
miRNAs were found to be not significantly different between untreated and treated 
cells, miR-15a, miR-16, miR-497, miR-34a, miR-125a and miR-125b. D'Agostino & 
Pearson omnibus normality test showed that the percentage of difference for these 
miRNAs was normally distributed but not for miR-34a. The data was analysed using 
Mann-Whitney test for miR-34a and unpaired t test for the remainder. Figures 7.1 to 7.6 
show the percentage of difference between untreated and treated cells. 
 
Figure 7. 1 Percentage of difference for miR-15a in SH-SY5Y cells. 
 
Figure shows the percentage of difference for miR-15a between untreated and treated 








Figure 7. 2 Percentage of difference for miR-16 in SH-SY5Y cells. 
 
Figure shows the percentage of difference for miR-16 between untreated and treated 
cells, error bars show the 95% confidence interval and the average is depicted. 
 
Figure 7. 3 Percentage of difference for miR-497 in SH-SY5Y cells. 
 
Figure shows the percentage of difference for miR-497 between untreated and treated 






Figure 7. 4 Percentage of difference for miR-34a in SH-SY5Y cells. 
 
Figure shows the percentage of difference for miR-34a between untreated and treated 
cells, error bars show the 95% confidence interval and the average is depicted. 
 
Figure 7. 5 Percentage of difference for miR-125a in SH-SY5Y cells. 
 
Figure shows the percentage of difference for miR-125a between untreated and treated 






Figure 7. 6 Percentage of difference for miR-125b in SH-SY5Y cells. 
 
Figure shows the percentage of difference for miR-125b between untreated and treated 
cells, error bars show the 95% confidence interval and the average is depicted. 
 
No significant difference was found with respect to levels of expression between 
untreated and treated cells for miR-15a, miR-16, miR-497, miR-34a, miR-125a and miR-
125b. Therefore, these miRNAs were used as calibrator genes to help calculate the 
average CT value with a new formula proposed in section 2.7. After selection of 
calibrator genes, calculation of miRNA changes and correlation analysis for each of the 
miRNA families covered in this thesis was performed. 
 
7.4.2. miR-16 family 
 
The miR-16 family is composed of miR-15a/15b/16/195/424/497. miR-15a and miR-16 
map to an intron in chromosome 13q14.2, both genes are clustered within 0.5 kb. miR-
15b is encoded in chromosome 3q25.33. miR-195 and miR-497 are both transcribed 
from chromosome 17p13.1, whilst miR-424 is derived from chromosome Xq26.3. Figure 
7.7 shows the percentage of difference for miR-16 family between untreated and 




Figure 7. 7 Percentage of difference for miR-16 family in SH-SY5Y cells. 
 
Figure shows the percentage of difference for miR-16 family between untreated (‘‘-‘’) 
(green) and treated (‘‘+‘’) (blue) cells, error bars show the 95% confidence interval and 
the average is depicted. 
 
Association between miRNAs of the miR-16 family was performed using Spearman 
correlation test and is shown in Table 7.2. Only miR-15b was found to significantly 
correlate with miR-15a, miR-195 and miR-424. No correlation was found between miRs 
that are coded within 50 kilobases from each other, such as miR-15a and miR-16, miR-
195 and miR-497. 
 
Table 7. 2 Spearman correlation test for members of the miR-16 family. 
 miR-15a miR-15b miR-16 miR-195 miR-424 miR-497 




























miR-424     r=1 r=0.4246 
p=0.169 
miR-497      r=1 
201 
 
7.4.3. miR-29 family 
 
As described in Chapter 5, the miR-29 family is composed of miR-29a/29b/29c. miR-29a 
is encoded in an intron from chromosome 7q32.3. MiR-29b can be derived from two 
precursors, miR-29b-1 and miR-29b-2 that are co-transcribed with miR-29a and miR-
29c respectively. miR-29b-2 and miR-29c are mapped to chromosome 1q32.2. Figure 7.8 
shows the percentage of difference for miR-29 family between untreated and treated 
cells, no statistical test was performed. 
 
Figure 7. 8 Percentage of difference for miR-29 family in SH-SY5Y cells. 
 
Figure shows the percentage of difference for miR-29 family between untreated (‘‘-‘’) 
(green) and treated (‘‘+‘’) (blue) cells, error bars show the 95% confidence interval and 
the average is depicted. 
 
Examination of the level of co-expression between miRNAs of the miR-29 family was 
performed using Spearman correlation test and is shown in Table 7.3. The three 







Table 7. 3 Spearman correlation test for members of the miR-29 family. 
 miR-29a miR-29b miR-29c 




miR-29b  r=1 r=0.930 
p=4.1e10-5*** 
miR-29c   r=1 
 
 
7.4.4. miR-34 family 
 
miR-34 family is composed of 4 miRNAs, miR-34a/34b/34c/449. miR-34a is transcribed 
from chromosome 1p36.22. miR-34b and miR-34c are transcribed from chromosome 
11q23.1. miR-449 is encoded in chromosome 5q11.2. Figure 7.9 shows the percentage of 
difference for miR-34 family between untreated and treated cells, no statistical test was 
performed. 
 
Figure 7. 9 Percentage of difference for miR-34 family in SH-SY5Y cells. 
 
Figure shows the percentage of difference for miR-29 family between untreated (‘‘-‘’) 
(green) and treated (‘‘+‘’) (blue) cells, error bars show the 95% confidence interval and 
the average is depicted. 
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Association between miRNAs of the miR-34 family was performed using Spearman 
correlation test and is shown in Table 7.3. Only miR-34c was found to significantly 
correlate with miR-449. No correlation was found with the rest of miRNAs.  
 
Table 7. 4 Spearman correlation test for members of the miR-34 family. 
 miR-34a miR-34b miR-34c miR-449 










miR-34c   r=1 r=0.706 
p=0.013* 
miR-449    r=1 
 
 
7.4.5. miR-125 family 
 
This miRNA family is composed by miR-125a and miR-miR-125b. Whilst miR-125a is 
transcribed from chromosome 19q13.41, miR-125b is transcribed from chromosome 
11q24.1. Figure 7.10 shows the percentage of difference for miR-125 family between 
















Figure 7. 10 Percentage of difference for miR-125 family in SH-SY5Y cells. 
 
Figure shows the percentage of difference for miR-125 family between untreated (‘‘-‘’) 
(green) and treated (‘‘+‘’) (blue) cells, error bars show the 95% confidence interval and 
the average is depicted. 
 
Pearson correlation test was used to evaluate the association between miR-125a and 
miR-125b. No correlation was found between members of the miR-125 family (R=0.164 
and p=0.611).  
 
7.4.6. miR-132/212 family 
 
This miRNA family is another small family composed of miR-132 and miR-212, both 
genes are clustered within 0.5 kb on chromosome 17p13.3. Figure 7.11 shows the 
percentage of difference for miR-132 family between untreated and treated cells, no 








Figure 7. 11 Percentage of difference for miR-132 family in SH-SY5Y cells. 
 
Figure shows the percentage of difference for miR-132 family between untreated (‘‘-‘’) 
(green) and treated (‘‘+‘’) (blue) cells, error bars show the 95% confidence interval and 
the average is depicted. 
 
Association between miRNAs of the miR-132 family was performed using Spearman 
correlation test. miR-132 and miR-212 were found to be significantly correlated (r=0.881 
and p=0.0003). 
 
7.4.7. miR-17 family 
 
miR-17 family was examined in Chapter 6 and is composed of miR-
17/20a/20b/93/106a/106b. miR-17 and miR-20a are co-transcribed from chromosome 
13q31.3. miR-20b and miR-106a are co-transcribed from chromosome Xq26.2. miR-93 
and miR-106b are co-transcribed from chromosome 7q22.1. Figure 7.12 shows the 
percentage of difference for miR-17 family between untreated and treated cells, no 






Figure 7. 12 Percentage of difference for miR-17 family in SH-SY5Y cells. 
 
Figure shows the percentage of difference for miR-17 family between untreated (‘‘-‘’) 
(green) and treated (‘‘+‘’) (blue) cells, error bars show the 95% confidence interval and 
the average is depicted. 
 
Spearman correlation test was used to evaluate the association between members of 
the miR-17 family. All miRNAs were found to significantly correlate with each other 
(Table 7.5). 
 
Table 7. 5 Spearman correlation test for members of the miR-17 family. 
 miR-17 miR-20a miR-20b miR-93 miR-106a miR-106b 




























miR-106a     r=1 r=0.916 
p=8.3e-5*** 





7.5 Discussion and conclusions 
 
The null hypothesis was that there is no correlation between the expression of miRNAs 
of same family. miR-29, miR-132/212 and miR-17 families showed significant 
correlation between miRNAs of the same family. Following investigation, the null 
hypothesis could be rejected for these three miRNA families. However, not all 
members of the miR-16, miR-34 and miR-125 families showed some correlations in 
expression amongst individual members of their family. 
 
Within the miR-16 family, only the expression of miR-15b was found to significantly 
correlate with miR-15a, miR-195 and miR-424. Similarly, only miR-34c expression was 
found to significantly correlate with miR-449 as part of the miR-34 family. No 
correlation was found within the miR-125 family, indeed no change was observed 
between treated and untreated cells for both miR-125a and miR-125b. 
 
Interestingly, there was no significant correlation between the expression of some 
miRNAs that are encoded within 50 kilobases of each other. O’Carrol et al stated that 
miRNAs that are clustered within 0.1–50 kilobases from each other display common 
expression patterns. This was based on observations from work of Baskerville and 
Bartel in 2005. Baskerville and Bartel profiled the expression of 175 miRNAs from 24 
different human tissues and HeLa cells. The authors observed a higher correlation 
between miRNAs encoded within 50 kilobases overall. However, their data also shows 
some pairs of miRNAs (within the 50 kilobase range) with correlation values ranging 
from 0.2 up to 1. 
 
Similar to my results, there might be exceptions to this phenomenon as observed also 
in Baskerville and Bartel’s results. The authors mentioned that some miRNAs fall 
within the 50 kilobases but they are not correlated, including miR-23b and miR-24 
(correlation of 0.19). Another possible factor that could explain why some miRNAs 
didn’t correlate with each other is the variable affinity of miRNAs within the same 
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family for their targets. miRNAs of the same family share the seed region by which 
they bind to the 3’UTR of their targets, however, their affinity is variable. 
 
Hansen et al used a combination of conditional knockout and transgenic mouse models 
for miR-132 and miR-212 (178). Using RNA sequencing they explored the possible 
differential effects that each of these miRNAs could have on the whole transcriptome 
of mice hippocampus. They found that there was some overlap between 
downregulated transcripts when each of these miRNAs was overexpressed. However, 
they found that there were substantively more downregulated transcripts for 
overexpression of miR-132 than miR-212. 
 
Although both miRNAs share the same seed region they have some different 
nucleotides in the rest of their sequence (189). This would give different binding 
affinity for transcripts and would affect in turn the levels of the miRNA (189). miRNA 
binding to the 3’UTR of a target is followed by recruitment of the RISC complex and 
eventually mRNA cleavage of the target. This reaction destabilizes the association of 
the RISC complex and the 3’ end of the miRNA, thus promoting its degradation and 
affecting the miRNA levels (190,191). 
 
This effect could explain why some miRNAs did not show correlation between 
miRNAs of the same family as most of the miRNAs within a family showed similar 
trends after treatment of SH-SY5Y cells. Furthermore, a similar effect was observed 
particularly for the miR-132/212 family. These miRNAs are simultaneously transcribed 
(189), yet miR-132 showed an increase of approximately 18-fold and a 27-fold for miR-
212. The difference in their levels could be explained by their predominance over 
certain transcripts. This is in accordance with the described above work of Hansen et al 
(178). 
 
Hansen et al found that there were substantively more downregulated transcripts 
when miR-132 was overexpressed than when miR-212 was overexpressed. The effect of 
miR-132 in downregulating such transcripts would in turn also reduce the levels of 
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miR-132 despite being co-transcribed with miR-212. However, it should be noted that 
this higher effect of miR-132 would depend on the transcriptome expressed at a cell in 
a certain time. Yet, miR-132 and miR-212 showed correlation between them and their 
levels after differentiation of SH-SY5Y cells into neuronal like cells are generally 
known to be high in comparison with other miRNA changes. 
 
Similar to my results, Meseguer and colleagues performed differentiation of SH-SY5Y 
into neuronal like cells (192). They found a significant increase in 26 microRNAs, 
including miR-132 and miR-212. Likewise, Skalsky and Cullen observed that after 
treatment of SH-SY5Y cells with retinoic acid, cells change their morphology, express 
neuronal markers and up regulated several brain-specific miRNAs including miR-128, 
miR-124 and miR-132 (193). 
 
Magill et al also found that both miR-132 and miR-212 were increased after 
differentiation of SH-SY5Y into neuronal like cells (194). The same effect has been 
observed by others when inducing neurite outgrowth in PC12 and SH-SY5Y cells (195). 
This is in accordance to the literature as miR-132 and miR-212 are highly expressed in 
dendrites and synapses, and are regulated by neuronal activity (150,176). These 
miRNAs have a prominent role in neuronal morphogenesis, dendritic plasticity and 
neuronal differentiation (189,195). 
 
Conversely, using hippocampal neurons from rat embryos, overexpression of miR-132 
increased dendritic spine width whilst knockdown of miR-132 showed a reduction in 
dendritic complexity (196). Dendritic outgrowth was also induced by miR-132 
overexpression in neuronal primary cell culture (197). Using olfactory bulb neurons, 
overexpression of miR-132 led to a more complex dendritic tree with more synaptic 
connections (198). Reduced spine density and dendritic complexity was observed when 
reducing miR-132 levels (198). 
 
In vivo experiments using transgenic mouse models have shown that induction of miR-
132 expression was sufficient to modulate cognitive capacity in a dose-dependent 
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manner (176). Likewise, miR-132 levels correlated with spine density and interestingly, 
expression of miR-132 over and above physiological levels led to excessive spine 
density and cognitive deficits (176). In vivo experimentation by Magill, et al have 
demonstrated that the degree of neuronal dendritic growth and arborisation depends 
on the levels of miR-132 and miR-212 (194). Similarly, in vivo inhibition of miR-132 
resulted in reduced spine density and more immature spines, characterised by a 
reduced percentage of mushroom spines and increased proportion of immature 
filopodia (199). 
 
The miR-132/212 family has attracted marked examination as downregulation of this 
miRNA family is the only consistent finding according to a meta-analysis of profiling 
studies of miRNAs in dementia (64). Nevertheless, miRNA changes can be particular to 
the different brain areas analysed and the consistent downregulation of miR-132/212 
across different brain areas might be explained by a widespread synaptic loss. 
 
Another miRNA that has attracted attention in dementia research is miR-29. Hebert et 
al showed that miR-29a/b-1 was significantly decreased in AD patients showing high 
BACE1 protein (121). This finding was replicated in primary neuronal culture and they 
suggested a relationship between miR-29a/b-1 expression and amyloid production 
(121). Certainly, miR-29 might have a strong effect on BACE1 as it is the miRNA with 
the highest affinity for BACE1 according to TargetScan (63). 
 
A knockout mouse model of miR-29 showed that members of the microRNA 29 family 
are strongly expressed in neurons of the olfactory bulb, hippocampus and Purkinje 
cells of the cerebellum (200). The mice showed motor impairment and ataxia by 
affecting cerebellar Purkinje cells (200). This effect was also observed by others when 
delivering miR-29 inhibitors to the mouse brain using a neurotropic peptide (201). 
While miR-29 expression in mice is observed in neurons, particularly in the cerebellum, 
its expression in humans is unknown but might be accentuated in glial cells (172). 
Interestingly, in the results here shown, SH-SY5Y cells differentiated into neuronal like 
cells demonstrated a decrease in all members of the miR-29 family. 
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The evidence reinforces some important aspects to be considered in miRNA research: 
the need for in situ localization of miRNAs in the human brain and the possible 
differential expression of a miRNA between species, cell types and even brain areas. 
The same effect of cell type miRNAs is also observed for target validation of miRNAs 
in cell culture. 
 
Varendi et al reviewed the effect of 21 miRNAs that target BDNF using luciferase 
assays (202), which are commonly used for target validation but usually with 
inconsistent results.  Some miRNAs showed an effect on protein levels while others 
had no effect, all of them predicted to target the 3’UTR. Some studies included, where 2 
forms of the 3’UTR were cloned (short and long), showed that there were even 
differences between different forms of the same 3’UTR. Other studies showed that the 
same miRNA had different effects in different cell lines, causing no effect, increasing or 
reducing BDNF protein levels (202). Although there was inconsistency between the 
studies, this phenomenon is expected as part of normal miRNA biology. 
 
miRNAs are already present under physiological conditions and the proteome in a 
certain cell type at a certain time is already remodelled by the miRNAs expressed. 
Thus, assumptions derived from experimentation of miRNAs in cell culture should be 
taken with caution as every cellular population will show specific miRNA signatures. 
Instead, miRNAs are a useful tool to identify changes in hundreds of proteins and as 










Chapter 8.- General discussion and conclusions 
 
 
8.1 Recapitulation of chapters 
 
In Chapter 1, I proposed a novel approach for the study of miRNAs in dementia. This 
involved how one should consider multiple targets, previously reported number of 
copies of miRNAs, and the affinity for their targets in an attempt to overcome 
proposed caveats, previously described in miRNA research. I hypothesized that 
dysregulation of certain miRNAs might simultaneously affect different transcripts 
involved in the development of the two most common forms of dementia, AD and 
VaD. 
 
Chapter 3 described an investigation of miRNAs that were chosen because they 
targeted proteins involved in amyloid production, transport and amyloid degrading 
enzymes, tau phosphorylation, BBB integrity, glymphatic system and immune 
response, and therefore should be important in the pathogenesis of AD. Some 
significant results were found between diagnostic groups, and an interesting pattern of 
expression was found across Braak stages for five miRNAs that had three targets in 
common. One of these targets, the RORA protein represents an attractive target for the 
multiple points at which it is associated with characteristics observed in dementia. 
 
Despite the interesting results, a major methodological issue was identified. I found 
that the most commonly used calibrator gene in the scientific literature was 
significantly reduced by three-fold in AD cases of Braak stage VI. Given that a key 
property of a reliable calibrator gene is that it is not altered in circumstances of 
pathology then this calibrator was no longer useful to perform this role in studies of 
AD. Therefore, it was necessary to first identify new calibrators and evaluate their 




Chapter 4 described the identification and evaluation of six different calibrators. This 
chapter describes the assessment of these calibrators with respect to their variability 
across the cohort and their stability in a simulation of post-mortem delay. Three of the 
six calibrators (RNU48, miR-9-5p and miR-9-3p) showed lower variability across the 
cohort and greater stability with simulation of post-mortem delay. 
 
Although miR-9-5p and miR-9-3p showed a greater degree of stability in the various 
investigations undertaken, it must be acknowledged that their localisation in human 
brain is still unknown. Furthermore, overall changes seen may be a result of the sum of 
both increases and decreases in homogenised tissue comprising different cell types. In 
addition, the use of a single calibrator gene can introduce bias in the results. Thus, 
RNU48, miR-9-5p and miR-9-3p were used as calibrators for the evaluation of miRNAs 
of interest in Chapters 5 and 6. 
 
A re-examination of previously measured miRNAs in Chapter 3 and additional 
miRNAs from the same families are presented in Chapter 5. Some significant results 
were found between diagnostic groups; however no patterns of expression were found 
like those first observed in Chapter 3. This would prompt one to suggest that the 
similar patterns of expression seen in Chapter 3 were perhaps the result of 
inappropriate calibrators, that would have been used throughout, rather than a 
disease-related phenomenon. 
 
What remains problematic is that downregulation of the miR-132/212 family across 
different brain areas has been the only consistent finding so far in AD (64), which the 
data presented in Chapter 3 agrees with. Indeed, similar but statistically more 
significant reductions were found for both AD and VaD, but also for early AD (EAC) 
changes. However, as was mentioned, the problematic calibrators identified here were 
also commonly used in the literature, so it is possible they are all reflecting the same 




To reinforce the reproducibility of the measurements reported in this study, the three 
new calibrators were also measured in the whole cohort (n=84) at three different times. 
The CT difference between each of the three measurements to the CT average of them 
was 0.008 for RNU48, 0.028 for miR-9-5p and 0.018 for miR-9-3p. The average 
percentage of difference was 0.61% for RNU48, 2.42% for miR-9-5p and 1.86% for miR-
9-3p. Although the results found in Chapter 5 are less interesting from the point of 
view of identifying disease-associated miRNAs, compared to what was observed in 
Chapter 3, the data is arguably more robust in terms of reproducibility and also in 
relation to the literature. 
 
In Chapter 6, a similar approach was considered but this time in a way looking for a 
functional or physiological impact. This analysis was performed considering multiple 
transcripts involved in the renin angiotensin system and hypoxia inducible factors that 
might be relevant for both AD and VaD. Unexpectedly, no change was observed in the 
VaD group, despite obvious links with relevant factors, and only significant changes 
were observed in the AD group. Chapter 6 also included a nested study of miR-320e 
that binds to a created binding site due to the SNP rs6857 at the PVRL2 gene. A 
significant increase in miR-320e was found in AD with respect to the other diagnostic 
groups. Although it could be argued that this would only have an effect on those 
carriers of the SNP rs6857, miRNAs are able to bind with imperfect mismatch. This 
creates a bulge that reduces the affinity by which the miRNA binds to the 3’UTR of the 
mRNA. Chapters 5 and 6 also considered some important aspects for miRNA research 
such as the location of miRNAs. 
 
Chapter 7 involved an exploration of the literature as to suggestions that miRNA 
changes derived from experimentation might be specific to cellular populations. It also 
helped to explore, using cell culture, whether miRNAs of the same family show similar 
expression patterns in the differentiation of a cell type, as well as exploring whether 
miRNAs that are co-located have similar patterns of expression. Most of the miRNAs 
within a family showed a significant correlation between them, although not all 
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reached statistical significance, whilst others showed similar trends to other miRNAs 
within the family. 
 
In summary, Chapter 4 proposed and evaluated a number of prospective calibrators 
for the accurate measurement of miRNAs of interest. Three calibrators were confirmed 
and subsequently used due to their low variability across the cohort and their 
resistance to RNA degradation. Chapter 3 and 5 investigated proteins related to 
classical histopathological hallmarks of AD. Some of the miRNAs measured showed 
significant differences between diagnostic groups. Chapter 6 also considered proteins 
related to the renin angiotensin system and hypoxia inducible genes that might be 
relevant for both AD and VaD. Unexpectedly, no changes were observed in the VaD 
group. Only significant differences were found in the AD group. Chapter 6 also 
investigated miR-320e that bound to the endothelial adhesion protein PVRL2. Finally, 
Chapter 7 evaluated cell culture for its use in miRNA research in dementia and 
investigated whether miRNAs of the same family show common expression patterns. 
 
Each of the miRNAs analysed in this project could have an impact in AD or VaD. 
However, the impact of a miRNA would relate to the number of proteins it targets and 
to the number of miRNAs that regulate a protein. Combinations of miRNAs are more 
likely to have a meaningful impact by reducing the number of proteins being affected 
at a higher degree (i.e. by several miRNAs at the same time). An interesting pattern of 
expression for a combination of miRNAs was found in Chapter 3, however no patterns 
of expression were subsequently found once the data was appropriately measured 
with more reliable calibrators. These findings and the identification of new calibrators 
highlights that a number of previously reported calibrators used in dementia-related 
research may be inappropriate and need validation, but equally further research also 
needs to further validate the calibrators reported here. 
 
The functions of single miRNA-protein relations have been questioned in this project. 
However, the creation of a binding site in the PVRL2 gene sequence opened the 
possibility that under certain conditions such miRNA-protein relations may exist. Yet, 
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other factors should be considered such as co-localisation of the miRNA with the 
protein of interest and validation of binding site. Furthermore, other 
posttranscriptional modifications might also be involved. This thesis attempted to 
demonstrate evidence for a more biologically relevant role of miRNAs. 
 
 
8.2 Strengths of this study 
 
This is the first study of miRNA research in dementia that considers several factors for 
selection of miRNAs of interest. Those factors are the selection of miRNAs based on the 
fact that they have multiple targets, their affinity for these targets and the number of 
copies of miRNAs that have been reported. Tens of publications in the study of 
dementia follow the rationale of single miRNA-protein relationship without 
consideration of these additional factors, which while perhaps demonstrable in a single 
cell experimental system may not be valid or translatable in the context of more 
complex experimental systems, multi-cellular systems and whole organisms. Witwer 
and Halushka have described that the applied and translational miRNA research is 
subject to many pitfalls and claims that many previous studies are neither scientifically 
rigorous nor reproducible (203). The approach taken in this study is therefore an 
attempt to conduct miRNA research in a more robust manner and with more 
biologically relevant results. 
 
In terms of methodology used, I have used the recommended gold standards, such as 
TargetScan for the selection of miRNAs of interest and qPCR for accurate measurement 
of them (66,204). Additionally, two novel formulas are proposed in order to improve 
accuracy and statistical analysis of the data. One formula is to calculate the percentage 
of difference rather than the relative quantity for miRNAs of interest and a second 
formula to calculate the average CT value for different calibrators. 
 
Furthermore, this is the first study that has investigated miRNA changes in the 
posterior cingulate cortex. The majority of publications have used other brain areas 
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such as the temporal, prefrontal, parietal cortexes and the hippocampus (64). The 
posterior cingulate gyrus shows a reduced metabolic rate and is able to predict 
progression from mild cognitive impairment to dementia with an accuracy of 94% 
(205–207). In addition, evaluation of this brain area in cognitively normal patients, 
shows a similar metabolic reduction in those patients with the APOE ε4 allele, which is 
the highest risk factor for AD and it is also reduced with increasing age (208). 
 
 
8.3 Weaknesses of this study 
 
The cohort presented in this study represents only 84 individuals with a common 
genetic (ethnic) background that (as a sample of more elderly cases) are not 
representative of the general population, although they are intended for study of an 
aged related disorder. The cohort could be further improved by increasing the number 
in particular to change the proportion of carriers with the APOE ɛ4 allele. There is only 
one APOE ɛ4 carrier in the control group (N=24), four carriers in the EAC group (N=20) 
and 16 carriers in the AD group (N=22), which limited some further investigations, 
although the cohort size is still larger than many studies conducted to-date. 
 
With respect to the methodology used, previously reported number of copies of a 
miRNA were used as a reference of their abundance. However, previously reported 
copies are derived from different experiments using RNA sequencing deposited in 
miRbase. Such experiments have used different organs and miRNAs can highly 
fluctuate between organs, cell types and even between multiple cultures of the same 
cell type (209). Similarly, the results are presented as a percentage of difference with 
respect to controls. However, it would be much more informative to know the absolute 







8.4 Recommendations for future research 
 
The understanding of the role of miRNAs in dementia research has so far been 
restricted to single miRNA-protein relations. However, the impact of a single miRNA 
via a specific protein is related to the total number of different transcripts it targets and 
also by the number of other miRNAs that regulates the same protein (65). In addition, 
numerous miRNAs have been found to be dysregulated in AD brain with inconsistent 
results. Inconsistencies are likely to relate partly to the size, stratification and analysis 
of investigated cohorts; the profiling techniques used including hybridization methods 
lacking specificity; use of inaccurate miRNA calibrators; and the study of different 
brain areas. Some of these aspects have already been acknowledged and addressed by 
others in the literature (64,66,138). 
 
This thesis did not find a combination or signature of miRNAs for AD or VaD. 
However, miRNA signatures have been reported to exist by others. Lau et al found 41 
microRNAs dysregulated in the prefrontal cortex that were grouped in four different 
clusters according to their expression patterns (138). Combinations of miRNAs, 
particularly those simultaneously targeting similar proteins and pathways are likely to 
produce a more relevant physiological response. By analysing such combinations of 
miRNAs it is possible to identify proteins that are more affected than others by being 
targeted by more miRNAs. 
 
Yet, in the case of particular miRNAs, the co-localisation of a miRNA with a target 
should be strongly recommended as well as the validation of the binding site to 
confirm interactions. The localisation of numerous miRNAs has been omitted by 
several in the literature and remains elusive for many miRNAs. Halushka and 
colleagues suggested that miRNA research particularly with respect to biomarker and 
functional studies has been affected by this (210). There was not scope within this 




miRNA research in dementia is still in its early stages and it is necessary to expand the 
conception of miRNA function. miRNAs are part of an evolutionary process and they 
are expressed under physiological conditions. The transcriptome present in cellular 
populations is constantly remodelled by already present miRNAs, some of which 
might be cell type specific that are in abundance and others with more precise levels 
that work to fine tune gene expression to respond to external stimuli. The biological 
impact of miRNAs is likely to be determined by their combinatorial signature, the 
number of miRNA copies, their affinity for different targets, and the existing 




























Human post-mortem brain tissue was obtained from South West Dementia Brain Bank 
(SWDBB), Southmead Hospital with approval from the local research ethics committee 





Age (σ) PMI (σ) ApoE4 
(No/Yes) 
Control 11/13 80 (9.7) 35.4 (16.2) 21/1 
Early Alzheimer changes 11/9 85 (6) 36.5 (15) 14/4 
Alzheimer’s Disease 11/11 78 (7.2) 23.7 (13.4) 3/16 
Vascular Dementia 9/9 83 (7.9) 34.7 (12.3) 9/4 












Demographic information of the cohort, age in years, post-mortem interval delay (PMI) 






















In Chapter 3, seven miRNAs were measured and an interesting pattern of expression 
was found across Braak stages for five miRNAs (miR-16, miR-29a/b, miR-34a and miR-
125b) that had three targets in common. One of these targets, RORA, represents an 
attractive candidate protein that participates in numerous processes linked to 
dementia. On the other side, the remainder two miRNAs (miR-132 and miR-212) 
showed a reduction along progression of Braak stages. These two miRNAs (described 
in detail in Chapter 7) are present in dendrites and synapses, regulated by synaptic 
activity and have been associated with cognition. Further evidence of the role of the 
miR-132/212 family in dementia could be provided by measurement of the miR-
132/212 family in post-mortem brain tissue in conjunction with protein levels of the 
microtubule associated protein 2 (MAP2), an essential protein for neuritogenesis. Thus, 
both proteins, RORA and MAP2 were attempted to be measured. Training was 
received from Dr. Hannah Tayler. 
 
 
Western blotting for MAP2 (lines 7-10) and RORA (lines 2-5) protein as described in 






Analysis of RAS-associated microRNAs according to their functional impact in the 
RAS physiology. From a total of 164 combinations (Appendix 3) of overlapping targets 
and miRNAs in common, 14 of them were selected (Chapter 6 Table 6.2) since these 
might have a functional impact in the RAS as they targeted multiple RAS components. 
 
RAS components miRNAs 
AGT AGTR1 AGTR2 DPP3 
ENPEP LNPEP MME RNPEP 
miR-3163 
AGT AGTR1 ENPEP LNPEP 
MME REN RNPEP 
miR-2467-3p 
ACE ACE2 AGT ANPEP 
ENPEP LNPEP MME 
miR-670-5p 
AGTR1 AGTR2 ENPEP 
LNPEP MME RNPEP 
miR-944 
ACE2 AGTR1 AGTR2 ENPEP 
MME RNPEP 
miR-4766-5p 
ACE AGTR2 ENPEP LNPEP 
MME RNPEP 
miR-495-3p 
AGT AGTR1 AGTR2 ENPEP 
LNPEP MME 
miR-513b-5p 
AGTR1 AGTR2 DPP3 ENPEP 
LNPEP MME 
miR-512-3p miR-302-3p/372-3p/373-3p/520-3p 
ACE AGT AGTR2 ENPEP 
LNPEP MME 
miR-142-5p 
ACE AGT ANPEP LNPEP 
RNPEP 
miR-665 miR-24-3p 
AGTR2 ENPEP LNPEP MME 
RNPEP 
miR-541-5p 
AGT ENPEP LNPEP MME 
RNPEP 
miR-129-5p 
ACE ENPEP LNPEP MME 
RNPEP 
miR-185-5p 
ACE DPP3 ENPEP LNPEP 
RNPEP 
miR-3150b-3p 
ACE ACE2 LNPEP REN 
RNPEP 
miR-3909 
AGTR2 ANPEP ENPEP 
LNPEP REN 
miR-676-3p 




ACE ACE2 ANPEP ENPEP 
LNPEP 
miR-125-5p 
ACE2 AGT ANPEP ENPEP 
MME 
miR-149-5p 
ACE AGT ANPEP ENPEP 
MME 
miR-3612 
AGT AGTR2 ENPEP LNPEP 
MAS1 
miR-224-5p 
AGTR1 AGTR2 DPP3 ENPEP 
LNPEP 
miR-431-5p miR-889-3p 
ACE2 AGTR1 AGTR2 LNPEP 
MME 
miR-371-5p 
AGTR2 ENPEP LNPEP MME 
REN 
miR-330-3p 
ACE AGTR2 ENPEP LNPEP 
MME 
miR-302c-3p.2/520-3p 
ACE2 AGT AGTR2 DPP3 
LNPEP 
miR-483-3p.2 
ACE2 AGT AGTR2 ENPEP 
MME 
miR-525-5p 
AGTR1 DPP3 ENPEP LNPEP 
MME 
miR-624-5p 
ACE AGTR1 DPP3 ENPEP 
LNPEP 
miR-148-3p/152-3p 
AGT AGTR1 LNPEP MME 
REN 
miR-605-3p 
ACE2 AGT AGTR1 LNPEP 
MME 
miR-513c-5p/514b-5p 
ACE2 AGT ENPEP LNPEP 
MME 
miR-218-5p miR-760 
ACE ACE2 LNPEP MME REN miR-326 
AGTR2 ANPEP MME RNPEP miR-874-3p 
AGT ANPEP REN RNPEP miR-423-5p 
AGTR2 LNPEP MME RNPEP miR-2115-3p 
ACE AGT AGTR1 RNPEP miR-7-5p 
ACE ENPEP LNPEP RNPEP miR-3150a-3p 
AGT LNPEP MME RNPEP miR-2278 
AGTR1 ANPEP ENPEP 
LNPEP 
miR-299-3p 
ANPEP ENPEP LNPEP MME miR-552-3p 
ACE2 ANPEP ENPEP LNPEP miR-345-3p 
ACE ANPEP ENPEP LNPEP miR-513a-5p 
ANPEP DPP3 ENPEP LNPEP miR-670-3p 
AGT ANPEP LNPEP MME miR-1197 
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ACE ANPEP LNPEP REN miR-378g 
AGTR1 AGTR2 LNPEP MME miR-493-5p 
ACE2 AGTR1 AGTR2 LNPEP miR-1277-5p 
AGTR2 ENPEP LNPEP MME miR-656-3p miR-128-3p miR-369-3p miR-3121-3p 
miR-3145-3p miR-4640-3p miR-186-5p miR-488-3p 
miR-126-5p miR-374-5p miR-202-5p miR-337-3p 
AGTR2 ENPEP LNPEP REN miR-28-5p/708-5p 
AGT AGTR2 ENPEP LNPEP miR-330-3p.2 miR-3690 
AGTR2 DPP3 LNPEP MME miR-17-5p/20-5p/93-5p/106-5p/519-3p 
AGT AGTR2 ENPEP MME miR-506-5p 
ACE2 AGTR2 ENPEP MME miR-335-5p 
AGTR1 ENPEP LNPEP MME miR-410-3p miR-3140-3p miR-802 miR-511-3p 
AGT AGTR1 ENPEP LNPEP miR-375 
AGT AGTR1 LNPEP MME miR-4739 miR-181-5p 
ACE2 AGTR1 LNPEP MME miR-505-3p.2 
AGTR1 DPP3 LNPEP MME miR-3164 
ACE2 ENPEP LNPEP MME miR-9-5p miR-200-3p/429 miR-942-5p 
ACE ENPEP LNPEP MME miR-27-3p miR-1252-5p miR-221-3p/222-3p 
DPP3 ENPEP LNPEP MME miR-379-5p 
ACE ENPEP LNPEP REN miR-138-5p 
ACE2 AGT ENPEP LNPEP miR-1278 
ACE DPP3 ENPEP LNPEP miR-340-5p 
ACE2 AGT LNPEP MME miR-421 miR-873-3p 
ACE AGT LNPEP MME miR-766-5p 
ACE2 AGT DPP3 LNPEP miR-1301-3p 
ACE2 AGT ENPEP MME miR-141-3p/200-3p 
ACE DPP3 ENPEP MME miR-1294 
ACE AGT DPP3 MME miR-339-5p 
AGTR2 ANPEP RNPEP miR-3173-5p 
AGT ANPEP RNPEP miR-5194 
LNPEP MAS1 RNPEP miR-448 
AGTR1 LNPEP RNPEP miR-455-3p.1 
ACE LNPEP RNPEP miR-491-5p 
ENPEP MME RNPEP miR-668-3p 
AGT MME RNPEP miR-545-3p 
AGTR2 ANPEP LNPEP miR-383-5p.2 
ANPEP ENPEP LNPEP miR-3200-3p miR-361-3p 
AGT ANPEP LNPEP miR-873-5p.1 
AGT ANPEP MME miR-642-3p 
AGTR2 LNPEP MAS1 miR-23-3p 
AGTR2 ENPEP MAS1 miR-651-5p 
AGTR2 ENPEP LNPEP miR-576-5p miR-384 miR-524-5p 
AGTR2 LNPEP MME miR-361-5p miR-6509-5p miR-483-3p.1 miR-380-3p 
miR-892-5p 
AGT AGTR2 LNPEP miR-556-3p miR-532-5p miR-577 miR-520g-3p 
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ACE AGTR2 LNPEP miR-516b-5p 
AGTR2 ENPEP MME miR-409-3p 
AGT AGTR2 MME miR-15-5p/16-5p/195-5p/424-5p/497-5p 
ACE AGTR2 MME miR-654-3p 
ACE AGTR2 DPP3 miR-203a-3p.1 
AGTR1 ENPEP LNPEP miR-155-5p miR-641/3617-5p miR-223-3p 
AGTR1 LNPEP MME miR-545-5p miR-33-5p miR-134-5p miR-579-3p 
ACE2 AGTR1 LNPEP miR-381-3p 
AGTR1 ENPEP MME miR-2681-5p 
AGT AGTR1 MME miR-103-3p/107 
ACE AGTR1 DPP3 miR-34-5p/449-5p 
ENPEP LNPEP MME miR-376c-3p miR-30-5p miR-3942-5p miR-132-
3p/212-3p miR-204-5p/211-5p miR-1269 miR-450b-5p 
miR-216-5p miR-518d-5p/519-5p miR-378-3p miR-
194-5p miR-26-5p miR-376-3p miR-653-5p miR-580-
3p miR-522-3p miR-4766-3p 
AGT ENPEP LNPEP miR-193-3p miR-4428 miR-1245b-5p miR-377-3p 
miR-5581-3p 
ACE2 ENPEP LNPEP miR-4424 miR-1306-5p miR-374-5p/655-3p miR-543 
ACE ENPEP LNPEP miR-432-5p miR-3605-5p miR-4731-5p 
DPP3 ENPEP LNPEP miR-197-3p 
LNPEP MME REN miR-3200-5p 
AGT LNPEP MME miR-3924 miR-31-5p miR-758-3p 
ACE2 LNPEP MME miR-5691 miR-3194-3p miR-374a-3p 
ACE LNPEP MME miR-873-5p.2 miR-3126-5p 
DPP3 LNPEP MME miR-876-5p miR-2355-5p miR-146-5p miR-183-5p.1 
miR-589-5p 
AGT LNPEP REN miR-6720-5p 
ACE LNPEP REN miR-214-3p/3619-5p 
ACE2 AGT LNPEP miR-3611 miR-212-5p miR-769-5p 
AGT DPP3 LNPEP miR-196-5p 
ACE ACE2 LNPEP miR-3187-3p miR-4677-3p miR-346 miR-582-5p 
ACE2 DPP3 LNPEP miR-329-3p/362-3p 
ACE DPP3 LNPEP miR-3179 
ACE2 ENPEP MME miR-140-3p.1 
ACE2 AGT ENPEP miR-489-3p 
ACE ACE2 ENPEP miR-642b-5p miR-331-3p 
ACE MME REN miR-3918 
AGTR2 RNPEP miR-129-3p 
LNPEP RNPEP miR-153-3p 
ENPEP RNPEP miR-383-5p.1 
AGT RNPEP miR-3194-5p 
AGTR2 ANPEP miR-193a-5p 
AGT ANPEP miR-328-3p 
ACE ANPEP miR-1908-5p 
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AGTR2 LNPEP miR-556-5p miR-154-3p/487-3p miR-539-3p miR-
3622a-5p miR-1276 miR-299-5p miR-561-5p 
AGTR2 ENPEP miR-629-5p 
AGTR2 MME miR-493-3p 
ACE AGTR2 miR-425-5p 
AGTR1 LNPEP miR-140-3p.2 miR-205-5p miR-96-5p/1271-5p 
AGTR1 MME miR-182-5p 
ACE2 AGTR1 miR-1266-3p 
ACE AGTR1 miR-5000-3p 
ENPEP LNPEP miR-320 miR-515-5p/519e-5p miR-122-5p miR-323-3p 
miR-323b-3p miR-382-3p miR-5579-3p miR-34b-
5p/449c-5p miR-144-3p miR-9-3p miR-19-3p miR-
642a-5p miR-29-3p miR-494-3p miR-105-5p miR-
514a-5p miR-3146 
LNPEP MME miR-452-5p/892-3p miR-411-5p.1 miR-325 miR-190-
5p miR-582-3p miR-542-3p miR-885-5p miR-599 
miR-3171 miR-411-5p.2 miR-433-3p miR-150-5p miR-
130-3p/301-3p/454-3p miR-411-3p 
AGT LNPEP miR-345-5p miR-4637 miR-584-5p miR-625-5p miR-
1323 miR-5010-5p 
ACE2 LNPEP miR-188-5p miR-7151-5p miR-574-5p 
ACE LNPEP miR-101-3p.2 miR-1270 
DPP3 LNPEP miR-5009-3p miR-324-3p/1913 
ENPEP MME miR-3064-5p miR-1911-5p miR-1295a miR-1296-5p 
miR-498 
ENPEP REN miR-136-5p miR-4761-3p 
AGT ENPEP miR-496.2 miR-145-5p 
ACE ENPEP miR-214-5p 
DPP3 ENPEP let-7-5p/98-5p 
AGT MME miR-2116-3p 
ACE2 MME miR-362-5p/500b-5p 
ACE MME miR-1286 miR-671-5p 
DPP3 MME miR-628-5p 
AGT REN miR-338-3p 
ACE REN miR-4640-5p 
ACE2 AGT miR-588 
ACE AGT miR-6509-3p miR-22-3p 
ANPEP miR-627-5p miR-151-3p miR-3622b-5p miR-3944-3p 
MAS1 miR-143-3p 
AGTR2 miR-6746-5p miR-2114-3p miR-888-5p miR-490-3p 
miR-770-5p 
AGTR1 miR-1-3p/206 
LNPEP miR-101-3p.1 miR-137 miR-552-5p miR-532-3p miR-
455-3p.2 miR-519-3p miR-4661-5p miR-147a miR-
518-3p miR-135-5p miR-18-5p miR-374b-3p miR-142-
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3p.1 miR-1287-5p miR-875-5p miR-3614-5p miR-28-
3p miR-3144-3p miR-324-5p miR-5687 miR-1343-3p 
miR-499b-5p miR-21-5p/590-5p miR-624-3p miR-501-
3p/502-3p miR-99-5p/100-5p miR-183-5p.2 miR-1247-
5p 
ENPEP miR-877-5p miR-451 miR-1185-5p miR-409-5p miR-
219-5p miR-142-3p.2 miR-508-3p miR-526b-5p miR-
371a-3p miR-133a-3p.1 miR-496.1 miR-133a-
3p.2/133b miR-5094 
MME miR-139-5p miR-10-5p miR-342-3p miR-500a-3p 
miR-25-3p/32-5p/92-3p/363-3p/367-3p miR-4662-5p 
miR-1251-5p miR-625-3p 
REN miR-3127-5p miR-5586-5p 
AGT miR-2114-5p miR-219a-2-3p miR-2277-5p miR-486-
5p miR-151-5p miR-124-3p.2/506-3p miR-370-3p 
miR-132-5p miR-184 miR-124-3p.1 miR-199-3p 
ACE2 miR-514a-3p miR-505-3p.1 miR-144-5p miR-1179 







Pubmed ID Initial sample size Replication sample size Region Gene SNP P value 
27770636 
1,825 African American ancestry cases,   
13q32.1 GPR180 rs187295598-T 6.00E-06 
3,784 African American ancestry controls 
27770636 
1,825 African American ancestry cases   
7q34 TAS2R5 rs2234017-C 7.00E-06 
3,784 African American ancestry controls 
30636644 
952 European ancestry male cases 
NA 19q13.32 TOMM40 rs405697 1.00E-13 
1,789 European ancestry female cases 
6,337 European ancestry male controls 
8,402 European ancestry female controls 
30636644 
952 European ancestry male cases 
NA 19q13.32 TOMM40 rs405697 1.00E-08 
1,789 European ancestry female cases 
6,337 European ancestry male controls 
8,402 European ancestry female controls 
30636644 952 European ancestry male cases NA 19q13.32 NECTIN2 rs6859-A 6.00E-13 
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1,789 European ancestry female cases 
6,337 European ancestry male controls 
8,402 European ancestry female controls 
30636644 
952 European ancestry male cases 
NA 19q13.32 NECTIN2 rs6859-A 1.00E-09 
1,789 European ancestry female cases 
6,337 European ancestry male controls 
8,402 European ancestry female controls 
30636644 
952 European ancestry male cases 
NA 19q13.32 NECTIN2 rs6859-A 2.00E-21 
1,789 European ancestry female cases 
6,337 European ancestry male controls 
8,402 European ancestry female controls 





1,190 European ancestry cases 
NA 12q24.22 HRK rs17429217 3.00E-06 
1,032 cases 
23535033 303 European ancestry cases   2q14.3 LIMS2 rs78022502 2.00E-06 
23535033 303 European ancestry cases   5q33.2 SAP30L rs148763909 1.00E-08 
23535033 303 European ancestry cases   7p15.3 CYCS rs1861525 2.00E-07 
26830138 2,478 European ancestry cases NA 6q25.3 TULP4 rs116886320-A 3.00E-07 
230 
 
979 ancestry controls 
26830138 
2,478 European ancestry cases 
NA 7q36.3 INSIG1 rs191603973-C 7.00E-07 
979 ancestry controls 
26830138 
2,478 European ancestry cases 
NA 16p12.2 SDR42E2 rs145049847-C 8.00E-09 
979 ancestry controls 
26830138 







979 ancestry controls both from the same 
26830138 
2,478 European ancestry cases 
NA 4q31.1 SETD7 rs72728723-A 2.00E-07 
979 ancestry controls both from the same 
22159054 
513 African American cases 
NA 19q13.32 NECTIN2 rs6859-A 5.00E-07 
496 African American controls 
20885792 
931 cases 1,338 cases 
19q13.32 NECTIN2 rs6859-A 1.00E-07 
 1,104 controls 2,003 controls 
18823527 
1,082 European ancestry cases 
1,400 controls 19q13.32 NECTIN2 rs6859-A 6.00E-14 
1,239 European ancestry controls 
29274321 190 European ancestry cases NA 20p13 RSPO4 rs62187521-T 5.00E-07 
29777097 
42,034 British ancestry with parental AD history 
272,244 British ancestry with no parental AD history 





25,580 Alzheimer's disease cases 
48,466 controls 
29777097 
42,034 British ancestry with parental AD history 
272,244 British ancestry with no parental AD history 
NA 19q13.32 TOMM40 rs405697 5.00E-08 
25,580 Alzheimer's disease cases 
48,466 controls 
29777097 
42,034 British ancestry with parental AD history 
272,244 British ancestry with no parental AD history 
NA 19q13.32 TOMM40 rs141864196 5.00E-08 
25,580 Alzheimer's disease cases 
48,466 controls 
29777097 
42,034 British ancestry with parental AD history 







25,580 Alzheimer's disease cases 
48,466 controls 
28183528 
13,100 European ancestry cases 





rs6857-T 6.00E-07 13,220 European ancestry controls 
20,474 European ancestry 
controls 
1,472 African American cases  
3,511 African American controls  
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951 Japanese ancestry cases  
894 Japanese ancestry controls  
51 Israeli-Arab ancestry cases  
64 Israeli-Arab ancestry controls   
28183528 
13,100 European ancestry case 
 13,220 European ancestry controls 
1,472 African American cases 
3,511 African American controls 
951 Japanese ancestry cases 
894 Japanese ancestry controls 
51 Israeli-Arab ancestry cases 
64 Israeli-Arab ancestry controls 
5,813 European ancestry 
cases 







24,087 European ancestry late-onset AD cases 
47,793 European ancestry with family history of AD 
383,378 European ancestry controls 




24,087 European ancestry late-onset AD cases 
47,793 European ancestry with family history of AD 
383,378 European ancestry controls 
NA 19q13.32 BCAM rs142092405-G 6.00E-12 
30617256 24,087 European ancestry late-onset AD cases NA 19q13.32 TOMM40 rs141864196-A 3.00E-10 
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47,793 European ancestry with family history of AD 
383,378 European ancestry controls 
30617256 
24,087 European ancestry late-onset AD cases 
47,793 European ancestry with family history of AD 
383,378 European ancestry controls 
NA 1q23.3 ADAMTS4 rs4575098-A 2.00E-10 
25778476 7,184 cases, 26,968 controls 
718 European ancestry cases, 
1,699 European ancestry 
controls 
8p21.2 PTK2B rs2271920-A 8.00E-06 
30820047 
21,982 European ancestry cases 
 41,944 European ancestry controls 
13,292 European ancestry 
cases 
17,219 European ancestry 
controls 










1.  World Health Organization. Priority diseases and reasons for inclusion. 
Alzheimer disease and other dementias. 2013 . Available from: 
http://www.who.int/medicines/areas/priority_medicines/BP6_11Alzheimer.pdf?
ua=1 
2.  Selkoe D, Mandelkow E, Holtzman D. Deciphering alzheimer disease. Cold 
Spring Harb Perspect Med. 2012;2(1).  
3.  Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer 
disease and mild cognitive impairment. Cold Spring Harb Perspect Med. 
2012;2(5).  
4.  Reitz C, Mayeux R. Alzheimer disease: Epidemiology, diagnostic criteria, risk 
factors and biomarkers. Biochem Pharmacol. 2014;88(4):640–51.  
5.  Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological 
alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):1–
23.  
6.  Mandelkow EME. Biochemistry and cell biology of Tau protein in 
neurofibrillary degeneration. Cold Spring Harb Perspect Biol. 2011;3:1–25.  
7.  MacArthur J, Bowler E, Cerezo M, Gil L, Hall P, Hastings E, et al. The new 
NHGRI-EBI Catalog of published genome-wide association studies (GWAS 
Catalog). Nucleic Acids Res. 2017;45(D1):D896–901.  
8.  Morris M, Maeda S, Vossel K, Mucke L. The many faces of tau. Neuron. 2011 
May 12;70(3):410–26.  
9.  Avila J, Lucas JJ, Pérez M, Hernández F. Role of Tau Protein in Both 
Physiological and Pathological Conditions. Physiol Rev. 2004 Apr;84(2):361–84.  
10.  Zhou F, Zhu X, Castellani RJ, Stimmelmayr R, Perry G, Smith MA, et al. 
Hibernation, a model of neuroprotection. Am J Pathol. 2001 Jun [cited 2019 Jan 
12];158(6):2145–51.  
11.  Le Freche H, Brouillette J, Fernandez-Gomez F-J, Patin P, Caillierez R, Zommer 
235 
 
N, et al. Tau Phosphorylation and Sevoflurane Anesthesia. Anesthesiology. 
2012;116(4):779–87.  
12.  Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, et al. Tau 
phosphorylation in Alzheimer’s disease: Pathogen or protector? Trends Mol 
Med. 2005;11(4):164–9.  
13.  León-Espinosa G, García E, García-Escudero V, Hernández F, Defelipe J, Avila J. 
Changes in tau phosphorylation in hibernating rodents. J Neurosci Res. 
2013;91(7):954–62.  
14.  Andresen M, Gazmuri JT, Marín A, Regueira T, Rovegno M. Therapeutic 
hypothermia for acute brain injuries. Scand J Trauma Resusc Emerg Med. 2015 
Jun 5;23:42.  
15.  Härtig W, Stieler J, Boerema AS, Wolf J, Schmidt U, Weißfuß J, et al. Hibernation 
model of tau phosphorylation in hamsters: Selective vulnerability of cholinergic 
basal forebrain neurons - Implications for Alzheimer’s disease. Eur J Neurosci. 
2007;25(1):69–80.  
16.  Arendt T, Stieler J, Strijkstra AM, Hut RA, Rüdiger J, Van der Zee EA, et al. 
Reversible paired helical filament-like phosphorylation of tau is an adaptive 
process associated with neuronal plasticity in hibernating animals. J Neurosci. 
2003 Aug 6;23(18):6972–81.  
17.  Arendt T, Stieler J, Holzer M. Brain hypometabolism triggers PHF-like 
phosphorylation of tau, a major hallmark of Alzheimer’s disease pathology. J 
Neural Transm. 2015;122(4):531–9.  
18.  Masters CL, Selkoe DJ, Mayeux R, Stern Y, Johnson KA, Fox NC, et al. 
Biochemistry of Amyloid b-Protein and Amyloid. Cold Spring Harb Perspect 
Med. 2012;  
19.  Holtzman DM, Mandelkow E, Selkoe DJ, Tanzi RE, Laferla FM, Green KN, et al. 
Trafficking and Proteolytic Processing of APP. Cold Spring Harb Perspect Med. 
2012;  
20.  Reinhard C, Hébert SS, De Strooper B. The amyloid-beta precursor protein: 




21.  Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. 
Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair 
synaptic plasticity and memory. Nat Med. 2008 Aug;14(8):837–42.  
22.  Iadecola C, Gottesman RF. Compendium on the Pathophysiology and Treatment 
of Hypertension Neurovascular and Cognitive Dysfunction in Hypertension 
Epidemiology, Pathobiology, and Treatment. 2019;124:1025–44.  
23.  Lauer A, Van Veluw SJ, William CM, Charidimou A, Roongpiboonsopit D, 
Vashkevich A, et al. Microbleeds on MRI are associated with microinfarcts on 
autopsy in cerebral amyloid angiopathy. Neurology. 2016;87(14):1488–92.  
24.  Banerjee G, Carare R, Cordonnier C, Greenberg SM, Schneider JA, Smith EE, et 
al. The increasing impact of cerebral amyloid angiopathy: essential new insights 
for clinical practice. J Neurol Neurosurg Psychiatry. 2017 Nov 1;88(11):982–94.  
25.  Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-A brief review of 
the basic science and clinical literature. Cold Spring Harb Perspect Med. 
2012;2(1).  
26.  Sarlus H, Heneka MT. Microglia in Alzheimer’s disease. J Clin Invest. 2017 Sep 
1;127(9):3240–9.  
27.  Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et 
al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015 
Apr;14(4):388–405.  
28.  Jessen NA, Munk ASF, Lundgaard I, Nedergaard M. The Glymphatic System: A 
Beginner’s Guide. Neurochem Res. 2015;40(12):2583–99.  
29.  Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Schöll M, 
et al. Diverging longitudinal changes in astrocytosis and amyloid PET in 
autosomal dominant Alzheimer’s disease. Brain. 2016;139(3):922–36.  
30.  Rodriguez-Vieitez E, Ni R, Gulyás B, Tóth M, Häggkvist J, Halldin C, et al. 
Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe 
transgenic mouse brain: a correlative positron emission tomography and in vitro 
imaging study. Eur J Nucl Med Mol Imaging. 2015;42(7):1119–32.  
31.  van Veluw SJ, Shih AY, Smith EE, Chen C, Schneider JA, Wardlaw JM, et al. 
Detection, risk factors, and functional consequences of cerebral microinfarcts. 
237 
 
Lancet Neurol. 2017;16(9):730–40.  
32.  Damasceno BP. Relationship between cortical microinfarcts and cognitive 
impairment in Alzheimer’s disease. Dement Neuropsychol. 2012;6(3):131.  
33.  Weintraub S, Wicklund A, Salmon D. The neuropsychological profile of 
Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(4).  
34.  Sacuiu SF. Dementias. Handb Clin Neurol. 2016;138:123–51.  
35.  Association Alzheimer. 2018 Alzheimer’s Disease facts and figures. Alzheimer’s 
Dement. 2018;14(3):367–429.  
36.  Lourida I, Hannon E, Littlejohns TJ, Langa KM, Hyppönen E, Kuzma E, et al. 
Association of Lifestyle and Genetic Risk With Incidence of Dementia. JAMA. 
2019 Aug 6;322(5):430.  
37.  Kamboh MI, Demirci FY, Wang X, Minster RL, Carrasquillo MM, Pankratz VS, 
et al. Genome-wide association study of Alzheimer’s disease. Transl Psychiatry. 
2012;2(5):1–7.  
38.  Tanzi RE. The Genetics of Alzheimer Disease. Cold Spring Harb Perspect Med. 
2012;55(3):294.  
39.  De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and γ-secretase: Structure, 
function, and role in Alzheimer disease. Cold Spring Harb Perspect Med. 
2012;2(1).  
40.  Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein e and Alzheimer disease: Risk, 
mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–18.  
41.  Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. 
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for 
Alzheimer’s disease. Nat Genet. 2013;45(12):1452–8.  
42.  Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, et al. 
Genetic evidence implicates the immune system and cholesterol metabolism in 
the aetiology of Alzheimer’s disease. PLoS One. 2010;5(11).  
43.  Finder VH. Alzheimer’s disease: A general introduction and pathomechanism. J 
Alzheimer’s Dis. 2010;22(3):5–19.  
44.  Pákáski M, Kálmán J. Interactions between the amyloid and cholinergic 
mechanisms in Alzheimer’s disease. Neurochem Int. 2008 Nov 1;53(5):103–11.  
238 
 
45.  Kehoe PG. The Coming of Age of the Angiotensin Hypothesis in Alzheimer’s 
Disease: Progress Toward Disease Prevention and Treatment? J Alzheimer’s Dis. 
2018 Mar 13;62(3):1443–66.  
46.  Bartel DP. Review MicroRNAs: Genomics, Biogenesis, Mechanism, and 
Function. Cell. 2004;116:281–97.  
47.  Bartel DP. MicroRNAs: Target Recognition and Regulatory Functions. Cell. 2009 
Jan 23;136(2):215–33.  
48.  Miyoshi K, Miyoshi T, Siomi H. Many ways to generate microRNA-like small 
RNAs: Non-canonical pathways for microRNA production. Mol Genet 
Genomics. 2010;284(2):95–103.  
49.  Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: 
microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009 Mar 
1;11(3):228–34.  
50.  Pelechano V, Steinmetz LM. Gene regulation by antisense transcription. Nat Rev 
Genet. 2013;14(12):880–93.  
51.  Mohr A, Mott J. Overview of MicroRNA Biology. Semin Liver Dis. 2015 Jan 
29;35(01):003–11.  
52.  O’Carroll D, Schaefer A. General principals of miRNA biogenesis and regulation 
in the brain. Neuropsychopharmacology. 2013;38(1):39–54.  
53.  Baskerville S, Bartel DP. Microarray profiling of microRNAs reveals frequent 
coexpression with neighboring miRNAs and host genes. RNA. 2005 Jan 
20;11(3):241–7.  
54.  Meunier J, Lemoine F, Soumillon M, Liechti A, Weier M, Guschanski K, et al. 
Birth and expression evolution of mammalian microRNA genes. Genome Res. 
2013 Jan 1;23(1):34–45.  
55.  Berezikov E. Evolution of microRNA diversity and regulation in animals. Nat 
Rev Genet. 2011 Dec 1;12(12):846–60.  
56.  Afonso Guerra-Assunção J, Enright AJ. Large-scale analysis of microRNA 
evolution. BMC Genomics. 2012;13:1.  
57.  Gregory RI, Yan K, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, et al. 
The Microprocessor complex mediates the genesis of microRNAs. Nature. 2004 
239 
 
Nov 11;432(7014):235–40.  
58.  Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat 
Rev Mol Cell Biol. 2013;14(8):475–88.  
59.  Kai ZS, Pasquinelli AE. MicroRNA assassins: Factors that regulate the 
disappearance of miRNAs. Nat Struct Mol Biol. 2010;17(1):5–11.  
60.  Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R. MicroRNA-dependent 
localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol. 2005 Jul 
5;7(7):719–23.  
61.  Braun JE, Huntzinger E, Fauser M, Izaurralde E. GW182 Proteins Directly 
Recruit Cytoplasmic Deadenylase Complexes to miRNA Targets. Mol Cell. 2011 
Oct 7;44(1):120–33.  
62.  Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are 
conserved targets of miRNAs. Genome Res. 2009;(19):92–105.  
63.  Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target 
sites in mammalian mRNAs. Elife. 2015;4:1–38.  
64.  Lau P, Sala Frigerio C, De Strooper B. Variance in the identification of 
microRNAs deregulated in Alzheimer’s disease and possible role of lincRNAs in 
the pathology: The need of larger datasets. Ageing Res Rev. 2014 Sep 1;17:43–53.  
65.  Gerardo-Aviles J, Allen S, Kehoe PG. Renin-Angiotensin System MicroRNAs, 
Special Focus on the Brain. In: Renin-Angiotensin System - Past, Present and 
Future. InTech; 2017.  
66.  Pritchard CC, Cheng HH, Tewari M, Division B, Hutchinson F, Health P, et al. 
MicroRNA profiling: approaches and considerations Colin. Nat Rev Genet. 
2015;13(5):358–69.  
67.  Benes V, Castoldi M. Expression profiling of microRNA using real-time 
quantitative PCR, how to use it and what is available. Methods. 2010;50(4):244–9.  
68.  Hunt EA, Broyles D, Head T, Deo SK. MicroRNA Detection: Current Technology 
and Research Strategies. Annu Rev Anal Chem. 2015;8(1):217–37.  
69.  Zhao Y, Lukiw WJ. TREM2 signaling, miRNA-34a and the extinction of 
phagocytosis. Front Cell Neurosci. 2013;7:131.  
70.  Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: Rationale, 
240 
 
strategies and challenges. Vol. 9, Nature Reviews Drug Discovery. 2010.  775–89.  
71.  Geekiyanage H, Chan C. MicroRNA-137/181c Regulates Serine 
Palmitoyltransferase and In Turn Amyloid , Novel Targets in Sporadic 
Alzheimer’s Disease. J Neurosci. 2011 Oct 12;31(41):14820–30.  
72.  Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. 
Acta Neuropathol. 1991;82(4):239–59.  
73.  Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-
time quantitative PCR and the 2 Delta Delta CT method. Methods. 
2001;25(3):402–8.  
74.  Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative 
CTmethod. Nat Protoc. 2008;3(6):1101–8.  
75.  Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. 
Accurate normalization of real-time quantitative RT-PCR data by geometric 
averaging of multiple internal control genes. Genome Biol. 2002;50:1–30.  
76.  Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence 
microRNAs using deep sequencing data. Nucleic Acids Res. 2014 
Jan;42(D1):D68–73.  
77.  Fromm B, Billipp T, Peck LE, Johansen M, Tarver JE, King BL, et al. A uniform 
system for the annotation of human microRNA genes and the evolution of the 
human microRNAome. Annu Rev Genet. 2015;23(49):213–42.  
78.  Huang DW, Sherman BT, Lempicki Richar. Systematic and integrative analysis 
of large gene lists using DAVID bioinformatics resources. Nat Protoc. 
2009;4(1):44–8.  
79.  Mi H, Muruganujan A, Huang X, Ebert D, Mills C, Guo X, et al. Protocol Update 
for large-scale genome and gene function analysis with the PANTHER 
classification system (v.14.0). Nat Protoc. 2019 Mar 25;14(3):703–21.  
80.  Müller UC, Zheng H. Physiological functions of APP family proteins. Cold 
Spring Harb Perspect Med. 2012;2(2):1–17.  
81.  Brai E, Alina Raio N, Alberi L. Notch1 hallmarks fibrillary depositions in 
sporadic Alzheimer’s disease. Acta Neuropathol Commun. 2016 Dec 1;4(1):64.  
82.  Kim J, Basak JM, Holtzman DM. The Role of Apolipoprotein E in Alzheimer’s 
241 
 
Disease. 2011;63(3):287–303.  
83.  Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: 
Normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect 
Med. 2012;2(3).  
84.  Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, et al. 
Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol 
Chem. 2004 Sep 24;279(39):41197–207.  
85.  Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM. Low-density lipoprotein 
receptor represents an apolipoprotein E-independent pathway of Aβ uptake and 
degradation by astrocytes. J Biol Chem. 2012 Apr 20;287(17):13959–71.  
86.  Yajima R, Tokutake T, Koyama A, Kasuga K, Tezuka T, Nishizawa M, et al. 
ApoE-isoform-dependent cellular uptake of amyloid-β is mediated by 
lipoprotein receptor LR11/SorLA. Biochem Biophys Res Commun. 2015 Jan 
2;456(1):482–8.  
87.  Yin R-H, Yu J-T, Tan L. The Role of SORL1 in Alzheimer’s Disease. Mol 
Neurobiol. 2015 Jun 16;51(3):909–18.  
88.  Shen J, Qin W, Xu Q, Xu L, Xu J, Zhang P, et al. Modulation of APOE and SORL1 
genes on hippocampal functional connectivity in healthy young adults. Brain 
Struct Funct. 2017 Aug 22;222(6):2877–89.  
89.  Andersen OM, Rudolph I-M, Willnow TE. Risk factor SORL1: from genetic 
association to functional validation in Alzheimer’s disease. Acta Neuropathol. 
2016 Nov 16;132(5):653–65.  
90.  Halliday MR, Rege S V, Ma Q, Zhao Z, Miller CA, Winkler EA, et al. Accelerated 
pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 
carriers with Alzheimer’s disease. J Cereb Blood Flow Metab. 2016 Jan;36(1):216–
27.  
91.  Liu C-C, Hu J, Zhao N, Wang J, Wang N, Cirrito JR, et al. Astrocytic LRP1 
Mediates Brain Aβ Clearance and Impacts Amyloid Deposition. J Neurosci. 
2017;37(15):4023–31.  
92.  Cai Z, Liu N, Wang C, Qin B, Zhou Y, Xiao M, et al. Role of RAGE in 
Alzheimer’s Disease. Cell Mol Neurobiol. 2016 May 15;36(4):483–95.  
242 
 
93.  Sagare AP, Bell RD, Zlokovic B V, Tanzi RE, Nixon R, Aisen PS, et al. 
Neurovascular Dysfunction and Faulty Amyloid. Spring. 2012;  
94.  Donahue JE, Flaherty SL, Johanson CE, Duncan JA, Silverberg GD, Miller MC, et 
al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta 
Neuropathol. 2006 Sep 28;112(4):405–15.  
95.  Cuchillo-Ibañez I, Mata-Balaguer T, Balmaceda V, Arranz JJ, Nimpf J, Sáez-
Valero J. The β-amyloid peptide compromises Reelin signaling in Alzheimer’s 
disease. Sci Rep. 2016;6:31646.  
96.  Sweeney MD, Ayyadurai S, Zlokovic B V. Pericytes of the neurovascular unit: 
Key functions and signaling pathways. Nat Neurosci. 2016;19(6):771–83.  
97.  Zhao Z, Nelson AR, Betsholtz C, Zlokovic B V. Establishment and Dysfunction 
of the Blood-Brain Barrier. Cell. 2015;163(5):1064–78.  
98.  Ueno M, Chiba Y, Murakami R, Matsumoto K, Kawauchi M, Fujihara R. Blood–
brain barrier and blood–cerebrospinal fluid barrier in normal and pathological 
conditions. Brain Tumor Pathol. 2016;33(2):89–96.  
99.  Jessen NA, Munk ASF, Lundgaard I, Nedergaard M. The Glymphatic System: A 
Beginner’s Guide. Neurochem Res. 2015 Dec;40(12):2583–99.  
100.  Miners JS, Schulz I, Love S. Differing associations between Aβ accumulation, 
hypoperfusion, blood–brain barrier dysfunction and loss of PDGFRB pericyte 
marker in the precuneus and parietal white matter in Alzheimer’s disease. J 
Cereb Blood Flow Metab. 2018 Jan 2;38(1):103–15.  
101.  Lynch MA. The impact of neuroimmune changes on development of amyloid 
pathology; relevance to Alzheimer’s disease. Immunology. 2014 Mar;141(3):292–
301.  
102.  Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue L-F. Decreased 
expression of CD200 and CD200 receptor in Alzheimer’s disease: a potential 
mechanism leading to chronic inflammation. Exp Neurol. 2009 Jan;215(1):5–19.  
103.  Holtzman DM, Mandelkow E, Selkoe DJ, Tanzi RE, Nixon R. Proteolytic 
Degradation of Amyloid beta Protein. Cold Spring Harb Perspect Med. 2012;  




105.  Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer’s disease. J 
Neurochem. 2008 Mar;104(6):1433–9.  
106.  Gerschütz A, Heinsen H, Grünblatt E, Wagner AK, Bartl J, Meissner C, et al. 
Neuron-Specific Alterations in Signal Transduction Pathways associated with 
Alzheimer’s Disease. J Alzheimer’s Dis. 2014 Mar 10;40(1):135–42.  
107.  Sontag J-M, Sontag E. Protein phosphatase 2A dysfunction in Alzheimer’s 
disease. Front Mol Neurosci. 2014;7:16.  
108.  Karch CM, Jeng AT, Goate AM. Calcium phosphatase calcineurin influences tau 
metabolism. Neurobiol Aging. 2013 Feb;34(2):374–86.  
109.  Wang AC, Jensen EH, Rexach JE, Vinters H V, Hsieh-Wilson LC. Loss of O-
GlcNAc glycosylation in forebrain excitatory neurons induces 
neurodegeneration. Proc Natl Acad Sci U S A. 2016;113(52):15120–5.  
110.  Lau P, Nixon SJ, Parton RG, Muscat GEO. RORα regulates the expression of 
genes involved in lipid homeostasis in skeletal muscle cells: Caveolin-3 and 
CPT-1 are direct targets of ROR. J Biol Chem. 2004;279(35):36828–40.  
111.  Kim EJ, Yoo YG, Yang WK, Lim YS, Na TY, Lee IK, et al. Transcriptional 
activation of HIF-1 by RORα and its role in hypoxia signaling. Arterioscler 
Thromb Vasc Biol. 2008;28(10):1796–802.  
112.  Boukhtouche F, Mariani J, Tedgui A. The “CholesteROR” Protective Pathway in 
the Vascular System. Arterioscler Thromb Vasc Biol. 2004;24(4):637–43.  
113.  Kehoe PG. The coming of age of the angiotensin hypothesis in Alzheimer’s 
disease: Progress toward disease prevention and treatment? J Alzheimer’s Dis. 
2018;62(3):1443–66.  
114.  Kochunov P, Glahn DC, Nichols TE, Winkler AM, Hong EL, Holcomb HH, et al. 
Genetic analysis of cortical thickness and fractional anisotropy of water 
diffusion in the brain. Front Neurosci. 2011;5:1–15.  
115.  Journiac N, Jolly S, Jarvis C, Gautheron V, Rogard M, Trembleau A, et al. The 
nuclear receptor RORα exerts a bi-directional regulation of IL-6 in resting and 
reactive astrocytes. Proc Natl Acad Sci. 2009;106(50):21365–70.  
116.  Delerive P, Monté D, Dubois G, Trottein F, Fruchart-Najib J, Mariani J, et al. The 
orphan nuclear receptor RORα is a negative regulator of the inflammatory 
244 
 
response. EMBO Rep. 2001;2(1):42–8.  
117.  Ming Q, Wang X, Chai Q, Yi J, Yao S. Retinoid-related orphan receptor alpha 
(RORA) gene variation is associated with trait depression. Psychiatry Res. 
2015;229(1–2):629–30.  
118.  Terracciano A, Tanaka T, Sutin A, Sanna S, Deiana B, Lai S, et al. Florida State 
University Libraries Genome-Wide Association Scan of Trait Depression. Biol 
Psychiatry. 2010;68(9):811–7.  
119.  Baker E, Sims R, Leonenko G, Frizzati A, Harwood J, Grozeva D, et al. Gene 
based Analysis in HRC Imputed Genome Wide Association Data Identifies 
Three Novel Genes for Alzheimer’s Disease. bioRxiv. 2018 Jul 23;374876.  
120.  Banzhaf-Strathmann J, Benito E, May S, Arzberger T, Tahirovic S, Kretzschmar 
H, et al. MicroRNA-125b induces tau hyperphosphorylation and cognitive 
deficits in Alzheimer’s disease. EMBO J. 2014 Aug 1;33(15):1667–80.  
121.  Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu 
AN, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s 
disease correlates with increased BACE1/ -secretase expression. Proc Natl Acad 
Sci. 2008;105(17):6415–20.  
122.  Craddock TJA, Tuszynski JA, Chopra D, Casey N, Goldstein LE, Hameroff SR, et 
al. The Zinc Dyshomeostasis Hypothesis of Alzheimer’s Disease. Gong C-X, 
editor. PLoS One. 2012 Mar 23;7(3):e33552.  
123.  Li L-B, Wang Z-Y. Disruption of brain zinc homeostasis promotes the 
pathophysiological progress of Alzheimer’s disease. Histol Histopathol. 2016 
Jun;31(6):623–7.  
124.  Ventriglia M, Brewer GJ, Simonelli I, Mariani S, Siotto M, Bucossi S, et al. Zinc in 
Alzheimer’s Disease: A Meta-Analysis of Serum, Plasma, and Cerebrospinal 
Fluid Studies. J Alzheimer’s Dis. 2015 May 7;46(1):75–87.  
125.  Acquaah-Mensah GK, Agu N, Khan T, Gardner A. A regulatory role for the 
insulin- and BDNF-Linked RORA in the hippocampus: Implications for 
Alzheimer’s disease. J Alzheimer’s Dis. 2015;44(3):827–38.  
126.  Dwyer R, Skrobot OA, Dwyer J, Munafo M, Kehoe PG. Using Alzgene-Like 
Approaches to Investigate Susceptibility Genes for Vascular Cognitive 
245 
 
Impairment. J Alzheimer’s Dis. 2013 Feb 6;34(1):145–54.  
127.  Fang Z, Du R, Edwards A, Flemington EK, Zhang K. The Sequence Structures of 
Human MicroRNA Molecules and Their Implications. PLoS One. 2013 Jan 
18;8(1):e54215.  
128.  Benes V, Castoldi M. Expression profiling of microRNA using real-time 
quantitative PCR, how to use it and what is available. Methods. 2010 
Apr;50(4):244–9.  
129.  Van Rooij E. The art of MicroRNA research. Circ Res. 2011;108(2):219–34.  
130.  Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, Chen C, et al. 
Evaluation of quantitative mirnA expression platforms in the micrornA quality 
control (mirQC) study. Nat Methods. 2014;11(8):809–15.  
131.  Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman 
F, et al. A novel and universal method for microRNA RT-qPCR data 
normalization. Genome Biol. 2009;10(6).  
132.  Redshaw N, Wilkes T, Whale A, Cowen S, Huggett J, Foy CA. A comparison of 
miRNA isolation and RT-qPCR technologies and their effects on quantification 
accuracy and repeatability. Biotechniques. 2013;54(3):155–64.  
133.  Garibyan L, Avashia N. Polymerase chain reaction. J Invest Dermatol. 2013 
Mar;133(3):1–4.  
134.  Schwarzenbach H, Silva AM da, Calin G, Pantel K. Which is the accurate data 
normalization strategy for microRNA quantification? Clin Chem. 
2015;61(11):1333–42.  
135.  Benz F, Roderburg C, Cardenas DV, Vucur M, Gautheron J, Koch A, et al. U6 is 
unsuitable for normalization of serum miRNA levels in patients with sepsis or 
liver fibrosis. Exp Mol Med. 2013;45(9):1–9.  
136.  Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, et al. The 
small-nucleolar RNAs commonly used for microRNA normalisation correlate 
with tumour pathology and prognosis. Br J Cancer. 2011 Mar 29;104(7):1168–77.  
137.  Geekiyanage H, Jicha GA, Nelson PT, Chan C. Blood serum miRNA: Non-
invasive biomarkers for Alzheimer’s disease. Exp Neurol. 2012 Jun;235(2):491–6.  
138.  Lau P, Bossers K, Janky R, Salta E, Frigerio CS, Barbash S, et al. Alteration of the 
246 
 
microRNA network during the progression of Alzheimer’s disease. EMBO Mol 
Med. 2013 Oct;5(10):1613–34.  
139.  Chen G, Zhao L, Feng J, You G, Sun Q, Li P, et al. Validation of Reliable 
Reference Genes for Real-Time PCR in Human Umbilical Vein Endothelial Cells 
on Substrates with Different Stiffness. PLoS One. 2013;8(6):1–9.  
140.  Andersen CL. Normalization of Real-Time Quantitative Reverse Transcription-
PCR Data: A Model-Based Variance Estimation Approach to Identify Genes 
Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets. 
Cancer Res. 2004;64(15):5245–50.  
141.  Pfaffl MW. Determination of most stable housekeeping genes, differentially 
regulated target genes and sample integrity: BestKeeper© - Excel spreadsheet 
tool using a Repeated Pair-wise Correlation. Biotechnol Lett. 2004;26:509–15.  
142.  Perkins JR, Dawes JM, McMahon SB, Bennett DLH, Orengo C, Kohl M. 
ReadqPCR and NormqPCR: R packages for the reading, quality checking and 
normalisation of RT-qPCR quantification cycle (Cq) data. BMC Genomics. 
2012;13(1).  
143.  Kitchen RR, Kubista M, Tichopad A. Statistical aspects of quantitative real-time 
PCR experiment design. Methods. 2010;50(4):231–6.  
144.  Ma J, Pan H, Zeng Y, Lv Y, Zhang H, Xue A, et al. Exploration of the R code-
based mathematical model for PMI estimation using profiling of RNA 
degradation in rat brain tissue at different temperatures. Forensic Sci Med 
Pathol. 2015;11(4):530–7.  
145.  Lv YH, Ma JL, Pan H, Zeng Y, Tao L, Zhang H, et al. Estimation of the human 
postmortem interval using an established rat mathematical model and multi-
RNA markers. Forensic Sci Med Pathol. 2017;13(1):20–7.  
146.  Peiró-Chova L, Peña-Chilet M, López-Guerrero JA, García-Giménez JL, Alonso-
Yuste E, Burgues O, et al. High stability of microRNAs in tissue samples of 
compromised quality. Virchows Arch. 2013;463(6):765–74.  
147.  Nagy C, Maheu M, Lopez J, Vaillancourt K, Cruceanu C, Gross J, et al. Effects of 
Postmortem Interval on Biomolecule Integrity in the Brain. J Neuropathol Exp 
Neurol. 2015;74(5):459–69.  
247 
 
148.  Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, et al. Identification 
of miRNA changes in Alzheimer’s disease brain and CSF yields putative 
biomarkers and insights into disease pathways. J Alzheimers Dis. 2008 
May;14(1):27–41.  
149.  Nunez-Iglesias J, Liu C-C, Morgan TE, Finch CE, Zhou XJ. Joint Genome-Wide 
Profiling of miRNA and mRNA Expression in Alzheimer’s Disease Cortex 
Reveals Altered miRNA Regulation. Maas S, editor. PLoS One. 2010 Feb 
1;5(2):e8898.  
150.  Bicker S, Lackinger M, Weiß K, Schratt G. MicroRNA-132, -134, and -138: a 
microRNA troika rules in neuronal dendrites. Cell Mol Life Sci. 
2014;71(20):3987–4005.  
151.  Martinez-Ramirez S, Greenberg SM, Viswanathan A. Cerebral microbleeds: 
overview and implications in cognitive impairment. Alzheimers Res Ther. 
2014;6(3):33.  
152.  Stokum JA, Gerzanich V, Simard JM. Molecular pathophysiology of cerebral 
edema. J Cereb Blood Flow Metab. 2016;36(3):513–38.  
153.  Arvanitakis Z, Capuano AW, Leurgans SE, Buchman AS, Bennett DA, Schneider 
JA. The Relationship of Cerebral Vessel Pathology to Brain Microinfarcts. Brain 
Pathol. 2017;27(1):77–85.  
154.  Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, et al. Synaptic 
activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005 Dec 
22;48(6):913–22.  
155.  Poels MMF, Vernooij MW, Ikram MA, Hofman A, Krestin GP, van der Lugt A, 
et al. Prevalence and Risk Factors of Cerebral Microbleeds: An Update of the 
Rotterdam Scan Study. Stroke. 2010 Oct 1;41(10, Supplement 1):S103–6.  
156.  Mateos L, Ismail MAM, Gil-Bea FJ, Schüle R, Schöls L, Heverin M, et al. Side 
chain-oxidized oxysterols regulate the brain renin-angiotensin system through a 
liver X receptor-dependent mechanism. J Biol Chem. 2011;286(29):25574–85.  
157.  Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: Clinical 
applications and controversies. Nat Rev Endocrinol. 2015;11(4):242–52.  
158.  Elkins EA, Walti KA, Newberry KE, Lema SC. Identification of an 
248 
 
oxytocinase/vasopressinase-like leucyl-cystinyl aminopeptidase (LNPEP) in 
teleost fish and evidence for hypothalamic mRNA expression linked to 
behavioral social status. Gen Comp Endocrinol. 2017 Sep 1;250:58–69.  
159.  Wigerup C, Påhlman S, Bexell D. Therapeutic targeting of hypoxia and hypoxia-
inducible factors in cancer. Pharmacol Ther. 2016 Aug 1;164:152–69.  
160.  Han Z, Huang H, Gao Y, Huang Q. Functional annotation of Alzheimer’s 
disease associated loci revealed by GWASs. PLoS One. 2017;12(6).  
161.  Ghanbari M, Ikram MA, De Looper HWJ, Hofman A, Erkeland SJ, Franco OH, et 
al. Genome-wide identification of microRNA-related variants associated with 
risk of Alzheimer’s disease. Sci Rep. 2016;6(June):1–9.  
162.  Lopez M, Aoubala M, Jordier F, Isnardon D, Gomez S, Dubreuil P. The human 
poliovirus receptor related 2 protein is a new hematopoietic/endothelial 
homophilic adhesion molecule. Blood. 1998;92(12):4602–11.  
163.  Rossignoli A, Shang MM, Gladh H, Moessinger C, Foroughi Asl H, Talukdar 
HA, et al. Poliovirus Receptor-Related 2: A Cholesterol-Responsive Gene 
Affecting Atherosclerosis Development by Modulating Leukocyte Migration. 
Arterioscler Thromb Vasc Biol. 2017;37(3):534–42.  
164.  Yashin AI, Fang F, Kovtun M, Wu D, Duan M, Arbeev K, et al. Hidden 
heterogeneity in Alzheimer’s disease: Insights from genetic association studies 
and other analyses. Exp Gerontol. 2018;107(October):148–60.  
165.  Miele E, Buttarelli FR, Arcella A, Begalli F, Garg N, Silvano M, et al. High-
throughput microRNA profiling of pediatric high-grade gliomas. Neuro Oncol. 
2014 Jan;16(2):228–40.  
166.  Northcott PA, Fernandez-L A, Hagan JP, Ellison DW, Grajkowska W, Gillespie 
Y, et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven 
medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar 
neural precursors. Cancer Res. 2009 Apr 15;69(8):3249–55.  
167.  Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, et al. Analysis of 13 
cell types reveals evidence for the expression of numerous novel primate- and 
tissue-specific microRNAs. Proc Natl Acad Sci. 2015;112(10):E1106–15.  
168.  Lipovich L, Hou Z-C, Jia H, Sinkler C, McGowen M, Sterner KN, et al. High-
249 
 
throughput RNA sequencing reveals structural differences of orthologous brain-
expressed genes between western lowland gorillas and humans. J Comp Neurol. 
2016 Feb 1;524(2):288–308.  
169.  Kent OA, McCall MN, Cornish TC, Halushka MK. Lessons from miR-143/145: 
The importance of cell-type localization of miRNAs. Nucleic Acids Res. 
2014;42(12):7528–38.  
170.  Witwer KW, Halushka MK. Toward the promise of microRNAs – Enhancing 
reproducibility and rigor in microRNA research. RNA Biol. 2016;13(11):1103–16.  
171.  Mellios N, Huang HS, Grigorenko A, Rogaev E, Akbarian S. A set of 
differentially expressed miRNAs, including miR-30a-5p, act as post-
transcriptional inhibitors of BDNF in prefrontal cortex. Hum Mol Genet. 
2008;17(19):3030–42.  
172.  Wang WX, Danaher RJ, Miller CS, Berger JR, Nubia VG, Wilfred BS, et al. 
Expression of miR-15/107 family microRNAs in human tissues and cultured rat 
brain cells. Genomics, Proteomics Bioinforma. 2014;12(1):19–30.  
173.  Kasai A, Kakihara S, Miura H, Okada R, Hayata-Takano A, Hazama K, et al. 
Double In situ Hybridization for MicroRNAs and mRNAs in Brain Tissues. 
Front Mol Neurosci. 2016;9:126.  
174.  Rao VTS, Ludwin SK, Fuh SC, Sawaya R, Moore CS, Ho MK, et al. MicroRNA 
expression patterns in human astrocytes in relation to anatomical location and 
age. J Neuropathol Exp Neurol. 2016;75(2):156–66.  
175.  Pogue AI, Cui JG, Li YY, Zhao Y, Culicchia F, Lukiw WJ. Micro RNA-125b 
(miRNA-125b) function in astrogliosis and glial cell proliferation. Neurosci Lett. 
2010 May 26;476(1):18–22.  
176.  Hansen KF, Karelina K, Sakamoto K, Wayman GA, Impey S, Obrietan K. 
miRNA-132: a dynamic regulator of cognitive capacity. Brain Struct Funct. 2013 
May 16;218(3):817–31.  
177.  Zhu Q-B, Unmehopa U, Bossers K, Hu Y-T, Verwer R, Balesar R, et al. 
MicroRNA-132 and early growth response-1 in nucleus basalis of Meynert 
during the course of Alzheimer’s disease. Brain. 2016 Mar 1;139(3):908–21.  
178.  Hansen KF, Sakamoto K, Aten S, Snider KH, Loeser J, Hesse AM, et al. Targeted 
250 
 
deletion of miR-132/-212 impairs memory and alters the hippocampal 
transcriptome. Learn Mem. 2016 Feb;23(2):61–71.  
179.  Jin J, Kim S-N, Liu X, Zhang H, Zhang C, Seo J-S, et al. miR-17-92 Cluster 
Regulates Adult Hippocampal Neurogenesis, Anxiety, and Depression. Cell 
Rep. 2016 Aug 9;16(6):1653–63.  
180.  Gangaraju VK, Lin H. MicroRNAs: Key regulators of stem cells. Nat Rev Mol 
Cell Biol. 2009;10(2):116–25.  
181.  Shi Y, Zhao X, Hsieh J, Wichterle H, Impey S, Banerjee S, et al. microRNA 
regulation of neural stem cells and neurogenesis. 2011;30(45):14931–6.  
182.  Le MTN, Xie H, Zhou B, Chia PH, Rizk P, Um M, et al. MicroRNA-125b 
Promotes Neuronal Differentiation in Human Cells by Repressing Multiple 
Targets. Mol Cell Biol. 2009;29(19):5290–305.  
183.  Sarkar S, Jun S, Rellick S, Quintana DD, Cavendish JZ, Simpkins JW. Expression 
of microRNA-34a in Alzheimer’s disease brain targets genes linked to synaptic 
plasticity, energy metabolism, and resting state network activity. Brain Res. 2016 
Sep 1;1646:139–51.  
184.  Zovoilis A, Agbemenyah HY, Agis-Balboa RC, Stilling RM, Edbauer D, Rao P, et 
al. microRNA-34c is a novel target to treat dementias. EMBO J. 2011 Sep 
23;30(20):4299–308.  
185.  De Antonellis P, Carotenuto M, Vandenbussche J, De Vita G, Ferrucci V, 
Medaglia C, et al. Early Targets of miR-34a in Neuroblastoma. Mol Cell 
Proteomics. 2014 Aug;13(8):2114–31.  
186.  Zhang L, Dong H, Si Y, Wu N, Cao H, Mei B, et al. miR-125b promotes tau 
phosphorylation by targeting the neural cell adhesion molecule in 
neuropathological progression. Neurobiol Aging. 2019 Jan 1;73:41–9.  
187.  Ma X, Liu L, Meng J. MicroRNA-125b promotes neurons cell apoptosis and Tau 
phosphorylation in Alzheimer’s disease. Neurosci Lett. 2017 Nov 20;661:57–62.  
188.  Forster JI, Köglsberger S, Trefois C, Boyd O, Baumuratov AS, Buck L, et al. 
Characterization of differentiated SH-SY5Y as neuronal screening model reveals 
increased oxidative vulnerability. J Biomol Screen. 2016;21(5):496–509.  
189.  Wanet A, Tacheny A, Arnould T, Renard P. MiR-212/132 expression and 
251 
 
functions: Within and beyond the neuronal compartment. Nucleic Acids Res. 
2012;40(11):4742–53.  
190.  Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. 
Silencing of microRNAs in vivo with “antagomirs.” Nature. 2005;438(7068):685–
9.  
191.  Ameres S, Horwich M, Hung J-H, Xu J, Ghildiyal M, Weng Z, et al. Target RNA-
directed trimming and tailing of small silencing RNAs. PLoS One. 
2017;32(7):736–40.  
192.  Meseguer S, Mudduluru G, Escamilla JM, Allgayer H, Barettino D. MicroRNAs-
10a and -10b contribute to retinoic acid-induced differentiation of 
neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 
(SF2/ASF). J Biol Chem. 2011;286(6):4150–64.  
193.  Skalsky RL, Cullen BR. Reduced expression of brain-enriched microRNAs in 
glioblastomas permits targeted regulation of a cell death gene. PLoS One. 
2011;6(9):20–3.  
194.  Magill ST, Cambronne XA, Luikart BW, Lioy DT, Leighton BH. microRNA-132 
regulates dendritic growth and arborization of newborn neurons in the adult 
hippocampus. 2010;107(47).  
195.  Lin LF, Chiu SP, Wu MJ, Chen PY, Yen JH. Luteolin induces microRNA-132 
expression and modulates neurite outgrowth in PC12 cells. PLoS One. 2012;7(8).  
196.  Edbauer D, Neilson JR, Foster KA, Wang C-F, Seeburg DP, Batterton MN, et al. 
Regulation of synaptic structure and function by FMRP- associated microRNAs 
miR-125b and miR-132. 2016;25(3):289–313.  
197.  Jasińska M, Miłek J, Cymerman IA, Łęski S, Kaczmarek L, Dziembowska M. 
miR-132 Regulates Dendritic Spine Structure by Direct Targeting of Matrix 
Metalloproteinase 9 mRNA. Mol Neurobiol. 2016;53(7):4701–12.  
198.  Pathania M, Torres-Reveron J, Yan L, Kimura T, Lin T V., Gordon V, et al. miR-
132 enhances dendritic morphogenesis, spine density, synaptic integration, and 
survival of newborn olfactory bulb neurons. PLoS One. 2012;7(5).  
199.  Mellios N, Sugihara H, Castro J, Banerjee A, Le C, Kumar A, et al. miR-132, an 




200.  Papadopoulou AS, Serneels L, Achsel T, Mandemakers W, Callaerts-Vegh Z, 
Dooley J, et al. Deficiency of the miR-29a/b-1 cluster leads to ataxic features and 
cerebellar alterations in mice. Neurobiol Dis. 2015;73:275–88.  
201.  Roshan R, Shridhar S, Sarangdhar MA, Banik A, Chawla M, Garg M, et al. Brain-
specific knockdown of miR-29 results in neuronal cell death and ataxia in mice. 
RNA. 2014 Aug;20(8):1287–97.  
202.  Varendi K, Mätlik K, Andressoo JO. From microRNA target validation to 
therapy: Lessons learned from studies on BDNF. Cell Mol Life Sci. 
2015;72(9):1779–94.  
203.  Witwer KW, Halushka MK. Toward the promise of microRNAs – Enhancing 
reproducibility and rigor in microRNA research. RNA Biol. 2016;13(11):1103–16.  
204.  Delay C, Grenier-Boley B, Amouyel P, Dumont J, Lambert JC. MiRNA-
dependent target regulation: Functional characterization of singlenucleotide 
polymorphisms identified in genome-wide association studies of Alzheimer’s 
disease. Alzheimer’s Res Ther. 2016;8(1):1–11.  
205.  Cohen AD, Klunk WE. Early detection of Alzheimer’s disease using PiB and 
FDG PET. Neurobiol Dis. 2014;72(Part A):117–22.  
206.  Morbelli S, Brugnolo A, Bossert I, Buschiazzo A, Frisoni GB, Galluzzi S, et al. 
Visual Versus semi-quantitative analysis of 18 F-FDG-PET in Amnestic MCI: An 
European Alzheimer’s Disease Consortium (EADC) project. J Alzheimer’s Dis. 
2015;44(3):815–26.  
207.  Pagani M, De Carli F, Morbelli S, Öberg J, Chincarini A, Frisoni GB, et al. 
Volume of interest-based [ 18 F]fluorodeoxyglucose PET discriminates MCI 
converting to Alzheimer’s disease from healthy controls. A European 
Alzheimer’s Disease Consortium (EADC) study. NeuroImage Clin. 2015;7:34–42.  
208.  Knopman DS, Jack CR, Wiste HJ, Lundt ES, Weigand SD, Vemuri P, et al. 18F-
fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E 
genotype in cognitively normal persons. Mol Psychiatry. 2015;20(6):1588–95.  
209.  Matthew N M, Kim M-S, Adil M, Patil AH, Lu Y, Mitchell CJ, et al. Towards the 
human cellular microRNAome Matthew. Genome Res. 2017;8138:1769–81.  
253 
 
210.  Halushka MK, Fromm B, Peterson KJ, McCall MN. Big Strides in Cellular 
microRNA Expression Marc. 2018;123(24):4757–63.  
 
